THE ROLE OF FOXM1 IN PANCREATIC BETA CELL MASS
REGENERATION AND EXPANSION

By
Amanda Ackermann Misfeldt

Dissertation
Submitted to the Faculty of the
Graduate School of Vanderbilt University
in partial fulfillment of the requirements
for the degree of

DOCTOR OF PHILOSOPHY
in
Molecular Physiology and Biophysics

December, 2008
Nashville, TN

Approved:
Professor Mark Magnuson, Chair
Professor Anna Means
Professor William Russell
Professor Roland Stein
Professor David Wasserman
ACKNOWLEDGEMENTS

If the best place to start is at the beginning, then I must first thank the Medical Scientist Training Program and its administration for granting me the opportunity to explore medicine and the basic sciences at a first-rate institution. Thank you to the Department of Molecular Physiology and Biophysics, the Program in Developmental Biology, and the Beta Cell Interest Group for providing strong training environments and faculty and for broadening my scientific scope.

Of course, I am grateful to my dissertation committee members Dr. Mark Magnuson, Dr. Anna Means, Dr. Bill Russell, Dr. Roland Stein, and Dr. David Wasserman for their suggestions and expertise with regard to my dissertation work. More than that, though, I appreciate their confidence in me and their guidance in making the most of my graduate school career. All of them have opened their laboratory and office doors to me for experiments and discussions that have been truly helpful.

So many people have been generous in their assistance in the experiments described in this dissertation, including: Dr. Robert H. Costa, Dr. Al Powers, Greg Poffenberger, Aramandla Radhika, Dr. Zhongyi Chen, Anastasia Golovin, Dr. Marcela Brissova, Rachel Reinert, Jeannelle Kantz, Leah Potter, Jennifer Plank, Dr. Shuangli Guo, Dr. Guoqiang Gu, Sui Wang, Dr. Kevin Niswender and his laboratory members, Dr. Richard O’Brien, Dr. Masa Shiota, Dr. Rob Carnahan, and Cassie Reid. Many thanks to the staff in the Hormone Assay and Analytical Services Core, the Islet Procurement and Analysis Core, the Microarray Shared Resource, the Molecular Biology Shared Resource, the Monoclonal Antibody Core, and the Mouse Metabolic Phenotyping Center.
There really is no way to appropriately thank the members of the Gannon lab, past and present, for their part in making it such a great place to work. I can’t say that the people are the only thing that makes a lab, but I can say that they have been the most important to me. Thank you, Laura Wilding Crawford and Elizabeth Tweedie Ables, for being wonderful friends, first and foremost, and for setting the precedent that we have tried to maintain in the lab despite your departures…and by that I mean getting married and changing your last name, of course. Thank you, Peter Wiebe, for always being available to answer questions and for not backing down if I didn’t agree with your response. Thank you to Hongjie Zhang, Venus Childress Roper, David Lowe, and Young Ah Oh for helping me with countless experiments. Gift Kopsombut and Xue Feng, you both are so incredible; thank you for all of your hard work and for keeping me young!

Jia Zhang, Renuka Menon, and Nik Patel, I am so glad that I got the chance to know you. Thank you for continuing to make lab an enjoyable workplace. Michelle Guney, Christine Pope, and Kathryn Henley, I will miss our discussions about science, reality TV, and everything in between. Thank you for being such great friends! Michelle, thank you for being my late-night lab partner and for making every conference and retreat ever so much more entertaining. Christine, thank you for understanding my OCD nature and not holding it against me. You are a tremendous asset to the lab. Kathryn, I am glad that someone with such spirit joined the lab. Good luck to all of you in your upcoming endeavors!

Certainly, my graduate school experience would not have been as valuable if Dr. Maureen Gannon had not been a part of it. Maureen is the sort of boss, colleague, and
friend that everyone wishes they had. Thank you, Maureen, for being all of those for me. Thank you for your never-ending support and encouragement. I am always impressed by your relentlessly positive attitude, and I hope that I will be able to take part of that with me. Thank you for encouraging all of your lab members to present their work, attend conferences, and pursue the goals from which others may discourage them. Foremost, thank you for being a great example to me of a principal investigator, leader, and mother. You are an inspiration to women in science.

To my family, thank you for always emphasizing the importance of education and hard work, and for encouraging me when things were more difficult than expected.

Saving the best for last, thank you to my husband Drew, without whom I am fairly certain I would not have endured these grueling years. Thank you for being a friend, confidant, and partner. Thank you for your love and support and your uncanny ability to know the answer to any question I ask, or at least to sound as if you do. Thank you for allowing three wonderful kitties to enter our home and our lives. I am glad that we have been able to share these experiences with each other, and I am looking forward to sharing many more in the years to come.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>ii</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>ix</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>x</td>
</tr>
<tr>
<td><strong>Chapter</strong></td>
<td></td>
</tr>
<tr>
<td>I. BACKGROUND AND SIGNIFICANCE</td>
<td>1</td>
</tr>
<tr>
<td>Pancreas Development</td>
<td>2</td>
</tr>
<tr>
<td>β Cell Differentiation</td>
<td>3</td>
</tr>
<tr>
<td><em>In Vivo</em> β Cell Differentiation</td>
<td>4</td>
</tr>
<tr>
<td><em>In Vitro</em> β Cell Differentiation</td>
<td>9</td>
</tr>
<tr>
<td>Establishing an Organism’s β Cell Mass</td>
<td>13</td>
</tr>
<tr>
<td>Maintaining an Organism’s β Cell Mass</td>
<td>17</td>
</tr>
<tr>
<td>Dynamic Changes in an Organism’s β Cell Mass</td>
<td>23</td>
</tr>
<tr>
<td>Therapeutic Implications</td>
<td>27</td>
</tr>
<tr>
<td>Forkhead Box M1 (FoxM1)</td>
<td>27</td>
</tr>
<tr>
<td>Identification of FoxM1</td>
<td>27</td>
</tr>
<tr>
<td>FoxM1 Gene and Protein</td>
<td>32</td>
</tr>
<tr>
<td>Transcriptional Regulation of Foxm1</td>
<td>34</td>
</tr>
<tr>
<td>Post-translational Regulation of FoxM1</td>
<td>37</td>
</tr>
<tr>
<td>FoxM1 Targets</td>
<td>39</td>
</tr>
<tr>
<td>FoxM1 Null Mice</td>
<td>43</td>
</tr>
<tr>
<td>Mouse Models of Altered FoxM1 Expression in the Liver</td>
<td>47</td>
</tr>
<tr>
<td>Mouse Models of Altered FoxM1 Expression in the Lung</td>
<td>49</td>
</tr>
<tr>
<td>Mouse Models of Altered FoxM1 Expression in the Colon</td>
<td>51</td>
</tr>
<tr>
<td>Mouse Models of Altered FoxM1 Expression in the Prostate</td>
<td>52</td>
</tr>
<tr>
<td>Mouse Models of Altered FoxM1 Expression in the Pancreas</td>
<td>52</td>
</tr>
<tr>
<td>Therapeutic Implications of FOXM1 Modification</td>
<td>55</td>
</tr>
<tr>
<td>Overview and Aims of Dissertation</td>
<td>57</td>
</tr>
<tr>
<td>II. MATERIALS AND METHODS</td>
<td>60</td>
</tr>
<tr>
<td>Mice</td>
<td>60</td>
</tr>
<tr>
<td>DNA Extraction and Genotyping</td>
<td>68</td>
</tr>
<tr>
<td>Intraperitoneal Glucose Tolerance Test</td>
<td>71</td>
</tr>
<tr>
<td>Intraperitoneal Insulin Tolerance Test</td>
<td>71</td>
</tr>
<tr>
<td>Plasma and Pancreatic Insulin Content</td>
<td>72</td>
</tr>
</tbody>
</table>
III. INVESTIGATING THE ROLE OF FOXM1 IN β CELL REGENERATION AND EXPANSION FOLLOWING 60% PARTIAL PANCREATECTOMY

Introduction.......................................................................................................100

Results.............................................................................................................102

60% PPx up-regulated Foxm1 and select targets within islets while maintaining normoglycemia .................................................................102
Regeneration of β cell mass within the splenic lobe was specifically impaired in FoxM1Δpanc mice ..............................................................................108
β cell proliferation was reduced in FoxM1Δpanc mice compared to Controls after 60% PPx .................................................................111
FoxM1Δpanc mice exhibited increased β cell and nucleus size compared to Controls .........................................................................................116
Islet size in FoxM1Δpanc mice was reduced compared to Control mice following 60% PPx .................................................................119
β cell neogenesis following 60% PPx was not impaired in FoxM1Δpanc mice ................................................................................................121
FOXM1c over-expression did not enhance β cell mass regeneration following 60% PPx ..................................................121

Discussion .......................................................................................................................123

IV. INVESTIGATING THE ROLE OF FOXM1 IN β CELL HYPERPLASIA
IN RESPONSE TO DIET-INDUCED OBESITY .................................................................134

Introduction ................................................................................................................134
Results ..........................................................................................................................138

FoxM1\textsuperscript{Δ\text{panc}} and Control mice on a Mixed Background ..............138

High-fat diet induced obesity in mixed background FoxM1\textsuperscript{Δ\text{panc}} and Control mice ..........................................................138

High-fat diet induced glucose intolerance in mixed background FoxM1\textsuperscript{Δ\text{panc}} and Control mice ..............................................................140

High-fat diet induced insulin resistance in mixed background FoxM1\textsuperscript{Δ\text{panc}} and Control mice ..............................................................143

FoxM1\textsuperscript{Δ\text{panc}} mice on a mixed background exhibited impaired insulin secretion on the high-fat diet ........................................143

FoxM1\textsuperscript{Δ\text{panc}} mice on a mixed background exhibited reduced β cell mass compared to Controls, and high-fat diet did not stimulate β cell mass expansion ..........................................................147

High-fat diet did not stimulate significant β cell proliferation or apoptosis ..............................................................................147

FoxM1\textsuperscript{Δ\text{panc}} mice on a mixed background displayed enlarged β cell size but reduced islet size and density compared to Control littermates ..............................................................................149

Isogenic C57Bl/6 Mice Pilot Study .................................................................151

High-fat diet induced obesity and glucose intolerance in C57Bl/6 mice ..................................................................................153

High-fat diet stimulated β cell mass expansion in C57Bl/6 mice ..................................................................................153

High-fat diet stimulated Foxm1 up-regulation in C57Bl/6 islets ..................................................................................156

Foxm1\textsuperscript{\text{floxed/floxed}} Mice on a C57Bl/6 Background ........................................156

High-fat diet induced obesity and glucose intolerance in Foxm1\textsuperscript{\text{floxed/floxed}} mice on the C57Bl/6 background ..................................................................................158

High-fat diet stimulated β cell mass expansion in Foxm1\textsuperscript{\text{floxed/floxed}} mice on the C57Bl/6 background ..................................................................................161

Investigating Insulin Secretory β Cell Function in FoxM1\textsuperscript{Δ\text{panc}} Mice on a Mixed Background ..................................................................................161

Discussion ................................................................................................................167

V. UTILIZING PDX1\textsuperscript{\text{PB-CRE-ER}\textsuperscript{TM}} MICE FOR ISLET-SPECIFIC DELETION OF FOXM1 AND LINEAGE TRACING ........................................172

Introduction ................................................................................................................172
Results ..........................................................................................................................176

Efficiency of Pdx1\textsuperscript{\text{PB-CreER}\textsuperscript{TM}}-Mediated Recombination of R26\textsuperscript{R} .............179
VI. GENERATING A FOXM1 ANTIBODY ...........................................................195
  Introduction....................................................................................................195
  Progress to Date and Future Directions .........................................................202

VII. SUMMARY AND FUTURE DIRECTIONS ......................................................215

REFERENCES ................................................................................................................223
LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Molecular regulators of postnatal β cell mass <em>in vivo</em></td>
<td>18</td>
</tr>
<tr>
<td>2.</td>
<td>Transcripts assessed by Custom TaqMan Low Density Array</td>
<td>78</td>
</tr>
<tr>
<td>3.</td>
<td>Summary of β cell proliferation results for Control and FoxM1^Δpanc^ mice</td>
<td>114</td>
</tr>
<tr>
<td></td>
<td>after Sham versus PPx</td>
<td></td>
</tr>
</tbody>
</table>
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>β cell differentiation from endoderm</td>
<td>5</td>
</tr>
<tr>
<td>2.</td>
<td>Sources of β cells for transplantation</td>
<td>10</td>
</tr>
<tr>
<td>3.</td>
<td>β cell mass dynamics</td>
<td>14</td>
</tr>
<tr>
<td>4.</td>
<td>Cell cycle regulation</td>
<td>19</td>
</tr>
<tr>
<td>5.</td>
<td>Winged-helix “forkhead” DNA binding domain structure</td>
<td>29</td>
</tr>
<tr>
<td>6.</td>
<td>Human FOXM1 and mouse Foxm1 cDNA structures</td>
<td>31</td>
</tr>
<tr>
<td>7.</td>
<td>FoxM1 protein structure</td>
<td>33</td>
</tr>
<tr>
<td>8.</td>
<td>NCBI BLAST Tree for mouse FoxM1 protein</td>
<td>35</td>
</tr>
<tr>
<td>9.</td>
<td>NCBI BLAST Tree for human FOXM1 protein</td>
<td>36</td>
</tr>
<tr>
<td>10.</td>
<td>FoxM1 transcriptional targets are involved in cell cycle regulation</td>
<td>40</td>
</tr>
<tr>
<td>11.</td>
<td>$Foxm1^{\text{Neo/Neo}}$ mice</td>
<td>44</td>
</tr>
<tr>
<td>12.</td>
<td>$Foxm1^{-/-}$ mice</td>
<td>45</td>
</tr>
<tr>
<td>13.</td>
<td>FoxM1 expression within the pancreas</td>
<td>53</td>
</tr>
<tr>
<td>14.</td>
<td>FoxM1 is highly expressed within the endocrine pancreas and is required for normal postnatal β cell growth and proliferation</td>
<td>54</td>
</tr>
<tr>
<td>15.</td>
<td>$Pdx1^{5.5\text{kb}-\text{Cre}}$ transgene</td>
<td>61</td>
</tr>
<tr>
<td>16.</td>
<td>$Pdx1^{\text{PB}-\text{CreER}^{\text{TM}}}$ transgene</td>
<td>63</td>
</tr>
<tr>
<td>17.</td>
<td>$Rosa26-FOXM1c$ transgene</td>
<td>64</td>
</tr>
<tr>
<td>18.</td>
<td>$Rosa26-LacZ$ reporter knock-in</td>
<td>66</td>
</tr>
<tr>
<td>19.</td>
<td>Z/EG mice</td>
<td>67</td>
</tr>
<tr>
<td>20.</td>
<td>pYX-Asc vector</td>
<td>87</td>
</tr>
<tr>
<td>21.</td>
<td>pCR-TOPO2.1 vector</td>
<td>.................................................................89</td>
</tr>
<tr>
<td>22.</td>
<td>pAT107b vector</td>
<td>.............................................................90</td>
</tr>
<tr>
<td>23.</td>
<td>60% partial pancreatectomy (PPx)</td>
<td>.........................................................103</td>
</tr>
<tr>
<td>24.</td>
<td>Expression of <em>Foxm1</em> and targets in Control islets</td>
<td>........................................104</td>
</tr>
<tr>
<td>25.</td>
<td>Analysis of transcript expression in Control islets after 60% PPx or Sham operation using Custom TaqMan Low Density Arrays</td>
<td>..................................................106</td>
</tr>
<tr>
<td>26.</td>
<td>Glucose tolerance was maintained in Control and <em>FoxM1</em>Δpanc mice following 60% PPx</td>
<td>........................................................107</td>
</tr>
<tr>
<td>27.</td>
<td>β cell mass and pancreas weight in Control and <em>FoxM1</em>Δpanc mice after 60% PPx or a Sham operation</td>
<td>........................................................109</td>
</tr>
<tr>
<td>28.</td>
<td>Regeneration of the splenic lobe was observed within 7 days after 60% PPx in Control and <em>FoxM1</em>Δpanc mice</td>
<td>.......................................................110</td>
</tr>
<tr>
<td>29.</td>
<td>β cell proliferation was reduced in <em>FoxM1</em>Δpanc mice after 60% PPx</td>
<td>.........................112</td>
</tr>
<tr>
<td>30.</td>
<td>β cell proliferation was only reduced in definitive islets, but not small endocrine cell clusters, in <em>FoxM1</em>Δpanc versus Control mice after 60% PPx</td>
<td>..........113</td>
</tr>
<tr>
<td>31.</td>
<td>β cell proliferation was unaffected in <em>FoxM1</em>Δpanc embryos versus Control littermates</td>
<td>........................................................115</td>
</tr>
<tr>
<td>32.</td>
<td>α cell proliferation was reduced in <em>FoxM1</em>Δpanc mice after 60% PPx, but acinar and ductal cell proliferation were not impaired</td>
<td>.............................................117</td>
</tr>
<tr>
<td>33.</td>
<td><em>FoxM1</em>Δpanc mice exhibited increased β cell and nucleus size</td>
<td>.........................118</td>
</tr>
<tr>
<td>34.</td>
<td><em>FoxM1</em>Δpanc mice exhibited impaired islet growth after 60% PPx</td>
<td>.........................120</td>
</tr>
<tr>
<td>35.</td>
<td><em>FoxM1</em>Δpanc mice did not exhibit impaired β cell neogenesis after 60% PPx</td>
<td>......122</td>
</tr>
<tr>
<td>36.</td>
<td>Over-expression of FOXM1C had no effect on glucose tolerance</td>
<td>.........................124</td>
</tr>
<tr>
<td>37.</td>
<td>Over-expression of FOXM1C had no effect on β cell regeneration after 60% PPx</td>
<td>........................................125</td>
</tr>
<tr>
<td>38.</td>
<td><em>Foxm1</em> transcript levels were dramatically reduced in <em>FoxM1</em>Δpanc mice versus Control littermates</td>
<td>................................................129</td>
</tr>
<tr>
<td>39.</td>
<td>Diet-induced obesity</td>
<td>.................................................................137</td>
</tr>
</tbody>
</table>
40. High-fat diet induced obesity in FoxM1\textsuperscript{Δpanc} and Control littermates ...............139

41. High-fat diet induced increased adiposity in FoxM1\textsuperscript{Δpanc} and Control littermates.............................................................................................................141

42. High-fat diet induced glucose intolerance in FoxM1\textsuperscript{Δpanc} and Control littermates.............................................................................................................142

43. High-fat diet did not induce significant insulin resistance.............................144

44. FoxM1\textsuperscript{Δpanc} mice fed the high-fat diet exhibited impaired insulin secretion ......145

45. FoxM1\textsuperscript{Δpanc} mice exhibited reduced β cell mass and pancreatic insulin content compared to Controls, and neither was altered by high-fat diet .............148

46. FoxM1\textsuperscript{Δpanc} mice exhibited reduced β cell proliferation after 12 weeks on the high-fat diet, but high-fat diet did not significantly stimulate β cell proliferation in Control mice ........................................................................150

47. FoxM1\textsuperscript{Δpanc} mice exhibited enlarged β cell size but reduced islet size and density compared to Control littermates......................................................................................................................152

48. High-fat diet induced obesity and glucose intolerance in C57Bl/6 female mice.................................................................................................................................154

49. High-fat diet stimulated pancreas growth and β cell mass expansion in C57Bl/6 female mice .................................................................................................................................155

50. High-fat diet up-regulated Foxm1 and some of its targets in C57Bl/6 female mice.................................................................................................................................157

51. Foxm1\textsuperscript{floxflo}\textsubscript{x}\textsubscript{x}Pdx1\textsubscript{5.5kb-Cre} on the C57Bl/6 background did not undergo Cre-mediated recombination of Foxm1 .................................................................159

52. High-fat diet induced obesity and glucose intolerance in Foxm1\textsuperscript{floxflo} C57Bl/6 female mice .................................................................................................................................160

53. High-fat diet stimulated β cell mass expansion in Foxm1\textsuperscript{floxflo} C57Bl/6 female mice .................................................................................................................................162

54. Preliminary analysis revealed a possible insulin secretory defect in FoxM1\textsuperscript{Δpanc} islets.................................................................................................................................163

55. Real-time qRT-PCR analysis of transcript expression in FoxM1\textsuperscript{Δpanc} and Control islets .................................................................................................................................165
Analysis of transcript expression in FoxM1\textsubscript{\textDelta}panic and Control islets using Custom TaqMan Low Density Arrays

Pulse-chase lineage labeling of \(\beta\) cells

The Foxm1 and Rosa26 loci are closely located on mouse chromosome 6

\(Pdx1^{PB-CreER}\textsuperscript{TM}\) mediated high levels of recombination of \(R26^R\) in \(\beta\) cells

Cre was primarily localized to islet nuclei 3 weeks after \(Pdx1^{PB-CreER}\textsuperscript{TM};R26^R\) mice were injected 3 times with 8 mg tamoxifen

Nuclear localization of Cre persisted until at least 8 weeks after tamoxifen injection

Tamoxifen dose correlated with nuclear localization of Cre protein in \(Pdx1^{PB-CreER}\textsuperscript{TM};R26^R\) mice

Tamoxifen dose directly correlated with \(\beta\)-galactosidase expression in \(Pdx1^{PB-CreER}\textsuperscript{TM};R26^R\) mice

FoxM1\textsubscript{dislet} and Control mice exhibited similar body weights and glucose tolerance

After 60\% PPx, \(\beta\) cell mass in the regenerating splenic lobe of FoxM1\textsubscript{dislet} mice was reduced compared to Control mice

Tamoxifen metabolism pathways

Available anti-FoxM1 antibodies are not specific

Confirmation of Foxm1\textsuperscript{-/-} tissue

In situ hybridization for Foxm1

Generation of FoxM1 fragments

T7 expression system

IPTG induced expression of FoxM1 Fragment 1-, 2-, and 3-MBP fusion proteins

Lower induction temperatures modestly improved FoxM1 Fragment 3-MBP solubility

FoxM1 Fragment 2- and 3-MBP fusion proteins were highly insoluble
75. Final purification of FoxM1 Fragment 1-, 2-, and 3-MBP fusion proteins .......209
76. Endogenous mouse FoxM1 was detected by sera from two antigen-injected mice .................................................................................................................................211
77. Recombinant FoxM1 was detected by sera from all antigen-injected mice .......212
78. Summary of FoxM1’s role in β cell mass regeneration and expansion ...............216
79. Working model of FoxM1’s role in β cell proliferation .............................................219
CHAPTER I

BACKGROUND AND SIGNIFICANCE

The number and functional capacity of an organism’s pancreatic β-cells, in combination with peripheral insulin sensitivity, determine the ability of that organism to maintain glucose homeostasis. Because β cells are the only cell type in the body to secrete insulin in response to glucose, the size of this cell population, or β cell mass, is an important determinant of an organism’s ability to regulate its blood glucose levels. Diabetes mellitus is characterized by either an absolute (Type I) or relative (Type II and gestational) insufficiency of insulin production by β cells. Existing treatments for diabetes primarily focus on replacing insulin and improving β cell function. However, increasing a patient’s β cell mass could potentially improve or cure their condition. To this end, islet transplantation has been used to treat some patients with Type I diabetes, but limited supply and low yield of islets from donor pancreata, as well as graft failure, prevent widespread use of this therapy. Currently, efforts are being made to differentiate β cells from precursor populations and to expand β cells in vitro to generate an unlimited supply of β cells for transplantation. Theoretically, the same could be done in vivo to expand a patient’s existing or transplanted β cell population. Thus, it is important to understand the molecular regulation of β cell mass development, maintenance, and expansion.
Pancreas Development

The pancreas originates from the foregut endoderm as ventral and dorsal buds beginning at embryonic day (e) 9.5 in the mouse, and the two buds later fuse at approximately e12.5 (Kim and MacDonald, 2002). The endodermal epithelium proliferates in response to various fibroblast growth factors (FGFs) produced by the adjacent mesenchyme (Bhushan et al., 2001), undergoes branching morphogenesis, and differentiates into ductal, exocrine, and endocrine cells. Evagination and development of the ventral pancreatic bud is slightly delayed compared to that of the dorsal bud, and the ventral bud gives rise to fewer endocrine cells than does the dorsal bud (Spooner et al., 1970). The ventral and dorsal buds also differ with regard to the signals they require for development. For example, the homeobox 9 (Hb9) transcription factor is required for formation of the dorsal, but not ventral, bud (Harrison et al., 1999; Li et al., 1999). Additionally, the LIM homeodomain protein islet 1 (Isl1) is specifically expressed in the mesenchyme surrounding the dorsal, but not ventral, bud at e9.0, as well as later in differentiated endocrine cells throughout the pancreas. Isl1−/− mice reveal that Isl1 is required specifically in the dorsal mesenchyme for formation of the dorsal pancreatic bud, and is required in the endoderm for differentiation of all endocrine cells (Ahlgren et al., 1997).

Pancreatic progenitors within the foregut epithelium are marked by expression of pancreatic-duodenal homeobox 1 (Pdx1), which is induced at e8.5 in the posterior foregut endoderm and is expressed throughout the pancreatic epithelium at e9.5 (Guz et al., 1995). Forkhead box A2 (FoxA2), previously called hepatic nuclear factor 3β (Hnf3β), can activate transcription of Pdx1, although there are many other upstream regulators of
Pdx1 (Melloul et al., 2002; Gerrish et al., 2004). Pdx1 is required for growth, rather than formation, of the pancreatic buds, as evidenced by Pdx1^{-/-} mice in which both pancreatic buds initially form but then arrest at a very early stage of development, resulting in an apancreatic phenotype at birth (Jonsson et al., 1994; Offield et al., 1996). The same phenotype has been observed in a human infant with a homozygous inactivating point mutation of PDX1 (Stoffers et al., 1997b). Pdx1 expression is down-regulated in acinar and ductal cells beginning at approximately e13.0 but is maintained in differentiated endocrine cells and up-regulated specifically in β cells (Guz et al., 1995). This expression pattern is maintained throughout life.

Pancreas transcription factor 1a (Ptf1a) is also expressed throughout the developing pancreas beginning at e9.5 and is required for growth of the pancreatic buds (Krapp et al., 1998; Kawaguchi et al., 2002). Ptf1a is later down-regulated in ductal and endocrine cells but is maintained in acinar cells throughout life, where it induces expression of Amylase and Elastase. Ptf1a^{-/-} mice form a rudimentary dorsal pancreas that fails to grow or produce differentiated acinar tissue (Krapp et al., 1998). Differentiated endocrine cells are present in these mice, although these cells are reduced in number and found scattered throughout the adjacent spleen. Furthermore, the cells that would otherwise have expressed Ptf1a and contributed to the pancreas become incorporated into the duodenum (Kawaguchi et al., 2002).

**β Cell Differentiation**

No “master regulator” of β cell differentiation has been identified. Instead, the process of β cell differentiation is a complex pathway requiring the specification of
pancreas versus other endodermal organs, endocrine cells versus ductal or exocrine cells, and β cells versus non-β endocrine cells (Figure 1). Proper differentiation of β cells requires dynamic changes in transcription factor expression levels in appropriate sequences and within an appropriate timeline. Much of what is currently known regarding β cell differentiation has been discovered by studying endocrine cell differentiation in vivo, with the hope that these findings will aid attempts to differentiate β cells in vitro.

**In Vivo β Cell Differentiation**

The murine pancreas undergoes two waves of endocrine cell differentiation, the first of which gives rise to glucagon⁺, insulin⁺, and double-positive cells between e9.5 and e13.5. These cells appear to be a transient population, however, and lineage tracing studies show that they do not contribute to mature islets (Herrera, 2000). The second wave of endocrine differentiation begins at approximately e13.5 and yields endocrine cells that contribute to mature islets (Prasadan et al., 2002). Second wave endocrine differentiation, unlike the first wave, relies on the transcription factors Pdx1 and Hnf6 (Offield et al., 1996; Jacquemin et al., 2000).

Differentiation of endocrine versus exocrine cells is regulated by the Notch signaling pathway (Apelqvist et al., 1999; Jensen et al., 2000). The pro-endocrine basic helix-loop-helix (bHLH) transcription factor neurogenin 3 (Ngn3), a downstream target of Hnf6 (Jacquemin et al., 2000), induces expression of Notch ligands, which bind to Notch receptors on and activate the Notch pathway in adjacent cells (Heremans et al., 2002). Downstream targets of the Notch pathway (e.g. Hairy/enhancer-of-split 1, Hes1)
Figure 1. β cell differentiation from endoderm. During embryogenesis, the pancreas differentiates from foregut endoderm, which also gives rise to the liver and duodenum. Pancreatic progenitors are specified for an endocrine or non-endocrine fate, after which the non-endocrine progenitors differentiate into either duct or exocrine cells, while the endocrine progenitors differentiate into α, β, δ, PP, or ε cells. Transcription factors expressed in each of the cell populations preceding and including β cells are listed. Figure is from Ackermann and Gannon (2007).
repress Ngn3 expression, which inhibits endocrine differentiation. Additionally, Hes1 represses the cell cycle inhibitor $p57^{kip2}$, which maintains a proliferative pool of pancreatic progenitor cells within the embryonic ductal epithelium (Georgia et al., 2006). Therefore, cells in which the Notch signaling pathway is activated maintain their proliferative capacity, while cells in which Notch signaling is not activated express Ngn3, exit the cell cycle, and differentiate into endocrine cells. Genetic mouse models of impaired Notch signaling, via deletion of Delta-like ligand 1 (Dll1$^{-/-}$), Recombination signal binding protein for immunoglobulin kappa J region (Rbp-Jκ$^{-/-}$), or Hes1$^{-/-}$, exhibit increased endocrine cell differentiation at the expense of the pancreatic progenitor population (Apelqvist et al., 1999; Jensen et al., 2000).

Ngn3 is required for endocrine cell differentiation, as evidenced by Ngn3$^{-/-}$ mice, which lack all pancreatic endocrine cell types and die postnatally due to severe diabetes (Gradwohl et al., 2000). Additionally, lineage tracing analysis revealed that all endocrine cells arise from Ngn3$^{+}$ cells (Gu et al., 2002). Ngn3 induces expression of essential β cell transcription factors including neurogenic differentiation 1 (Neurod1), also known as Beta2 (Huang et al., 2000), and paired box gene 4 (Pax4) (Smith et al., 2003), but is not itself expressed in hormone-producing cells. The bHLH transcription factor NeuroD1 induces expression of several endocrine genes, including Insulin, and its expression is maintained in mature endocrine cells (Naya et al., 1995). NeuroD1$^{-/-}$ mice are diabetic due to severely reduced numbers of all endocrine cell types (Naya et al., 1997), and humans with heterozygous mutations in NEUROD1 suffer from a type of diabetes referred to as maturity-onset diabetes of the young type 6 (MODY6) (Kristinsson et al., 2001). In contrast, ectopic expression of Ngn3 or NeuroD1 in the pancreatic epithelium
results in premature and expansive differentiation of endocrine cells, primarily glucagon-producing \( \alpha \) cells, at the expense of the pancreatic progenitor pool, resulting in a hypoplastic pancreas (Apelqvist et al., 1999; Schwitzgebel et al., 2000).

The basic-leucine zipper (bZIP) transcription factor Musculoaponeurotic fibrosarcoma oncogene family protein B (MafB) is expressed in developing insulin\(^+\) and glucagon\(^+\) cells beginning during the first wave of endocrine cell differentiation, and then is subsequently down-regulated in \( \beta \) cells, concurrent with up-regulation of MafA in these cells (Artner et al., 2006; Nishimura et al., 2006). MafB can activate transcription of the insulin and glucagon genes, and is required for proper differentiation of \( \alpha \) and \( \beta \) cells (Artner et al., 2007). Loss of MafB (Mafb\(^{-/-}\)) results in impaired differentiation of \( \alpha \) and \( \beta \) cells, but no change in total endocrine cell number and no alterations in endocrine cell lineage allocation, and insulin expression is delayed in these mice until the onset of MafA expression at e13.5.

Endocrine cells produced by the second wave of differentiation can first be identified at e13.5, forming endocrine cords adjacent to ducts (Pictet et al., 1972). These cells delaminate from the ductal epithelium, differentiate, proliferate, and then cluster to form islets, which contain \( \beta \) cells, \( \alpha \) cells, somatostatin-producing \( \delta \) cells, pancreatic polypeptide-producing PP cells, and ghrelin-producing \( \varepsilon \) cells. Regulation of differentiation down each of these endocrine lineages from a Ngn3\(^+\) cell is complex and still not completely understood. However, lineage tracing analyses have revealed that the \( \beta \) and \( \alpha \) cell lineages diverge early, while \( \beta \) cells and PP cells may differentiate from the same lineage (Herrera, 2000). Additionally, \( \beta \) cells and \( \delta \) cells share a requirement for Pax4, as Pax4\(^{-/-}\) mice have increased numbers of \( \alpha \) cells at the expense of \( \beta \) and \( \delta \) cells.
Pax4 is expressed in early insulin⁺, but not glucagon⁺, cells and is later restricted to mature β cells, but Pax4 alone is not sufficient to drive Ngn3⁺ cells toward either a β or δ cell fate (Grapin-Botton et al., 2001). A putative antagonist of Pax4 is aristaless related homeobox (Arx), whose expression pattern and loss-of-function phenotype directly contrast with that of Pax4 (Collombat et al., 2003). Arx is expressed in pancreatic progenitor cells beginning at e9.5 and is later restricted to mature α and δ cells. Arx⁻/⁻ mice exhibit increased numbers of β and δ cells at the expense of α cells. Furthermore, Arx is up-regulated in Pax4⁻/⁻ mice, while Pax4 is up-regulated in Arx⁻/⁻ mice. Thus, Pax4 and Arx function in the differential specification of endocrine cell types.

Early broad expression of Pdx1 induces expression of the NK homeodomain transcription factors Nkx2.2 and Nkx6.1, but while Nkx2.2 expression becomes restricted to α, β, and PP cells (Sussel et al., 1998), Nkx6.1 expression becomes tightly restricted to β cells (Sander et al., 2000). Nkx2.2⁻/⁻ mice reveal that Nkx2.2 is absolutely required for β cell differentiation and plays a lesser role in differentiation of α and PP cells (Sussel et al., 1998), while Nkx6.1⁻/⁻ mice have impaired but not complete loss of β cell differentiation (Sander et al., 2000). Several pieces of evidence suggest that Nkx2.2 is upstream of Nkx6.1: initiation of expression of Nkx2.2 precedes that of Nkx6.1 (e9.5 versus e10.5, respectively); all Nkx6.1⁺ cells also express Nkx2.2, while not all Nkx2.2⁺ cells express Nkx6.1; Nkx2.2⁻/⁻ mice lack expression of Nkx6.1; and Nkx2.2⁻/⁻;Nkx6.1⁻/⁻ mice exhibit a similar phenotype to Nkx2.2⁻/⁻ mice.

In addition to its early role in pancreas development, Pdx1 plays a role in the terminal differentiation of β cells by inducing expression of Insulin, Glucose transporter 2
(Glut2), Glucokinase, and Î¬slet amyloid polypeptide (Iapp) (Edlund, 2001), and Pdx1 is necessary for maintaining mature β cell function. MafA has also recently been identified as an important regulator of β cell function and a marker of mature β cells (Zhang C et al., 2005; Nishimura et al., 2006; Artner et al., 2007). MafA-/- mice undergo normal pancreatic development but develop diabetes postnatally, associated with progressively impaired insulin secretion, abnormal islet morphology, and reduced expression of Insulin, Pdx1, NeuroD1, and Glut2. Additionally, insulin has been shown to be a direct transcriptional target of MafA (Kataoka et al., 2002; Olbrot et al., 2002; Matsuoka et al., 2004; Artner et al., 2008).

**In Vitro β Cell Differentiation**

As described above, β cell differentiation in vivo requires that expression of specific transcription factors be initiated, maintained, and repressed in a precise temporal and sequential manner, which is difficult to control in an in vitro setting. Furthermore, simply inducing insulin expression in a progenitor population does not equate with differentiating β cells because an important quality of mature β cells is their ability to sense blood glucose levels and appropriately respond by synthesizing and secreting proper amounts of insulin. These functions require expression of several transporter, receptor, and exocytosis proteins. To overcome these obstacles, many different approaches are being utilized to generate β cells, as shown in Figure 2: proliferation of existing β cells, differentiation of β cells from embryonic stem (ES) cells, differentiation of β cells from pancreatic progenitor cells (residing in pancreatic ductal epithelium), and
Figure 2. Sources of β cells for transplantation. A supply of β cells for transplantation may be derived by 1. inducing proliferation of existing β cells, either isolated or within islets; 2. by inducing differentiation of ES cells into β cells; 3. by inducing differentiation of isolated ductal epithelium into β cells or islets; and 4. by inducing transdifferentiation of related cell types, such as exocrine cells, hepatocytes, or intestinal enteroendocrine cells, into β cells. Figure is from Ackermann and Gannon (2007).
transdifferentiation of \( \beta \) cells from related cell types (e.g. pancreatic exocrine cells, hepatocytes, and intestinal enteroendocrine cells) (Bonner-Weir and Weir, 2005).

Although the prospect of deriving \( \beta \) cells from ES cells is intriguing, there has been much controversy in the field, and several early studies have since become cautionary tales. For example, initial reports claiming a 10-30% efficiency rate of differentiating \( \beta \) cells from ES cells failed to confirm *Insulin* mRNA expression, which was later observed in less than 0.00001% of cells (Rajagopal *et al.*, 2003). Improved results have been obtained by applying what has been learned about \( \beta \) cell differentiation *in vivo*. For example, transfection of ES cells with *Pax4*, and to a lesser extent *Pdx1*, results in increased differentiation of insulin-producing cells and increased expression of Isl1, Ngn3, Insulin, Iapp, and Glut2 (Blyszczuk *et al.*, 2003). Currently, the preferred method to produce \( \beta \) cells from ES cells is directed differentiation. Ku *et al.* showed that stepwise application of various growth factors known to influence \( \beta \) cell development (FGF, activin, betacellulin, exendin-4, and nicotinamide) induces 2.73% of ES cells to differentiate into insulin-producing cells (Ku *et al.*, 2004). D'Amour *et al.* developed a five-stage protocol to systematically induce differentiation of definitive endoderm, primitive gut tube, posterior foregut endoderm, pancreatic endoderm and endocrine precursors, and finally insulin-producing cells, along with the four other hormone-producing cell types (D'Amour *et al.*, 2006). This method induced 7-12% of ES cells to differentiate into insulin-producing cells, although these cells had limited glucose-stimulated insulin secretion. More recently, the same group optimized this protocol to differentiate ES cells to the fourth stage (pancreatic endoderm and endocrine precursors), which is characterized by expression of Pdx1, FoxA2, Hnf6, and Nkx6.1, and they then
implanted these cell aggregates into recipient mice (Kroon et al., 2008). These grafts produced insulin within 44 days post-implantation, and by 90 days were producing as much insulin as did grafts of 3,000-5,000 adult human islets. Importantly, the ES cell-derived grafts appropriately secreted insulin in response to glucose but not in response to fasting or hypoglycemia. Additionally, these grafts were able to maintain glucose homeostasis in mice whose endogenous β cells were eliminated. Histological analysis of the grafts after 78 days revealed that hormone+ cells formed islet-like clusters with relatively appropriate proportions of each cell type, no endocrine hormones were co-expressed within the same cell, and hormone+ cells also expressed mature endocrine cell type-specific markers. Despite these encouraging results, grafts derived from ES cells have been shown in some cases to form teratomas after transplantation (Fujikawa et al., 2005; Kroon et al., 2008).

Isolation and culture of ductal epithelium from adult mouse pancreas also yielded insulin+ cells, as well as islets, through islet producing stem cell (IPSC) and islet progenitor cell (IPC) intermediates (Ramiya et al., 2000). Increased islet yield was obtained by culturing IPSCs with epidermal growth factor (EGF), hepatocyte growth factor (HGF), and nicotinamide. IPSCs can be maintained in culture long-term (>3 years) and can withstand freezing, and the islets derived from them can reverse streptozotocin (STZ)-induced diabetes in mice. Duct cells have also been isolated from humans, from the normally-discarded non-islet fraction of pancreatic tissue utilized for islet transplantation (Heremans et al., 2002). Adenoviral infection of these cells with Ngn3 or Neurod1 results in differentiation into primarily insulin+ cells (10-fold over that observed in control cells), although intracellular insulin content is relatively low. Similar
results were observed when immortalized ductal cell lines from mice or humans were transfected with Ngn3 or Neurod1 (Gasa et al., 2004). However, whether or not the insulin+ cells and islets that are derived from these various sources are fully differentiated and fully functioning is unknown.

Establishing an Organism’s β Cell Mass

β cell mass is increased by β cell neogenesis (differentiation from precursor cells), β cell proliferation, and β cell hypertrophy (increased cell size), and is decreased by β cell death, primarily via apoptosis, and β cell atrophy (decreased cell size) (Figure 3A) (Ackermann and Gannon, 2007). From embryogenesis to adulthood, there is a net increase in β cell mass as the organism’s size increases (Figure 3B), and the majority of new β cells are formed by replication (Meier et al., 2008). β cell differentiation, as described above, gives rise to the initial β cells of an organism during embryogenesis, but there is much debate regarding whether and to what extent β cell neogenesis occurs in the postnatal and adult stages under normal circumstances. Lineage studies using DNA analog incorporation to assess sequential cell division showed that β cells in adult mice arise by uniform proliferation of pre-existing β cells, with no contributions from specialized populations of progenitor or stem cells (Teta et al., 2007). However, β cell neogenesis has been reported in models of pancreatic injury in adult mice (Xu et al., 2008; Bonner-Weir et al., 2008).

β cell proliferation proceeds at a high rate (approximately 10% per day in mice) during late embryogenesis (Bernard-Kargar and Ktorza, 2001) but begins to decline postnatally (Scaglia et al., 1997). During adulthood, β cells proliferate at a low rate that
Figure 3. \( \beta \) cell mass dynamics. (A) \( \beta \) cell proliferation, neogenesis, and hypertrophy (enlarged cell size) increase \( \beta \) cell mass, while \( \beta \) cell apoptosis and atrophy (reduced cell size) decrease \( \beta \) cell mass. (B) Graphs represent approximate changes in these processes over the course of a lifetime in normal individuals (gray solid line), in non-diabetic obesity (black solid line), in Type II diabetes mellitus (T2DM; black dashed line), and in Type I diabetes mellitus (T1DM; black dotted line), based on rodent and human studies. Embryo denotes the period of time prior to birth. Neonate denotes the period of time between birth and weaning (approximately 3 weeks in the rodent). Figure is from Ackermann and Gannon (2007).
may gradually decline with age. Approximately 1-4% of β cells replicate per day in rats between 30 and 100 days old (Finegood et al., 1995), while <1% of β cells replicate per day in mice at 1 year of age (Teta et al., 2005). The differences observed in the rates of β cell proliferation at these timepoints is thought to be due to differences in the percentage of β cells that are able to be recruited to enter the cell cycle, rather than differences in cell cycle lengths. The mechanism by which more β cells are recruited to enter the cell cycle during embryonic versus postnatal and adult stages is currently unknown. However, evidence from several genetic mouse models indicates that the factors that regulate β cell proliferation during embryogenesis may differ from those that regulate β cell proliferation postnatally (Rane et al., 1999; Georgia and Bhushan, 2004; Kushner et al., 2005a; Georgia and Bhushan, 2006; Zhang H et al., 2006). For example, global deletion of the cell cycle inhibitor p27Kip1 (p27Kip1−/−) increases β cell proliferation during embryogenesis and adulthood, but not during the early postnatal period, resulting in increased β cell mass at birth and throughout life (Georgia and Bhushan, 2006). In contrast, β cell-specific deletion of Pdx1 (Pdx1fl/fl;RIP-Cre) impairs embryonic β cell proliferation and alters islet morphology with increased proportions of α and δ cells at the expense of β cells (Gannon et al., 2008).

β cell apoptosis occurs at very low rates during embryogenesis, but there is evidence that a transient burst of β cell apoptosis occurs at weaning, which may be associated with islet remodeling and/or changes in β cell maturation (Scaglia et al., 1997). During adulthood, β cell apoptosis again normally occurs at very low rates, although it modestly increases in mice fed a high-fat or high-fat/high-protein diet (Linn et al., 1999). Average β cell size is fairly stable during the postnatal period (Scaglia et al.,
1997), but it increases with age during later adulthood (Montanya et al., 2000) and with increased adiposity (Park et al., 2007).

Proper development of an organism’s β cell mass requires appropriate nutrition during embryogenesis. Poor maternal nutrition results in intrauterine growth retardation (IUGR), low birth weight, and underdeveloped β cell mass in newborn rats, which predisposes them to glucose intolerance and diabetes later in life (Breant et al., 2006). When IUGR is caused by total caloric restriction, the reduction in β cell mass is due to reduced β cell differentiation, with decreased expression of Pdx1, Pax6, and Nkx6.1, rather than due to reduced β cell proliferation. These changes are associated with increased levels of glucocorticoids, which can independently reduce fetal β cell mass when exogenously administered to the mother. IUGR caused by protein restriction also results in under-developed β cell mass in newborn rats, but this is due to reduced β cell proliferation and increased β cell apoptosis, associated with reduced levels of insulin-like growth factors (IGFs) (Reusens and Remacle, 2006). IUGR initiated by surgical ligation of uterine arteries resulted in epigenetic modification of the Pdx1 promoter, causing reduced islet Pdx1 expression in offspring at birth and during the neonatal period and absence of Pdx1 expression in the adult after diabetes onset (Park JH et al., 2008). In contrast, maternal obesity and/or diabetes results in newborn macrosomia (large birth weight) and increased β cell mass associated with increased β cell proliferation, likely in response to maternal hyperglycemia. These offspring are also predisposed to obesity, insulin resistance, and diabetes, associated with early β cell exhaustion.
Maintaining an Organism’s β Cell Mass

Although it was once thought that an organism was born with all of the β cells it would ever have, prevailing evidence now shows that new β cells can form throughout life. Several studies have revealed that the primary mechanism by which new β cells form during adulthood is via proliferation rather than neogenesis (Dor et al., 2004; Georgia and Bhushan, 2004; Teta et al., 2007). Thus, organisms born with reduced β cell mass, as discussed above, have fewer β cells available to enter the cell cycle later in life. Under normal circumstances during adulthood, β cells are a slowly-renewing population, with steady low levels of proliferation and apoptosis. However, β cell mass continuously expands over the lifespan of an organism (Montanya et al., 2000), likely due to age-related increases in body weight and insulin resistance. In rats, β cells achieve this progressive increase in β cell mass by increasing their cell size, rather than increasing proliferation (Montanya et al., 2000).

The ability of an organism to maintain its β cell mass during adulthood is paramount to maintaining glucose homeostasis and preventing diabetes. Table 1 summarizes the mouse models in which molecular regulators of postnatal β cell mass are perturbed, and many of these factors are key regulators of the cell cycle (Figure 4). Several genetic mouse models of cell cycle dysregulation impair postnatal β cell proliferation, and cause a progressive decline in β cell mass, associated with a progressive glucose intolerant and diabetic phenotype. For example, global inactivation of Cyclin-dependent kinase 4 in mice (Cdk4−/−) specifically affects endocrine cells within the pancreas, causing diabetes by 2 months of age, and within the pituitary, causing reduced body size and infertility (Rane et al., 1999). The diabetes observed in these mice
<table>
<thead>
<tr>
<th>Transcription Factors</th>
<th>Mouse Models</th>
<th>Effects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pdx1</td>
<td>Pdx1&lt;sup&gt;+/−&lt;/sup&gt;</td>
<td>↑ β cell mass, ↑ β cell apoptosis</td>
<td>(Johnson et al., 2003)</td>
</tr>
<tr>
<td>Forkhead</td>
<td>Forkhead&lt;sup&gt;−/−&lt;/sup&gt;,Rip-Cre</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size; ↑ β cell apoptosis</td>
<td>(Ahlgren et al., 1998)</td>
</tr>
<tr>
<td>Cyclic AMP Response Element Binding Protein</td>
<td>Cyp&lt;sup&gt;−/−&lt;/sup&gt;,Pdx&lt;sup&gt;−&lt;/sup&gt;Cre</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size; ↑ β cell apoptosis</td>
<td>(Fajars et al., 2006)</td>
</tr>
<tr>
<td>E2Fs</td>
<td>Rip-ΔCREB&lt;sup&gt;Tg&lt;/sup&gt;</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size; ↑ β cell apoptosis</td>
<td>(Kushner et al., 2006)</td>
</tr>
<tr>
<td>Nuclear Factor of Activated T Cells, cytoplasmic, calcineurin-dependent 1</td>
<td>Rip-ΔT4&lt;sup&gt;Tg&lt;/sup&gt;</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size; ↑ β cell apoptosis</td>
<td>(Heit et al., 2006a)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cell Cycle Proteins</th>
<th>Cyclin-Dependent Kinases</th>
<th>↑ β cell mass</th>
<th>(Rane et al., 1999)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclins</td>
<td>Cdk&lt;sup&gt;−/−&lt;/sup&gt;,Tg</td>
<td>↑ β cell mass</td>
<td>(Rane et al., 1999)</td>
</tr>
<tr>
<td>Cyclin-Dependent Kinase Inhibitors</td>
<td>Cyclin D&lt;sup&gt;−/−&lt;/sup&gt;,Cyclin D&lt;sup&gt;−&lt;/sup&gt;</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↔ β cell size; ↔ β cell apoptosis</td>
<td>(Zhang et al., 2005)</td>
</tr>
<tr>
<td>Tumor Suppressors</td>
<td>p16&lt;sup&gt;−/−&lt;/sup&gt;,Rip-Cre</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size; ↑ β cell apoptosis</td>
<td>(Kudsi et al., 2006a)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Growth Factors</th>
<th>Lactogens</th>
<th>Tg</th>
<th>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size</th>
<th>(Kudsi et al., 2006b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parathyroid Hormone-related Protein</td>
<td>PTHR&lt;sup&gt;+/−&lt;/sup&gt;</td>
<td>Tg</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size</td>
<td>(Kudsi et al., 2006b)</td>
</tr>
<tr>
<td>Growth Hormone</td>
<td>GHR&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Tg</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↑ β cell size</td>
<td>(Kudsi et al., 2006b)</td>
</tr>
<tr>
<td>Hepatocyte Growth Factor</td>
<td>HGF&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Tg</td>
<td>↑ β cell mass, ↑ β cell proliferation</td>
<td>(Kudsi et al., 2006b)</td>
</tr>
</tbody>
</table>

| Epidermal Growth Factor | c-Met<sup>+/−</sup>,Rip-Cre | ↑ β cell mass, ↑ β cell proliferation, ↔ β cell size | (Williams et al., 2005) |
| Keratinocyte Growth Factor | HGF<sup>−/−</sup> | Tg | ↑ β cell mass, ↑ β cell proliferation, ↔ β cell size | (Rane et al., 1999) |
| Insulin, Insulin-like Growth Factors | IGF-1<sup>−/−</sup>,Rip-Cre | ↑ β cell mass, ↑ β cell proliferation, ↔ β cell size | (Kudsi et al., 2006b) |

<table>
<thead>
<tr>
<th>Cellular Signaling Proteins</th>
<th>Insulin Receptor Substrate</th>
<th>↑ β cell mass, ↑ β cell proliferation, ↔ β cell size</th>
<th>(Williams et al., 2005)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein Kinase H/Akt</td>
<td>Insulin&lt;sup&gt;−/−&lt;/sup&gt;</td>
<td>Tg</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↔ β cell size</td>
</tr>
<tr>
<td>P70S6K</td>
<td>PDK1&lt;sup&gt;+/−&lt;/sup&gt;,Rip-Cre</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↔ β cell size</td>
<td>(Williams et al., 2005)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Others</th>
<th>Menin&lt;sup&gt;+/−&lt;/sup&gt;</th>
<th>↑ β cell mass, ↑ β cell proliferation</th>
<th>(Karnik et al., 2005)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-phase kinase-associated protein 2</td>
<td>Skp2&lt;sup&gt;+/−&lt;/sup&gt;</td>
<td>Tg</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↔ β cell size</td>
</tr>
<tr>
<td>Phosphatase and Tensin homologue</td>
<td>PTEN&lt;sup&gt;+/−&lt;/sup&gt;</td>
<td>Tg</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↔ β cell size</td>
</tr>
<tr>
<td>Calcineurin b1</td>
<td>Calcineurin&lt;sup&gt;−/−&lt;/sup&gt;,Rip-Cre</td>
<td>↑ β cell mass, ↑ β cell proliferation, ↔ β cell size</td>
<td>(Williams et al., 2005)</td>
</tr>
</tbody>
</table>
**Figure 4. Cell cycle regulation.** The G₁/S transition is controlled by Cdk2, 4, 5, or 6 bound to Cyclin D or E, which phosphorylates Rb, releasing the E2F transcription factor. Rb phosphorylation is maintained through the G₂/M transition by Cdk2 bound to Cyclin A and Cdk1 bound to Cyclin A or B. Figure is adapted from Dzau et al. (2002).
is associated with severely reduced β cell mass, although β cell mass is comparable to that of wild-type mice at postnatal days (P) 1 and 2. Progression from G_1 to S phase in the cell cycle requires phosphorylation of the Retinoblastoma protein (Rb) by Cdk4/6 complexed with a D Cyclin, which releases E2F allowing it to activate transcription of necessary cell cycle target genes. Thus, Cdk6 function is redundant with Cdk4; however, mouse β cells do not express detectable levels of Cdk6 (Martin et al., 2003), making them uniquely susceptible to cell cycle perturbations caused by loss of Cdk4. In contrast, human islets express Cdk6 but not Cdk4 (Fiaschi-Taesch et al., 2008). Similarly, global deletion of Cyclin D2 (CyclinD2^-/-), the predominant D Cyclin expressed in β cells, fails to stimulate adequate compensatory up-regulation of Cyclin D1 or D3 within islets and drastically impairs postnatal β cell proliferation (Georgia and Bhushan, 2004). CyclinD2^-/- mice exhibit normal β cell mass at e17.5 but significantly reduced β cell mass postnatally, causing progressive glucose intolerance and diabetes.

Cdk inhibitor proteins (Cips, Kips, INKs) also play important roles in β cell proliferation. Transgenic over-expression of p27^Kip1 within β cells using the rat insulin promoter (Rip-p27^Kip1) impairs β cell proliferation, resulting in decreased β cell mass and diabetes in mice (Uchida et al., 2005). In contrast, as mentioned before, global deletion of p27^Kip1 (p27^Kip1^-/-) increases β cell proliferation under normal circumstances (Georgia and Bhushan, 2006). Loss of p27^Kip1 also increases β cell proliferation in genetic models of insulin resistance and diabetes (Irs2^-/- or db/db) and restores glucose homeostasis in the latter model (Uchida et al., 2005). β cell hyperplasia is also observed in humans with focal loss of heterozygosity of p57^Kip2, and these subjects suffer from hyperinsulinism of infancy (Kassem et al., 2001). Additionally, mice that express a mutant Cdk4 that cannot
be bound and inhibited by p16\(^{INK4a}\) (Cdk4\(^{R24C/R24C}\)) exhibit postnatal increases in β cell proliferation and β cell mass that improve glucose regulation (Rane et al., 1999).

Our lab has recently found that FoxM1 also plays an important role in β cell proliferation (Zhang H et al., 2006). FoxM1 is a transcription factor known to regulate expression levels of several cell cycle proteins. Pancreas-wide deletion of Foxm1 using a Cre-lox strategy (Foxm1\(^{floxflo}Pdx1^{5.5kb-Cre}\)) in mice results in postnatal defects in β cell proliferation, which contribute to a postnatal deficiency in β cell mass and a progressive glucose intolerant and diabetic phenotype. However, β cell mass and islet morphology are normal at P1, despite inactivation of Foxm1 early in embryogenesis. Increased nuclear p27\(^{Kip1}\), which is an indirect target of FoxM1, and β cell senescence are associated with impaired β cell proliferation in these mice. Thus, FoxM1 is critical for maintaining β cell mass during adulthood by properly coordinating cell cycle progression.

One of FoxM1’s transcriptional targets, S-phase kinase-associated protein 2 (Skp2), mediates degradation of p21\(^{Cip1}\) and p27\(^{Kip1}\) and has also been directly linked to β cell proliferation. Skp2\(^{-/-}\) mice exhibit a phenotype similar to that observed in Foxm1\(^{floxflo}Pdx1^{5.5kb-Cre}\) mice, with reduced postnatal β cell mass, reduced β cell proliferation, progressive diabetes, β cell hypertrophy and polyploidy, and accumulation of nuclear p27\(^{Kip1}\) in β cells (Zhong et al., 2007). These effects of loss of Skp2 on β cells are attributed to increased nuclear p27\(^{Kip1}\), as the metabolic and morphologic phenotypes are reversed in Skp2\(^{-/-}p27^{Kip1/-}\) double knock-out mice.

Another regulator of cell cycle genes is the transcriptional coactivator Menin, encoded by Men1, mutation of which results in Multiple Endocrine Neoplasia type 1 (MEN1) in humans (Crabtree et al., 2003). This syndrome is characterized by
hyperplasia of endocrine cell types primarily within the parathyroids, anterior pituitary, and pancreas, resulting in tumor formation, most commonly insulinomas composed of β cells. *Men1*⁻/⁻ mice display a similar phenotype. β cell-specific deletion of *Men1* (*Men1*⁺/⁻; *Rip-Cre*) also results in β cell hyperplasia, insulinomas, hyperinsulinemia, and hypoglycemia. Significantly increased β cell proliferation is observed, and this is associated with reduced levels of *p18^INK4c* and *p27^Kip1*, both of which are direct targets of Menin-mediated histone methylation (Karnik et al., 2005). Furthermore, a MEN1-like phenotype is observed in *p18^INK4c⁻/⁻; p27^Kip1⁻/⁻* mice (Franklin et al., 2000). Other mouse models of impaired and enhanced β cell proliferation have been reviewed by (Cozar-Castellano et al., 2006a) and (Heit et al., 2006b).

Just as impaired β cell proliferation causes a net loss of β cells, increased β cell death can have the same effect. Inherent defects that make β cells more susceptible to apoptosis, for example, result in a negative balance of β cell turnover, as observed in *Pdx1*⁺/⁻ mice, which exhibit normal β cell mass at 3 months of age but are unable to appropriately increase their β cell mass as they age (Johnson et al., 2003). Haploinsufficiency of *Pdx1* makes β cells more susceptible to undergoing apoptosis, associated with reduced expression levels of the anti-apoptotic genes *Bcl-XL* and *Bcl-2*. Increased β cell apoptosis results in insufficient β cell mass and progressive glucose intolerance. A more dramatic phenotype is observed in mice with adult-onset β cell-specific deletion of *Pdx1* (*Pdx1*⁺/⁻; *Rip-Cre*) (Ahlgren et al., 1998). These mice suffer from worsening glucose intolerance due to both progressive loss of β cell mass and impaired β cell function. Mutations of *PDX1* in humans result in similar phenotypes; a dominant-negative mutation of *PDX1* causes MODY4 (Stoffers et al., 1997a), while a
heterozygous inactivating mutation of *PDX1* predisposes to late-onset Type 2 diabetes (Macfarlane *et al.*, 1999). Thus, Pdx1 is a critical regulator of β cell survival and maintenance of β cell mass and function during adulthood.

**Dynamic Changes in an Organism’s β Cell Mass**

In addition to maintaining β cell mass under normal circumstances, as just discussed, an organism must also be able to alter its β cell mass in accordance with its requirements for insulin. In states of insulin resistance, such as pregnancy and obesity, β cell mass is known to increase (Rhodes, 2005) (Figure 3). In mice, such β cell mass expansion is accomplished primarily by increasing β cell proliferation (Karnik *et al.*, 2007), whereas β cell neogenesis humans accounts for β cell mass expansion (Butler *et al.*, 2003; Cao Minh *et al.*, 2008). Regardless of the mechanism, when compensatory β cell mass expansion is inadequate, diabetes ensues – gestational diabetes in the case of pregnancy, and Type II diabetes in the case of obesity. Although the majority of humans do not become diabetic in these circumstances, a significant portion of the population is predisposed to β cell failure, for currently unknown reasons. It is likely that factors that regulate β cell proliferation and neogenesis may play a role, although whether the factors that regulate β cell mass expansion are the same as those that regulate β cell mass maintenance is unclear. Recent genome-wide association studies have identified several polymorphisms in patients with Type II diabetes that correlate with disease risk (Sladek *et al.*, 2007; Zeggini *et al.*, 2008). Some of the identified loci include genes that play roles in cellular proliferation, such as *TCF7L2, HHEX, EXT2*, and *CDC123*. TCF7L2 and HHEX also play important roles in pancreas development, as do other identified loci.
including NOTCH2. However, distinct functions of identified loci with regard to Type II diabetes are still unclear.

During pregnancy, rats exhibit over a 50% increase in β cell mass, which is accomplished primarily via an approximate 3-fold increase in β cell proliferation (Scaglia et al., 1995). The chief stimuli of β cell proliferation during pregnancy are placental lactogens (PLs), although prolactin (Prl) and growth hormone (GH) also have similar effects on β cells and are also elevated during pregnancy. After delivery, β cell mass returns to normal levels within 10 days via increased β cell apoptosis, decreased β cell proliferation, and β cell atrophy.

To determine the direct role of PLs on β cell mass in non-pregnant animals, transgenic mice expressing PL1 within their β cells (Rip-Pl1) were developed (Cozar-Castellano et al., 2006c). These mice exhibited hypoglycemia and improved glucose clearance due to hyperinsulinemia, which was associated with a doubling of β cell mass. This expansion of β cell mass was attributed to a 2-fold increase in β cell proliferation and a 20% increase in β cell size. Similar results were observed in transgenic mice expressing HGF within their β cells (Rip-Hgf) (Garcia-Ocana et al., 2000; Garcia-Ocana et al., 2001; Cozar-Castellano et al., 2006c). These mice also exhibited a doubling of β cell mass, but the increase in β cell proliferation was not as significant as that in Rip-Pl1 mice. Interestingly, islet number was significantly increased in Rip-Hgf mice but not in Rip-Pl1 mice versus wild-type mice, suggesting that HGF may stimulate neogenesis.

In pregnant female mice, the negative cell cycle regulator Menin normally becomes down-regulated within islets, inversely correlated with β cell proliferation (Karnik et al., 2007). β cell-specific over-expression of Menin using the Tet-on system
(RIP-rtTA, TRE-Men1) abrogates pregnancy-associated increases in β cell proliferation and β cell mass, associated with relatively increased levels of p18\textsuperscript{INK4c} and p27\textsuperscript{Kip1}.

Diet-induced obesity results in insulin resistance and β cell mass expansion in humans and mice. The C57Bl/6 mouse strain is notoriously susceptible to these effects, exhibiting a 2.2-fold increase in β cell mass and proliferation after four months on a high-fat diet versus a control diet (Sone and Kagawa, 2005). However, these mice eventually become diabetic and lose their β cell mass due to increased β cell apoptosis and reduced β cell proliferation.

In genetic models of obesity and insulin resistance, there is also a compensatory expansion of β cell mass. For example, db/db mice, which lack a functional leptin receptor, exhibit a 2-fold increase in β cell mass by 8 weeks of age (Wang and Brubaker, 2002). This timepoint correlates with the onset of diabetes, which progresses from glucose intolerance that is first observed between 4-6 weeks of age. A similar rat model, the Zucker diabetic fatty (ZDF) rat (fa/fa), also has a homozygous mutation in the gene encoding the leptin receptor. ZDF rats exhibit increased β cell mass and increased β cell proliferation prior to the onset of diabetes, but increased β cell apoptosis prevents them from adequately expanding their β cell mass after the onset of diabetes, despite continued high rates of β cell proliferation (Pick et al., 1998). This phenotype contrasts with what is observed in non-diabetic Zucker fatty (ZF) rats, which possess the same mutation as ZDF rats and also become obese and insulin resistant but do not develop diabetes due to sufficient β cell mass expansion via increased β cell proliferation, neogenesis, and hypertrophy (Pick et al., 1998).
Another model of insufficient β cell mass expansion is the insulin receptor substrate 2 null mouse (Irs2\(^{-/-}\)) (Kubota et al., 2004). Global inactivation of Irs2 results in severe insulin resistance, both centrally in the brain causing obesity, and peripherally, for which β cell mass expansion should be able to compensate. However, because β cells require Irs2 for proper proliferation and function, Irs2\(^{-/-}\) mice are unable to expand their β cell mass, and they develop diabetes by 10 weeks of age. This phenotype is not observed in Irs1\(^{-/-}\) mice, despite the fact that these mice exhibit similar insulin resistance, because Irs1 is not required for β cell mass expansion. Deletion of Irs2 specifically within β cells and the hypothalamus (Irs2\(^{\text{floxed/floxed}}\);Rip-Cre) causes central insulin resistance and obesity, with glucose intolerance developing at 8 weeks of age but without progression to diabetes, likely due to the lack of peripheral insulin resistance (Kubota et al., 2004). These mice also exhibit reduced β cell proliferation and β cell mass at 8 weeks of age, although these impairments are not observed before the onset of insulin resistance (between 4 and 8 weeks). These experiments provide additional evidence that Irs2 is required for β cell mass expansion in response to insulin resistance. Furthermore, over expression of Irs2 in β cells (Rip-Irs2) is sufficient to prevent β cell failure in diet-induced obesity and streptozotocin-induced diabetic models (Hennige et al., 2003).

Several downstream effectors of the insulin signaling pathway have been shown to play a role in β cell mass expansion in models of insulin resistance. For example, haploinsufficiency of FoxO1 (Foxo1\(^{+/\}}\)) restores β cell mass and proliferation to nearly normal levels in Irs2\(^{\text{floxed/floxed}}\) mice, possibly due to reduced FoxO1-mediated repression of Pdx1 (Kitamura et al., 2002). In contrast, expression of constitutively-nuclear FoxO1 prevents β cell mass expansion in two other models of insulin resistance (Okamoto et al., 2006).
Therapeutic Implications

In understanding how β cell mass is developed, maintained, and manipulated, we seek to better understand diabetes etiology, identify new and optimal therapeutic targets, and develop new therapeutic techniques. Out of necessity, much of the work in this field has been and is being performed in lower mammals, and thus much of it must still be confirmed in humans. Furthermore, outside fields, such as gene therapy and immunology, must make substantial progress before some clinical interventions can be feasible. However, there remains great optimism regarding the future ability to manipulate β cell differentiation and proliferation in vitro to provide an unlimited supply of β cells for transplantation into patients with diabetes. Although studies in this area have revealed that it is difficult to achieve full differentiation and maturation of β cells, which is essential for clinical application, techniques are continuously being improved. Tumor formation, either from ES cell-derived cells or from induction of β cell proliferation which may induce transient de-differentiation, is another concern that must be considered. Ultimately, however, the processes of β cell differentiation and proliferation will likely one day be controlled in vivo as a means to treat or prevent diabetes.

Forkhead Box M1 (FoxM1)

Identification of FoxM1

FoxM1 is a member of the forkhead box family of transcription factors, so named for their relation to the Drosophila melanogaster gene fork head (fkh). Mutation of fkh
results in formation of ectopic head structures in place of the foregut and hindgut (Weigel et al., 1989). The first mammalian homologue of fkh to be identified was Hepatocyte nuclear factor 3α (Hnf3α), which binds to and activates transcription of the liver-specific genes Transferrin (TTR) and α1-antitrypsin (Costa et al., 1989; Lai et al., 1990). Hnf3α and fkh were found to share significant sequence similarity within their DNA binding domain, which was termed a “fork head domain” (Weigel and Jäckle, 1990).

Two related mammalian gene products were then identified in the liver and were termed Hnf3β and Hnf3γ, the first evidence of a family of forkhead proteins (Lai et al., 1990; Lai et al., 1991). Structural analysis of Hnf3γ’s forkhead domain bound to DNA revealed a variation on the helix-turn-helix motif, with three α-helices (H1-3), three β-sheets (S1-3), and two loops (W1-2) (Clark et al., 1993) (Figure 5). As the loops resemble wings attached to a helical core, the DNA binding domain was termed a “winged-helix” domain.

Protein sequence comparisons revealed that Drosophila forkhead most closely resembles Hnf3β, with 91% identity (100/110 amino acids) within the DNA binding domain (Lai et al., 1991). Expression pattern comparisons between the two proteins also revealed high similarity, suggesting that Hnf3β is the true mammalian orthologue of Drosophila forkhead (Monaghan et al., 1993). Since this time, more than 100 forkhead family members have been identified in species ranging from yeast to humans (reviewed in Kaufman and Knochel 1996), and due to their diverse means of discovery a unified nomenclature was devised (Kaestner et al., 2000). Currently, there are 44 murine forkhead family members, organized into 19 (A-S) phylogenetic subclasses (Tuteja and Kaestner, 2007a; Tuteja and Kaestner, 2007b; Montelius et al., 2007).
Figure 5. Winged-helix “forkhead” DNA binding domain structure. The characteristic forkhead DNA binding domain is a variation of the helix-turn-helix motif, with three α-helices (H1-3), three β-sheets (S1-3), and two loops (W1-2).
FoxM1 was originally identified as an M phase phosphoprotein (MPP) by its interaction with the Mitotic protein monoclonal antibody MPM2 (Westendorf et al., 1994). This antibody recognizes several phosphorylated epitopes, including F-phosphoT-P-L-Q. At that time, FoxM1 was referred to as MPP2. Soon thereafter, FoxM1 was simultaneously cloned by three groups looking for new forkhead family members, who assigned the names of Trident (Korver et al., 1997a), Winged helix in INS-1 cells (WIN) (Yao et al., 1997), and HNF3/forkhead homolog 11 (HFH11) (Ye et al., 1997).

Trident was cloned from murine thymus and was found by northern blot analysis to be expressed broadly within the brain, heart, lung, liver, kidney, and limb of embryos but only within the thymus in 6 week old mice (Korver et al., 1997a). Trident expression was also observed within multiple cell lines, and this expression was reduced upon serum starvation and stimulated upon serum return, coinciding with initiation of S phase. The DNA binding domain consensus site for Trident was identified as TAAACA.

WIN was cloned from the rat insulinoma cell line INS-1 and was found by northern blot analysis to be expressed in multiple rodent endocrine cell lines, as well as embryonic and neonatal, but not adult, pancreas and liver (Yao et al., 1997). Evaluation of e12, e14, e18, neonatal, and adult whole pancreas revealed a progressive decline in WIN expression. Furthermore, WIN expression was detected within the testis and to a lesser extent the lung of adult mice, but not within brain, heart, liver, kidney, spleen, or skeletal muscle; and within the testis and thymus of adult humans, but not within stomach, intestine, pancreas, thyroid, adrenal cortex, adrenal medulla, or the human hepatoma cell line HepG2. Importantly, Yao et al. identified three splice variants of human WIN, which they termed classes a, b, and c (Figure 6), and they found that these
Figure 6. Human FOXM1 and mouse Foxm1 cDNA structures. Foxm1 introns and exons are depicted in the diagram as lines and boxes, respectively. The human FOXM1 cDNA contains two alternatively-spliced exons, producing three transcript variants. Although there exists conflicting variant nomenclature within the literature, the NCBI denotes these transcript variants as 1, 2, and 3, and we refer to them as a, b, and c, respectively, in accordance with Yao et al. (1997). Mouse Foxm1 is most homologous to human FOXM1b.
variants were differentially expressed. Because these variants are derived by alternative splicing of two exons that encode portions of the DNA binding and transcription activation domains (Figure 7), it was suggested that they may have different transcriptional activities and targets. The consensus binding site for WIN was identified as AGATTGAGTA.

HFH11 was cloned from the human colon carcinoma cell line Caco-2, and it was found by northern blot analysis to be expressed in multiple human carcinoma cell lines including HeLa (cervical carcinoma), A549, and H441 (both pulmonary adenocarcinoma) (Ye et al., 1997). Interestingly, HFH11 expression was observed within HepG2 cells, in contrast to observations made by the group that identified WIN (Yao et al., 1997). Further northern blot analysis revealed that HFH11 was expressed at high levels in adult human thymus, testis, and intestine (small and large), and to a lesser extent in ovary, lung, heart, and placenta. Only two splice variants of HFH11 were identified by this group, and they were termed HFH11A and HFH11B. As HFH11A is the full-length transcript (encoding a 801-amino-acid protein), and HFH11B is missing two exons (encoding a 748-amino-acid protein), these variants are analogous to the human WIN class a and c variants (Yao et al., 1997). The consensus binding site for HFH11 was identified as TACGTTGTTATTTGTTTTTTTCG.

FoxM1 Gene and Protein

FOXM1A has been shown to have little, if any, transcriptional activity, while FOXM1B and FOXM1C, along with murine FoxM1, which is most homologous to FOXM1B, are transcriptional activators (Ye et al., 1997; Leung et al., 2001; Ma et al.,
Figure 7. FoxM1 protein structure. This diagram depicts the domains and phosphorylation sites present within both mouse FoxM1 and human FOXM1, with the appropriate corresponding coding exons. The N-terminal domain is encoded by exon 2 and part of exon 3, and it contains two destruction boxes (D-box), as well as a KEN box, all of which are required for FoxM1 degradation. The DNA binding domain (DBD) is encoded by part of exon 3 and exons 4-6. As exon 6 is alternatively-spliced in humans, this may result in the transcript variants having different targets. The C-terminal transcription activation domain (TAD) is encoded by exons 7-10 (or 7 and 8 in the mouse). The presence of the alternatively-spliced exon 9 within transcript variant 1 (FOXM1a) accounts for the different activity observed in FOXM1A versus the B and C isoforms. FoxM1 is phosphorylated by ERK1/2 at a serine residue near the nuclear localization signal (NLS), as well as in the TAD near a protein interaction (LXL) sequence. Several Cdk phosphorylation sites are also located within the TAD.
The lack of FOXM1A transcriptional activity is due to the presence of an additional exon (6 or A2) within the C-terminal transcription activation domain, which interferes with its activity (Ye et al., 1997). Interestingly, FOXM1A is also expressed at much lower levels than are either FOXM1B or FOXM1C in many tissues (Yao et al., 1997). Additionally, FOXM1c has been shown to be the predominant transcript found in human fibroblast cell lines (Ma et al., 2005). Murine FoxM1 and human FOXM1B share 78% amino acid sequence identity and 86% sequence similarity.

FoxM1 is the only isoform within the M subclass of Fox proteins, and beyond the characteristic forkhead or winged-helix DNA binding domain, it does not share homology with other proteins. Based on amino acid sequence analysis, FoxM1 is most closely related to the P and O Fox subclasses, in both mouse and human (Figures 8, 9).

**Transcriptional Regulation of Foxm1**

Currently, little is known regarding transcriptional regulation of Foxm1. The same group that cloned Trident published the only FOXM1 promoter analysis to date (Korver et al., 1997b). This group reported that a 0.3 kb (-296 to +60 bp) fragment of the FOXM1 promoter was activated during S-phase compared to G0, and that fragments extending to -437 bp, -1411 bp, and -2436 bp upstream of the transcription start site also exhibited activation but to a lesser extent. Furthermore, they identified a putative E-box at -49 to -44 bp but did not find a TATA box. Teh et al. identified FOXM1 as a downstream target of Sonic hedgehog (SHH) and Gli1 signaling, and although a direct transcriptional link was not established, a putative Gli response element was identified at
Figure 8. NCBI BLAST Tree for mouse FoxM1 protein. The basic local alignment search tool (BLAST) on the National Center for Biotechnology Information (NCBI) website was queried for the murine FoxM1 protein sequence (NP_032047.4) against the mouse refseq_protein database using pairwise alignment. The results are displayed in a rectangular arrangement, and they depict the relative sequence similarities between FoxM1 and other murine proteins. (rid7WT536TT012, performed on July 16, 2008)
Figure 9. NCBI BLAST Tree for human FOXM1 protein. The BLAST tool on the NCBI website was queried for the human FOXM1 protein sequence (NP_973731) against the human refseq_protein database using pairwise alignment. The results are displayed in a rectangular arrangement, and they depict the relative sequence similarities between FOXM1 and other human proteins. (rid7WTMNA35015, performed on July 16, 2008)
-230 bp upstream of the transcription start site within the FOXM1 promoter (Teh et al., 2002).

**Post-translational Regulation of FoxM1**

FoxM1 is larger than most Fox proteins (predicted molecular weight is 83.3 kDa), and it contains unique domains and phosphorylation sites, primarily within the C-terminal transactivation domain, many of which have not yet been fully-characterized (Figure 7). These include multiple serine/threonine phosphorylation sites for Cdk/Cyclin complexes and Mitogen-activated protein kinases (MAPKs). A nuclear localization signal (NLS) is located near the DNA binding domain, and it has been shown that serine phosphorylation of FOXM1B by ERK1/2 near the NLS may mediate its nuclear localization and enhanced activity in response to MAPK signaling (Ma et al., 2005). Importantly, activity of FOXM1C was not enhanced in response to MAPK signaling, as this isoform lacks the phosphorylation site due to alternative splicing of exon 6. An additional ERK1/2 serine phosphorylation site is located within the C terminus of FoxM1 near a Cdk/Cyclin complex interaction domain, and mutation of this residue impairs FoxM1 activity, possibly by interfering with this important protein-protein interaction. The domain by which FoxM1 interacts with Cdk/Cyclin complexes contains an LXL sequence, which is required for binding (Major et al., 2004). Once bound to FoxM1, Cdns (specifically Cdk2 complexed with Cyclin E and Cdk1 complexed with Cyclin B) can phosphorylate specific serine/threonine residues within the transcription activation domain, which is required for recruitment of the p300/CREB-binding protein (CBP) transcriptional coactivators and for FoxM1 transcriptional activity. As Cdk2/Cyclin E are present during
the G$_1$/S transition and Cdk1/Cyclin B are present during the G$_2$/M transition (Dzau et al., 2002), FoxM1 phosphorylation is maintained as the cell progresses through the cell cycle. Interestingly, the Cdk inhibitor p27$^{Kip1}$ can be found in the Cdk/Cyclin/FoxM1 complex, where it indirectly inhibits FoxM1 transcriptional activity, likely by reducing Cdk-mediated phosphorylation of FoxM1 (Kalinichenko et al., 2004). FoxM1 is also inhibited by the tumor suppressor p19$^{ARF}$, which binds to FoxM1 via a 19 amino acid sequence (p19$^{ARF26-44}$). Indeed, this peptide alone can inhibit FoxM1 activity both \textit{in vitro} and \textit{in vivo}, due at least in part to its ability to target FoxM1 to the nucleolus (Kalinichenko et al., 2004; Gusarova et al., 2007). In addition, FoxM1 has been shown to interact with the Rb protein, particularly during G$_1$, but hyper-phosphorylation of Rb disrupts this interaction (Major et al., 2004), suggesting the FoxM1 may be negatively regulated by Rb. This hypothesis is supported by the finding that over-expression of the human papilloma virus type 16 E7 protein, which inhibits Rb and targets it for degradation in addition to binding to FoxM1 directly, enhanced FoxM1 activity in a reporter assay (Luscher-Firzlaff et al., 1999).

FoxM1 is also negatively regulated by proteosome-mediated degradation (Park HJ et al., 2008a). During late mitosis and early G$_1$, FoxM1 is found in a complex with the \textit{Anaphase-promoting complex/cyclosome} (APC/C) E3 ubiquitin ligase and its adaptor Cdc20 homolog 1 (Cdh1). The N terminus of FoxM1 contains two “destruction” sequences (D-boxes; RXXL) and a KEN sequence (KEN box), which interact with Cdh1 and are required for FoxM1 degradation. Such negative regulation of FoxM1 is necessary in order to prevent inappropriate re-entry into S phase.
There is also evidence that the N terminus of FoxM1 acts as an auto-inhibitory domain by interacting with the C-terminal transactivation domain (Park HJ et al., 2008b; Laoukili et al., 2008). Deletion of the N terminal domain (amino acids 1-232) resulted in prolonged and increased transcriptional activity, even in the absence of MAPK signaling or Cdk/Cyclin complex binding. However, activated Cdk/Cyclin complexes disrupted the interaction between the N and C termini. These results suggest that phosphorylation of the C terminus by Cdk/Cyclin complexes releases the C-terminal transactivation domain from autoinhibition, providing a possible mechanism by which FoxM1 is kept inactive during initiation of the G1/S transition.

**FoxM1 Targets**

Once within the nucleus and properly activated, FoxM1 drives transcription of various genes that coordinate the G1/S and G2/M transitions, as well as karyokinesis and cytokinesis (Figure 10) (Costa, 2005; Laoukili et al., 2007). During the G1/S transition, the pocket proteins Rb, p107, and p130 are phosphorylated by Cdk4 and Cdk6, both of which must bind D-type Cyclins in order to be active (Massague, 2004). Phosphorylation of the pocket proteins causes dissociation from the E2F transcription factor, allowing E2F to activate transcription of S phase-promoting genes, including *Cyclin E*. Cyclin E complexes with Cdk2, which is required for hyperphosphorylation of Rb. As mentioned before, Rb hyperphosphorylation disrupts its interaction with FoxM1, likely releasing FoxM1 from inhibition. In agreement with this theory, during the G1/S transition, FoxM1 is required for transcription of *Cell division cycle 25 homolog A* (Cdc25A), which dephosphorylates and activates Cdk2 (Wang et al., 2005). Cdk2 not only
Figure 10. FoxM1 transcriptional targets are involved in cell cycle regulation. This diagram depicts key cell cycle regulators. Transcription factors, including FoxM1, are shown in green, Cyclins are shown in purple, Cdns are shown in orange, cell cycle inhibitors are shown in red, and FoxM1 transcriptional targets are shown in yellow. FoxM1 targets regulate the G₁/S transition, G₂/M transition, karyokinesis, and cytokinesis. Proteins that have been shown to play an important role in β cell proliferation are designated with an asterisk (*). Figure is adapted from Wang et al. (2005).
hyperphosphorylates Rb but also phosphorylates the Cdk inhibitor (CDKI) proteins p21\textsuperscript{Cip1} and p27\textsuperscript{Kip1}, targeting them for recognition by the Skp1-Cullin1-F box (SCF) ubiquitin ligase complex, which initiates their proteosome-mediated degradation (Sheaff \textit{et al.}, 1997; Carrano \textit{et al.}, 1999; Montagnoli \textit{et al.}, 1999; Bornstein \textit{et al.}, 2003). The SCF ubiquitin ligase complex is composed of three proteins, two of which, Skp2 and Cdk subunit 1 (Cks1), confer substrate specificity to the SCF complex and are direct transcriptional targets of FoxM1 (Wang \textit{et al.}, 2005). FoxM1 also indirectly regulates p27\textsuperscript{Kip1} via direct transcriptional activation of Kinase interacting stathmin (Kis), a nuclear kinase that phosphorylates p27\textsuperscript{Kip1} and promotes its nuclear export (Petrovic \textit{et al.}, 2008). There is conflicting evidence regarding whether FoxM1 activates Cyclin D1 expression (Leung \textit{et al.}, 2001; Wang \textit{et al.}, 2001). Therefore, it is unclear whether initiation of the G\textsubscript{1}/S transition involves FoxM1; however, progression into S phase does require FoxM1.

During the G\textsubscript{2}/M transition, FoxM1 directly activates transcription of Cdc25B, which dephosphorylates and activates Cdk1 (Wang \textit{et al.}, 2005). Cdk1 activity also depends on its binding to Cyclin B1, another direct transcriptional target of FoxM1 (Leung \textit{et al.}, 2001; Wang \textit{et al.}, 2005). The Cdk1/Cyclin B1 complex was previously referred to as the M-phase promoting factor (MPF) (Fung and Poon, 2005), and as discussed, this complex phosphorylates and activates FoxM1 (Major \textit{et al.}, 2004), thus forming a positive feedback loop. FoxM1 also directly activates transcription of Polo-like kinase 1 (Plk1), Aurora B kinase, Centromere protein A (Cenp-A), Cenp-B, Cenp-F, and Survivin (Birc5) (Laoukili \textit{et al.}, 2005; Wang \textit{et al.}, 2005). Plk1 is necessary for centrosome duplication and, with Aurora B kinase, mediates attachment of the microtubule spindles to kinetochores (Barr \textit{et al.}, 2004). Plk1 also phosphorylates and
activates Cdc25C, which dephosphorylates and activates Cdk1. Survivin regulates Aurora B kinase centromere localization, while Cenp-A, Cenp-B, and Cenp-F are involved in kinetochore assembly and chromosome segregation (Howman et al., 2000; Laoukili et al., 2005). FoxM1 also activates transcription of the proliferation-associated genes C-myc, C-fos, Hsp70, and Histone H2B/a (Wierstra and Alves, 2006; Wierstra and Alves, 2008).

Other transcriptional targets of FoxM1 that are not directly involved in cell cycle regulation include Estrogen receptor α (ERα) (Madureira et al., 2006), Laminin α4 (Lama4) (Kim et al., 2005), and c-Jun N-terminal kinase 1 (Jnk1) (Wang et al., 2008a). Madureira et al. found that FOXM1 expression correlated with ERα expression in breast cancer cell lines and that FOXM1 activated the ERα promoter in reporter assays (Madureira et al., 2006). In addition, they found that FOXM1 directly bound to forkhead response elements (FHREs) within the proximal region of the ERα promoter in vivo. Interestingly, FOXM1 was found to interact in vivo with FOXO3a, a previously-identified transcriptional activator of ERα. However, Laoukili et al. found that over-expression of FoxO3a could not rescue expression of Plk1, Cyclin B1, or Cenp-F in Foxm1−/− mouse embryonic fibroblasts (MEFs) (Laoukili et al., 2005).

Kim et al. found that mice with a global deletion of FoxM1 (Foxm1−/−) exhibit defects in development of the pulmonary vasculature (Kim et al., 2005). They attributed these defects to, among other things, alterations in TGF-β signaling and laminin expression. In particular, they found that FoxM1 activated the Lama4 promoter in reporter assays, identified two putative FoxM1 binding sites within the Lama4 promoter, and determined that endogenous FoxM1 could bind to the Lama4 promoter.
Wang et al. found that FoxM1 directly activates transcription of Jnk1 in the osteosarcoma cell line U2OS (Wang et al., 2008a). Activation/phosphorylation of Jnk1 is associated with many cellular processes, including proliferation, due to the variety of transcription factors that it phosphorylates. Interestingly, Wang et al. found that overexpression of Jnk1 in Foxm1-depleted U2OS cells rescued the cells from G1/S, but not G2/M, blockade. Furthermore, they found that Jnk1 was required downstream of FoxM1 for anchorage-independent growth, migration, and invasion of U2OS cells in vitro, at least partially via expression of matrix metalloproteinases (MMPs) 2 and 9. Thus, FoxM1 may play roles in other cellular processes in addition to proliferation.

**FoxM1 Null Mice**

As previously discussed, FoxM1 is broadly expressed during embryogenesis and is restricted to tissues with high rates of cell turnover in the adult, in accordance with its role in regulating cell proliferation. Two groups have generated mice with global disruption of the Foxm1 allele (Korver et al., 1998; Krupczak-Hollis et al., 2004). Korver et al. generated mice with targeted insertion of a *Phosphoglycerate kinase (PGK)*-Neomycin resistance (Neo) cassette into the fourth exon of Foxm1 (Foxm1Neo), which codes for the DNA binding domain (Figure 11A). In contrast, Krupczak-Hollis et al. generated mice with deletion of exons 4-8, which code for the DNA binding and transactivation domains (Figure 12A). These mice were generated by crossing mice with loxP sequences inserted into the third intron and the 3’ UTR of the Foxm1 locus to mice expressing a ubiquitous Cre recombinase (E2A-Cre). Cre-mediated recombination of the floxed Foxm1 alleles within the germline allowed for propagation of a mouse line with a
Figure 11. *Foxm1*<sub>Neo/Neo</sub> mice. (A) A FoxM1 hypomorph was generated by inserting a PGK-Neo cassette into exon 4, which codes for the DNA binding domain. (B) These mice exhibit variable neonatal lethality and polyploid hepatocytes and cardiomyocytes. A DAPI-labeled section from a neonatal *Foxm1*<sup>Neo/+</sup> heart is shown on the left, and from a *Foxm1*<sup>Neo/Neo</sup> heart on the right. Figure is adapted from Korver *et al.* (1998).
**Figure 12. Foxm1<sup>+/−</sup> mice.** (A) A Foxm1<sup>flox</sup> allele was generated by inserting loxP sequences within the third intron and in the 3’ untranslated region, flanking a PGK-Neo cassette. Deletion of the sequence between the loxP sites is accomplished by Cre recombinase driven by either a global (EIIA) or hepatoblast-specific (AFP) promoter. Deletion of the floxed region of Foxm1 results in a null allele. (B) Global Foxm1<sup>+/−</sup> mice exhibit embryonic lethality with edema and hemorrhaging. Shown here are e17.5 embryos. Figure is adapted from Krupczsk-Hollis et al. (2004).
global functionally null *Foxm1* allele (*Foxm1*\(^{null}\)). Comparison of these two lines suggests that the *Foxm1*\(^{Neo}\) allele acts as a hypomorph, rather than as a true null.

Surprisingly, global deletion of *Foxm1* in mice (*Foxm1*\(^{-/-}\)) does not have catastrophic results, as gross embryological morphology is unaffected (Figure 12B) (Krupczak-Hollis *et al.*, 2004). However, *Foxm1* deletion does cause late embryonic lethality (between e13.5 and e18.5) due to hepatic and cardiac defects, with severe edema and hemorrhaging. These embryos exhibited significant reductions in hepatoblast proliferation and number, but gross liver size was unchanged due to hepatoblast hypertrophy. Part of the hypertrophic phenotype can be explained by the presence of polyploid hepatoblasts. Polyploid cardiomyocytes were also observed (Figure 11B) (Korver *et al.*, 1998), which was likely due to endoreduplication (DNA synthesis without subsequent cytokinesis) (Wonsey and Follettie, 2005). Furthermore, *Foxm1*\(^{-/-}\) embryos displayed reduced proliferation of mesenchymal and vascular smooth muscle cells and defective vasculogenesis within the lungs due to impaired differentiation of mesenchymal cells into endothelial cells (Kim *et al.*, 2005), in addition to defects in development of intra-hepatic biliary ducts, hepatic vessels, hepatic sinusoids, and the gall bladder (Krupczak-Hollis *et al.*, 2004).

Consistent with the proliferation and polyploid phenotypes observed in *Foxm1*\(^{-/-}\) embryos, MEFs collected from these embryos exhibited delayed entry into G\(_2\), and those cells that did enter mitosis exhibited inappropriate chromosome segregation, resulting in frequent aneuploidy and mitotic failure (Laoukili *et al.*, 2005). These findings were associated with reduced expression of Cyclin A2, Cyclin B1, Cyclin B2, Plk1, Aurora B kinase, Cdc25B, and Cenp-F in *Foxm1*\(^{-/-}\) MEFs compared to wild-type (WT) MEFs.
Mouse Models of Altered FoxM1 Expression in the Liver

Early deletion of Foxm1 specifically within hepatoblasts using a Cre-lox system with an α-fetoprotein (Afp) enhancer driving Cre recombinase expression (Foxm1<sup>flox/flox</sup>; Afp-Cre) yielded similar lethality as observed in global Foxm1 null embryos, suggesting that the liver defects in the Foxm1<sup>−/−</sup> embryos were responsible for the lethal phenotype (Krupczak-Hollis et al., 2004). Additionally, these embryos exhibited polyploid hepatoblasts and impaired development of intra-hepatic biliary ducts. However, hepatoblast proliferation and number were less-dramatically reduced in these embryos than in Foxm1<sup>−/−</sup> embryos, suggesting that Foxm1 deletion is incomplete in the Foxm1<sup>flox/flox</sup>; Afp-Cre mouse model. Thus, FoxM1 is necessary for proliferation of hepatoblasts, which are bipotential cells that can differentiate into hepatocytes or biliary epithelial cells.

FoxM1 is also required for proliferation of adult hepatocytes, evidenced by Foxm1<sup>flox/flox</sup>; Albumin-Cre mice, which develop normally but exhibit significant reductions in hepatocyte proliferation and liver regeneration following partial hepatectomy (PHx) (Wang et al., 2002a). These mice also displayed hepatocyte hypertrophy following PHx, which compensated for the reduced amounts of proliferation, resulting in regeneration of gross liver size similar to that of Foxm1<sup>flox/flox</sup> Control mice. These findings were associated with increased nuclear p21<sup>Cip1</sup> expression, reduced expression of Cdc25A, Cdc25B, and Cyclin B1, and reduced hyperphosphorylation of Rb, but no changes in Cyclin D (<i>Ccnd</i>) or Cyclin E (<i>Ccne</i>) transcripts.

As FoxM1 is required for proliferation in some cell types and is highly-expressed in embryonic cells and most, if not all, cancer cell lines studied to date, several groups
have induced transgenic over-expression of FOXM1 in order to study its role in aging and cellular transformation. Ye et al. found that transgenic liver-specific over-expression of FOXM1c (TTR-FOXM1c) accelerated hepatocyte proliferation following PHx (Ye et al., 1999). However, the peak amount of hepatocyte proliferation was similar to that observed in WT, and hepatocyte proliferation under normal conditions was not affected by over-expression of FOXM1c, likely due to the fact that FOXM1 remained localized to the cytoplasm unless stimulated by PHx. These data are consistent with post-translational modification of FoxM1 being required for nuclear localization, and they suggest that the amount of endogenous FoxM1 limits the timeframe in which replication can occur, as increasing the expression of FoxM1 allowed for earlier nuclear localization and proliferation. Interestingly, Wang et al. found that over-expression of FOXM1c, either by transgenic (TTR-FOXM1c) or adenoviral (Ad-FOXM1c) means, reversed the normal age-related decrease in hepatocyte proliferation (Wang et al., 2001; Wang et al., 2002b). Using either means of FOXM1C over-expression, this group observed an increase in the absolute amount of proliferation in old (12 month old) mice following PHx to levels similar to those observed in young (2 month old) mice after the operation. Likewise, treatment with human GH (hGH), alone or in conjunction with PHx, induced FoxM1 expression and stimulated hepatocyte proliferation in old mice to levels comparable to those observed in young, untreated mice (Krupczak-Hollis et al., 2003). Interestingly, even without the stimulus of PHx, treatment with hGH dramatically stimulated hepatocyte proliferation to a similar extent in young and old mice, in comparison to untreated mice. Importantly, such results were not observed in mice with hepatocyte-specific deletion of Foxm1 (Foxm1floxflox;Albumin-Cre), indicating that
FoxM1 acts downstream of the GH signaling pathway to mediate hepatocyte proliferation.

Importantly, over-expression of FOXM1C within the liver (TTR-FOX1c) was not found to be associated with hepatocellular carcinoma (HCC) progression, but was associated with increased proliferation of pre-neoplastic and early neoplastic lesions induced by diethylnitrosamine/phenobarbital (DEN/PB), resulting in increased size of these lesions (Kalinina et al., 2003). However, FoxM1 was required for formation of hepatic adenomas and HCC, as Foxm1floxflox;Albumin-Cre mice exhibited no tumor formation, associated with reduced hepatocyte proliferation but increased hepatocyte size (hypertrophy), in response to DEN/PB treatment in comparison to Foxm1floxflox Control mice. These results suggest that FoxM1 is necessary but not sufficient for initiation and progression of HCC (Kalinichenko et al., 2004).

Mouse Models of Altered FoxM1 Expression in the Lung

FoxM1 has also been shown to play an important role within the lung. Kalinichenko et al. exposed transgenic mice that ubiquitously over-expressed FOXM1C driven by a fragment of the reverse orientation splice acceptor (Rosa) 26 promoter (Rosa26-FOX1c) to butylated hydroxytoluene, a chemical known to induce lung injury that initiates within the epithelial population and then affects the endothelial and smooth muscle cells (Kalinichenko et al., 2003). After exposure, these mice exhibited accelerated and enhanced proliferation of all of these cell types within the lungs in comparison to WT mice, and these changes were associated with earlier nuclear
localization of FoxM1, increased expression of Cyclin A2, Cyclin B1, Cyclin E, Cyclin F, and Cdk1, and decreased expression of p21\textsuperscript{Cip1}.

As discussed before, endothelial cell differentiation and smooth muscle cell proliferation were impaired within the lungs of global Foxml\textsuperscript{−/−} embryos (Kim \textit{et al.}, 2005). However, these embryos died prior to the normal timepoint of completion of pulmonary vasculogenesis. Thus, mice with endothelial cell-specific deletion of Foxml (Foxml\textsuperscript{flox/flox};Tie2-Cre) were used to study the role of FoxM1 in mature endothelial cells (Zhao \textit{et al.}, 2006). These mice displayed no phenotype at baseline, indicating that FoxM1 is not required for normal endothelial cell turnover. However, when these mice were injected with lipopolysaccharide (LPS), a potent mediator of inflammation that induces microvascular injury within the lungs, they exhibited reduced endothelial cell proliferation, impaired endothelial barrier repair, increased vascular permeability, and increased mortality. These findings were associated with reduced expression of Cyclin B1 and Cdc25C, as well as increased expression of p27\textsuperscript{Kip1}. Additionally, LPS injection into WT mice resulted in a significant increase in Foxml expression within the lungs, indicating that FoxM1 is normally up-regulated following microvascular injury and that this up-regulation is necessary for normal microvascular repair.

FoxM1 has also been shown to play an important role in lung tumorigenesis. In contrast to the results observed within the liver (Kalinina \textit{et al.}, 2003), Rosa26-FOXM1c mice exposed to the tumor-inducing combination of 3-methylcholanthrene and butylated hydroxytoluene did exhibit enhanced lung adenoma progression compared to WT mice (Wang \textit{et al.}, 2008b). The adenomas found within the lungs of Rosa26-FOXM1c mice were of greater number, size, and proliferative index than those found in WT mice after
the same treatment, and they developed more quickly. However, mice with an inducible global deletion of Foxm1 driven by the Myxovirus (influenza virus) resistance 1 promoter (Foxm1<sup>flox/flox</sup>;Mx-Cre), which is activated by exposure to Interferon (IFN) α, IFNβ, or double-stranded (ds) RNA, exhibited reduced number, size, and proliferative index of lung tumors after treatment with urethane than did Foxm1<sup>flox/flox</sup> Control mice after the same treatment (Kim et al., 2006). Additionally, urethane treatment of Foxm1<sup>flox/flox</sup> Control mice stimulated expression FoxM1 within the pulmonary epithelium, whereas FoxM1 was undetectable in untreated Foxm1<sup>flox/flox</sup> Control pulmonary epithelium. Thus, FoxM1 expression levels clearly correlate with tumor burden in the lung.

Mouse Models of Altered FoxM1 Expression in the Colon

Similar to the lungs, FoxM1 expression levels within the colon also correlate with tumor burden. Over-expression of FOXM1C in Rosa26-FOXM1c mice exacerbated tumor development and progression in response to the carcinogen azoxymethane and dextran sodium sulfate (Yoshida et al., 2007). These mice developed larger and more invasive tumors in greater number than those found in WT mice after the same treatment, associated with increased proliferation specifically within neoplastic lesions. Alternatively, mice with gut-specific deletion of Foxm1 (Foxm1<sup>flox/flox</sup>;Villin-Cre) exhibited reduced tumor development and growth after the same treatment versus Foxm1<sup>flox/flox</sup> Control mice. The neoplastic lesions that did develop in Foxm1<sup>flox/flox</sup>;Villin-Cre mice exhibited reduced proliferation and never became invasive. Both mouse models (Rosa26-FOXM1c and Foxm1<sup>flox/flox</sup>;Villin-Cre) exhibited alterations in expression of the FoxM1 targets Cyclin B1 and Survivin, as well as Cyclin A2.
Mouse Model of Altered FoxM1 Expression in the Prostate

Transgenic FOXM1C over-expression in Rosa26-FOXM1c mice also accelerated the progression of prostate carcinoma initiated in two mouse models of prostate cancer (Kalin et al., 2006). Transgenic (Tg) adenocarcinoma of the mouse prostate (TRAMP) mice express the SV40 virus large T and small t tumor antigen oncoproteins in prostate epithelial cells, driven by the Probasin promoter. These proteins inactivate the tumor suppressors Rb and p53, resulting in hyperplasia, prostatic intraepithelial neoplasia, and invasive prostatic carcinoma. LADY mice express only the SV40 virus large T antigen oncoprotein driven by the same promoter and exhibit a similar progressive phenotype. Over-expression of FOXM1C on either the LADY or TRAMP background resulted in an increased propensity towards development of prostate carcinoma, as well as increased proliferation of prostatic cells within the carcinoma.

Mouse Models of Altered FoxM1 Expression in the Pancreas

One of the initial groups that identified FoxM1 (WIN) found it to be highly expressed in early embryonic pancreas, and to a progressively lesser extent in later embryonic and neonatal pancreas, with undetectable levels of expression in adult whole pancreas by northern blot analysis (Figure 13) (Yao et al., 1997). Our laboratory utilized immunohistochemistry to confirm these results and to demonstrate that at all timepoints, FoxM1 is more abundant in endocrine than exocrine pancreatic cells (Figure 14A-C) (Zhang H et al., 2006). Mice with a pancreas-wide deletion of Foxm1 (Foxm1^{flox/flox};Pdx1^{5.5kb-Cre}) exhibited normal pancreas development, but displayed postnatal effects of loss of FoxM1, including polyploidy of endocrine and exocrine cells,
Figure 13. FoxM1 expression within the pancreas. Northern blot analysis shows that Foxm1 (WIN) is expressed at high levels in embryonic liver and pancreas, but is expressed at a lower level in neonatal pancreas, and is undetectable in adult whole pancreas and liver. Figure is from Yao et al. (1997).
Figure 14. FoxM1 is highly expressed within the endocrine pancreas and is required for normal postnatal β cell growth and proliferation. FoxM1 protein is highly expressed within the endocrine cords (arrowheads) at e15.5 (A) and within the developing islets at e18.5 (B). At these timepoints, FoxM1 is expressed to a lesser degree in acinar (a) and ductal (arrow) tissue. At 9 weeks of age (C), FoxM1 is expressed at a low level in a subset of islet (outlined) cells, and to an even lesser extent in exocrine cells. Pancreas-wide deletion of Foxm1 in Foxm1floxflox;Pdx1^5.5kb-Cre mice resulted in reduced growth of postnatal β cell mass (D) and reduced β cell proliferation (E) as early as 4 weeks of age. Pancreas and β cell mass development during embryogenesis were not impaired. Figure is adapted from Zhang et al. (2006).
reduced β cell mass (Figure 14D), reduced islet size, decreased pancreatic insulin content and reduced β cell proliferation (Figure 14E). These β cell effects were associated with increased nuclear p27Kip1 and evidence of β cell senescence, and they resulted in a progressive diabetic phenotype specifically within male Foxm1<sup>flox/flox;Pdx1<sup>5.5kb</sup>-Cre</sup> mice. Thus, FoxM1 is required for normal postnatal growth of β cell mass and normal β cell turnover in the adult mouse.

**Therapeutic Implications of FOXM1 Modification**

As the above studies indicate, FoxM1 is involved in the processes of development, regeneration, aging, and tumorigenesis. Thus, it is a highly desirable target for clinical manipulation of these processes. However, these studies also highlight the importance of balancing FoxM1’s beneficial and detrimental effects. Aberrantly high expression of FOXM1 is associated with many human cancers, including HCC (Okabe et al., 2001), intrahepatic cholangiocarcinoma (Obama et al., 2005), colorectal carcinoma (Douard et al., 2006), basal cell carcinoma (Teh et al., 2002), infiltrating ductal breast carcinoma (Wonsey and Follettie, 2005), and anaplastic astrocytoma and glioblastoma (van den Boom et al., 2003; Liu et al., 2006). A meta-analysis approach also identified FoxM1 as being up-regulated in tumors of the bladder, cervix, kidney, ovary, testis, pancreas, prostate, small intestine, stomach, trachea, and uterus (Pilarsky et al., 2004). These data, combined with the findings that deletion of Foxm1 protects mice against various forms of cancer formation and progression makes down-regulating FOXM1 expression and/or inhibiting its activity a potential treatment for multiple human cancers.
Three potentially therapeutic inhibitors of FoxM1 that have been identified are the p19\textsuperscript{ARF26-44} peptide (Kalinichenko et al., 2004; Gusarova et al., 2007) and the thiazole antibiotics Siomycin A and thiostrepton (Radhakrishnan et al., 2006; Gartel, 2007; Kwok et al., 2008). Siomycin A and thiostrepton were identified using a high-throughput screen looking for agents that changed FoxM1 activity. In addition to inhibiting FoxM1 activity, these compounds also inhibited FoxM1 expression, as FoxM1 is involved in a positive autoregulatory loop. Importantly, both Siomycin A and thiostrepton specifically inhibited growth and stimulated apoptosis of cancer cell lines. p19\textsuperscript{ARF} is an endogenous tumor suppressor, so named for its size (19 kDa) and the fact that it is encoded by an alternative reading frame within the \textit{ARF/INK4a} locus that also encodes the CDKI p16\textsuperscript{INK4a}, reviewed in (Costa et al., 2005). p19\textsuperscript{ARF} is normally up-regulated in response to tumorigenic stimuli, and it functions to stabilize the p53 tumor suppressor and inhibit the functions of E2F, c-Myc, and FoxM1. However, p19\textsuperscript{ARF} is silenced in many human cancers. Gusarova et al. successfully administered p19\textsuperscript{ARF26-44} peptide, the portion required for its interaction with FoxM1, to mice with HCC and reduced their tumor burden, associated with reduced tumor cell proliferation, impaired angiogenesis, and increased tumor cell apoptosis (Gusarova et al., 2007). As these effects were specific to HCC areas but not adjacent normal areas, this study indicates that whole-body administration of p19\textsuperscript{ARF26-44} peptide can be used to specifically treat tumors. Additionally, these results highlight the two primary therapeutic effects of FoxM1 inhibitors: reducing proliferation of cancer cells and stimulating their apoptosis via mitotic catastrophe (Wonsey and Folletti, 2005).
Despite the concerns regarding tumorigenicity, up-regulation of FoxM1 expression or activity is of interest for enhancing tissue regeneration and preventing/reversing the aging process. In fact, FOXM1 is significantly down-regulated in a human disorder of premature aging termed Hutchinson-Gilford progeria (Ly et al., 2000), and reduced FoxM1 expression with age has been described in multiple tissues. Over-expression of FoxM1 within the liver has been shown to reverse age-associated reductions in proliferation (Wang et al., 2002a; Wang et al., 2002b), and it is likely that FoxM1 would have such an effect in other tissues as well. However, because of the complexity of FoxM1’s post-translational modifications that are required for both its nuclear localization and activation, it is clear that mere over-expression of FoxM1 is not sufficient to induce dramatic changes in cellular proliferation.

Overview and Aims of Dissertation

Previous studies in our laboratory showed that FoxM1 is highly expressed within pancreatic endocrine cells and is required for normal growth and maintenance of postnatal β cell mass via regulating postnatal β cell proliferation (Zhang H et al., 2006). However, several questions remained, which this thesis sought to address. First, Zhang et al. showed that β cell mass at birth in Foxm1\textsuperscript{flox/flox};Pdx1\textsuperscript{5.5kb-Cre} mice was comparable to that of Foxm1\textsuperscript{flox/flox} Control mice (Zhang H et al., 2006), but no analysis of β cell proliferation during embryogenesis was performed. Because other studies have shown that several of the factors that regulate β cell proliferation differ between embryonic and adult stages, it is possible that FoxM1 is not required during embryogenesis for β cell proliferation. Alternatively, FoxM1 could be required for embryonic β cell proliferation,
but neogenesis is able to compensate for this deficiency in $\text{Foxm1}^{\text{flox/flox}};\text{Pdx1}^{5.5\text{kb}-\text{Cre}}$ mice in order to generate a normal β cell mass by birth. Second, although Zhang et al. showed that $\text{Foxm1}^{\text{flox/flox}};\text{Pdx1}^{5.5\text{kb}-\text{Cre}}$ adult mice exhibited reduced β cell proliferation, it is unclear whether FoxM1 is absolutely required for β cell proliferation under all conditions, or whether only normal turnover of the β cell population relies on FoxM1. Third, because FoxM1 has been primarily described as a regulator of the cell cycle, Zhang et al. focused on analysis of β cell proliferation in $\text{Foxm1}^{\text{flox/flox}};\text{Pdx1}^{5.5\text{kb}-\text{Cre}}$ mice, but it is unclear whether the other processes that contribute to β cell mass are also affected by loss of FoxM1.

To address these questions, this thesis sought to determine whether FoxM1 regulated β cell proliferation and β cell mass during embryogenesis, following pancreatic injury, and in response to diet-induced obesity. Chapter II describes the methods used. Chapter III presents data regarding the role of FoxM1 in β cell proliferation, β cell size, and β cell neogenesis following 60% partial pancreatectomy (PPx) using $\text{Foxm1}^{\text{flox/flox}};\text{Pdx1}^{5.5\text{kb}-\text{Cre}}$ and Rosa26-FOXM1c mice. Chapter III also includes analyses of FoxM1’s role in embryonic β cell proliferation. Chapter IV presents data regarding using a high-fat diet to induce β cell mass expansion, in order to assess the role of FoxM1 in this process. This chapter also describes preliminary studies of islet function in $\text{Foxm1}^{\text{flox/flox}};\text{Pdx1}^{5.5\text{kb}-\text{Cre}}$ mice. Chapter V presents an experimental design to assess β cell lineage labeling and β cell neogenesis following 60% PPx, as well as preliminary results regarding the use of tamoxifen in this system to activate the $\text{Pdx1}^{\text{PB}-\text{Cre}}^{\text{ERT2}}$ fusion protein. Chapter VI describes the generation of a monoclonal
antibody against FoxM1. Conclusions, implications, and future directions for the studies described in this dissertation are presented in Chapter VII.
CHAPTER II

MATERIALS AND METHODS

Mice

\( \text{Foxm1}^{\text{flox/flo}} \) mice on a mixed background (129SvJ, C57Bl/6) were generously provided by Dr. Robert H. Costa (University of Illinois at Chicago) and were described by (Wang et al., 2002a). Briefly, loxP sequences were inserted within the third intron and the 3’ untranslated region (UTR) of the \( \text{Foxm1} \) allele (Figure 12A). Thus, upon recombination by the P1 phage Cre recombinase protein, exons 4-8, which encode the DNA binding and transcription activation domains, will be deleted, yielding a null allele. Of note, a PGK-Neo cassette remains within the 3’ UTR of the \( \text{Foxm1}^{\text{flo}} \) allele, flanked by an additional loxP sequence. Therefore, recombination can occur among 3 different loxP sequences, and complete recombination results in removal of exons 4-8 of \( \text{Foxm1} \) as well as the PGK-Neo cassette. For some experiments, \( \text{Foxm1}^{\text{flo}} \) mice were backcrossed for 8 generations to the C57Bl/6JBom strain (Taconic).

\( \text{Pdx1}^{5.5\text{kb-Cre}} \) mice (on a mixed ICR, CBA, C57Bl/6 background) were generously provided by Dr. Guoqiang Gu (Vanderbilt University) (Gu et al., 2002). These mice express Cre recombinase driven by a 5.5 kb region of the \( \text{Pdx1} \) promoter (between the SalI and SmaI restriction sites), which includes the endogenous \( \text{Pdx1} \) promoter (Figure 15A). This promoter region directs \( \text{Cre} \) expression throughout the endogenous \( \text{Pdx1} \) domain, including the antral stomach, rostral duodenum, and the entire pancreatic epithelium, as early as e10.5 (Gannon et al., 2001; Stoffers et al., 1999).
Figure 15. **Pdx1<sup>5.5kb-Cre</sup> transgene.** *Pdx1<sup>5.5kb-Cre</sup>* mice carry a transgene consisting of a 5.5 kb region of the *Pdx1* promoter, from the *Sal*I restriction site to the *Sma*I restriction site, placed upstream of the *Cre* coding sequence (A). X-gal staining reveals that the *Pdx1<sup>5.5kb-Cre</sup>* transgene mediates recombination of the Rosa26 reporter allele throughout the entire pancreatic epithelium as early as e11.5 (B) (arrow), as well as in the remainder of the endogenous Pdx1 expression domain, including the antral stomach and rostral duodenum (C) (pan = pancreas, st = stomach, int = intestine). All endodermally-derived cells within the pancreas underwent recombination (D) (arrows = islets, asterisks = ducts). Part A of the figure is from Gu *et al.* (2002). Parts B-D of the figure are from Zhang *et al.* (2006).
(Figure 15B-D). For some experiments, \( Pdx1^{5.5kb-Cre} \) mice were backcrossed for 8 generations to the C57Bl/6J Bom strain (Taconic).

\( Pdx1^{PB-CreER^{TM}} \) mice (on a mixed B6CBAF1 background) were generated and characterized in collaboration with Dr. Chris Wright’s laboratory (Vanderbilt University) (Zhang H et al., 2005). These mice express a Cre recombinase-Estrogen Receptor (ER) hormone binding domain fusion protein driven by a 1 kb enhancer fragment of the \( Pdx1 \) promoter (between the \( PstI \) and \( BstI \) restriction sites) and the \( Hsp68 \) minimal promoter (Figure 16A). The hormone binding domain within this fusion protein construct has a point mutation (G525R) that makes it selective for binding to tamoxifen but not to endogenous estrogen (Littlewood et al., 1995). The \( Pdx1^{PB} \) promoter drives expression of transgenes such as CreER\(^{TM}\) specifically within pancreatic endocrine cells as early as e11.5 (Gannon et al., 2000; Gannon et al., 2001; Zhang H et al., 2005).

**Rosa26-FOXM1c Tg** mice (on a mixed FVB/N, C57Bl/6 background) were generously provided by Dr. Robert H. Costa (University of Illinois at Chicago) and were described (Kalinichenko et al., 2003). These mice express a 2.7 kb region of the human \( FOXM1c \) cDNA (from the translation start site to the HindIII restriction site in the 3’ UTR) driven by a -800 bp fragment of the Rosa26 promoter (Figure 17). The construct used to generate these mice was modified from a transgene originally used for liver-specific over-expression of FOXM1C, in which a 2.7 kb region of \( FOXM1c \) cDNA was inserted into the second exon of a TTR minigene construct (Ye et al., 1999). This construct contained a mutated \( TTR \) translation start site and a 3’ SV40 polyadenylation sequence. Additionally, ~800 bp of the \( FOXM1c \) 3’ UTR were deleted from this construct, which enhanced mRNA stability.
Figure 16. *Pdx1*<sup>PB-CreER<sup>TM</sup></sup> transgene. *Pdx1*<sup>PB-CreER<sup>TM</sup></sup> mice carry a transgene consisting of a 1 kb enhancer region of the *Pdx1* promoter, from the *Pst*I restriction site to the *Bst*I restriction site (A). The CreER<sup>TM</sup> fusion protein is sequestered in the cytoplasm until binding of tamoxifen stimulates its nuclear translocation, allowing for its recombinase activity (B). Following tamoxifen injection, the *Pdx1*<sup>PB-CreER<sup>TM</sup></sup> transgene mediates recombination of the *Rosa26* reporter allele specifically within islets (C,D). Figure is adapted from Zhang et al. (2005).
Figure 17. *Rosa26-FOXM1c* transgene. *Rosa26-FOXM1c* mice carry a transgene consisting of an 800 bp region of the Rosa26 promoter driving expression of a TTR minigene with inserted *FOXM1c* cDNA. Figure is adapted from Kalinichenko et al. (2003).
Foxm1^{+/−} mice (on a mixed 129SvJ, C57Bl/6 background) were provided by Dr. Robert H. Costa (University of Illinois at Chicago) and were described by (Krupczak-Hollis et al., 2004). These mice were generated by crossing Foxm1^{fl/fl} mice with E2A-Cre mice, which ubiquitously express Cre recombinase. Progeny with germline recombination of Foxm1^{fl} were propagated to generate a line of mice with a global null Foxm1 allele (Foxm1^{−/−}).

Rosa26-LacZ reporter (R26R) mice on a C57Bl/6J background (B6.129S4-Gt[ROSA]26Sortm1Sor/J; The Jackson Laboratory) ubiquitously express β-galactosidase driven by the endogenous Rosa26 promoter after Cre-mediated excision of a floxed stop cassette 5’ of the LacZ gene (Soriano, 1999) (Figure 18).

LacZ/EGFP (Z/EG) reporter mice on a C57Bl/6J background (B6.Cg-Tg[CAG-Bgeo/GFP]21Lbe/J; The Jackson Laboratory) ubiquitously express β-galactosidase driven by a CMV enhancer/chicken β-actin promoter (Novak et al., 2000) (Figure 19). Upon Cre-mediated excision of a floxed stop cassette between the LacZ and EGFP coding regions, enhanced green fluorescent protein (EGFP) is expressed in place of β-galactosidase.

For most studies, mice were fed mouse diet 5015 (LabDiet). For diet studies, mice were fed one of three diets: rodent diet 5001 (13.5% total kcal from fat, LabDiet), mouse diet 5015 (25.3% total kcal from fat, LabDiet), or high-fat/high-carbohydrate mouse diet F3282 (58.7% total kcal from fat, Bio-Serv) beginning at 4 weeks of age, after weaning, and continuing for 5-12 weeks. All mice received food and drink ad libitum and were on a 12 hour light-dark cycle. Z/EG mice on the C57Bl/6 background had reduced viability and required additional time prior to weaning. All mouse studies were
Figure 18. *Rosa26-LacZ* reporter knock-in. *R26* mice were generated by knock-in of a floxed stop cassette (*PGK*-Neo-PolyA) upstream of a *LacZ* coding sequence into the *Rosa26* locus (A). Cre-mediated recombination of the *R26* allele removes the stop cassette (B). The *Rosa26* promoter drives ubiquitous expression, and crossing *R26* mice with mice expressing a ubiquitous Cre (*E2A-Cre*) results in ubiquitous expression of *LacZ*, as evidenced by whole-body X-gal staining (C,D). Parts A, C, and D of the figure are adapted from Soriano et al. (1999).
Figure 19. Z/EG mice. (A) The construct used to generate mice that express LacZ in the absence of Cre-mediated recombination, followed by expression of EGFP after recombination. (B) Z/EG mice ubiquitously express either LacZ or EGFP. Cre-mediated recombination of the Z/EG allele results in expression of EGFP in (C) brain, (D) eye, (E) heart, (F) lung, (G) pancreas, (H) intestine, (I) liver, and (J) ovary. Figure is adapted from Novak et al. (2000).
performed in accordance with the Vanderbilt Institutional Animal Care and Use Committee guidelines under the supervision of the Division of Animal Care.

For embryonic analyses, the morning of vaginal plug was considered e0.5.

**DNA Extraction and Genotyping**

DNA was extracted from ear-punch (adult mice), tail (late embryonic to adult mice), brain (embryos), yolk sac (embryos), or paraffinized tissue sections. Sections were deparaffinized in xylene and washed with 100% ethanol prior to extraction. All samples were digested overnight at 55ºC in Lab Tissue Buffer 68.8 (35.2 mM Tris, 2.5 mM ethylenediaminetetraacetic acid [EDTA], 2.5 mM sodium citrate, 8.8 mM ammonium sulfate, 5% [v/v] Tween-20) with 0.3 mg/ml Proteinase K and 0.3 mg/ml RNase A. Samples were then digested at 37ºC for 15 minutes and heat-inactivated at 95ºC for 10 minutes. Undigested material was removed by centrifugation at high speed (16,000 x g) for 10 minutes, and the supernatant was stored at 4ºC.

Genotyping for the *Foxm1*<sup>flox</sup> allele was performed as described in (Zhang H *et al.*, 2006) using PCR with the following primers: *Foxm1*<sup>flox</sup> forward 5’-TAG GAG ATA CAC TGT TAT AT-3’ and *Foxm1*<sup>flox</sup> reverse 5’-TGT GGG AAA ATG CTT ACA AAA G-3’, which amplify a 180 bp product for wild-type *Foxm1* and a 230 bp product for *Foxm1*<sup>flox</sup> due to insertion of a loxP sequence in the 3<sup>rd</sup> intron of *Foxm1* (Figure 10A). Each 10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each primer, 2X FailSafe PCR PreMix C (Epicenter Technologies), and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich). The following reaction conditions were used for amplification: 92ºC for 6 minutes (hot-start); 32 cycles of 92ºC for 30 seconds (denature), 48ºC for 30 seconds
(anneal), and 72°C for 1 minute (elongation); and 72°C for 6 minutes. PCR products were separated by 2% [w/v] agarose gel electrophoresis.

Genotyping for the Foxm1null allele was performed as described in (Zhang H et al., 2006) using PCR with the following primers: Foxm1null forward 5’-TAG GAG ATA CAC TGT TAT AT-3’ and Foxm1null reverse 5’-CTC ATG TAG CAT AGA GGG CTG-3’, which amplify a 510 bp product (Figure 10A). Primers for the internal control IL-2 were also included: IL-2 forward 5’-CTA GGC CAC AGA ATT GAA AGA TCT-3’ and IL-2 reverse 5’-GTA GGT GGA AAT TCT AGC ATC ATC C-3’, which amplify a 324 bp product. Each 10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each Foxm1null primer, 125 nM of each IL-2 primer, 2X FailSafe PCR PreMix C (Epicenter Technologies), and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich). The following reaction conditions were used for amplification: 92°C for 6 minutes (hot-start); 30 cycles of 92°C for 30 seconds (denature), 56°C for 30 seconds (anneal), and 72°C for 1 minute (elongation); and 72°C for 6 minutes.

Genotyping for the Cre transgene was performed as described in (Gu et al., 2002) using PCR with the following primers: Cre forward 5’-TGC CAC GAC CAA GTG ACA GC-3’ and Cre reverse 5’-CCA GGT TAC GGA TAT AGT TCA TG-3’, which amplify a 650 bp product. Primers for the internal control IL-2 were also included. Each 10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each Cre primer, 125 nM of each IL-2 primer, 10X PCR Buffer with 15 mM MgCl2 (Applied Biosystems), 200 µM dNTP mix, and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich). The following reaction conditions were used for amplification: 92°C for 6 minutes (hot-start); 32 cycles
of 92°C for 30 seconds (denature), 58°C for 30 seconds (anneal), and 72°C for 1 minute (elongation); and 72°C for 6 minutes.

Genotyping for the Rosa26-FOXM1c transgene was performed as described in (Ye et al., 1999) using PCR with the following primers: Rosa26-FOXM1c forward 5’-AAA GTC CTG GAT GCT GTC CGA G-3’ and Rosa26-FOXM1c reverse 5’-CAG ACA TGA TAA GAT ACA TTG ATG-3’, which amplify a 325 bp product. Each 10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each primer, 10X PCR Buffer with 15 mM MgCl₂ (Applied Biosystems), 200 µM dNTP mix, and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich). The following reaction conditions were used for amplification: 92°C for 6 minutes (hot-start); 32 cycles of 92°C for 30 seconds (denature), 58°C for 30 seconds (anneal), and 72°C for 1 minute (elongation); and 72°C for 6 minutes.

Genotyping for the Rosa26-LacZ reporter knock-in (R26R) was performed using PCR with the following primers: R26R primer #1 5’-AAA GTC GCT CTG AGT TGT TAT-3’, R26R primer #2 5’-GCG AGT TTG TCC TCA ACC-3’, and R26R primer #3 5’-GGA GCG GGA GAA ATG GAT ATG-3’, which amplify a 500 bp product for the WT R26 allele and a 250 bp product for the R26R allele. Each 10 µl PCR reaction included ~50-100 ng DNA, 400 nM of each primer, and 2X REDEXtract-N-Amp PCR Ready Mix (Sigma-Aldrich). The following reaction conditions were used for amplification: 93°C for 2 minutes (hot-start); 40 cycles of 93°C for 30 seconds (denature), 58°C for 30 seconds (anneal), and 65°C for 1 minute (elongation); and 65°C for 5 minutes.
Genotyping for the Z/EG reporter transgene was performed using PCR with the following primers: Z/EG forward 5’-AAG TTC ATC TGC ACC ACC G-3’ and reverse 5’-TCC TTG AAG AAG ATG GTG CG-3’, which amplify a 173 bp product. Primers for the internal control IL-2 were also included. Each 10 µl PCR reaction included ~50-100 ng DNA, 250 nM of each primer, 10X PCR Buffer with 15 mM MgCl₂ (Applied Biosystems), 200 µM dNTP mix, and 0.5 U REDTaq DNA Polymerase (Sigma-Aldrich). The following reaction conditions were used for amplification: 94°C for 1.5 minutes (hot-start); 35 cycles of 94°C for 30 seconds (denature), 60°C for 1 minute (anneal), and 72°C for 1 minute (elongation); and 72°C for 2 minutes.

**Intraperitoneal Glucose Tolerance Test (IPGTT)**

Mice were fasted overnight for 16 hours, after which their fasting blood glucose level was measured using blood obtained from the tail and a FreeStyle glucometer (Abbott Diabetes Care). The mice were then weighed, and 2 mg dextrose/g body weight (FisherBiotech) in sterile PBS, pH 7.4 (2.7 mM KCl, 14.7 mM KH₂PO₄, 136.9 mM NaCl, 8.1 mM NaHPO₄•7H₂O) was injected intraperitoneally, and blood glucose levels were measured at 15, 30, 60, 90, and 120 minutes post-injection.

**Intraperitoneal Insulin Tolerance Test (IPITT)**

Mice were fasted in the morning for 6 hours, after which their fasting blood glucose level was measured using blood obtained from the tail and a FreeStyle glucometer (Abbott Diabetes Care). 0.75U/kg insulin (Novolin R, recombinant regular human insulin; Novo Nordisk) in 0.9% normal saline was injected intraperitoneally, and...
blood glucose levels were measured at 15, 30, 60, 90, and 120 minutes post-injection. Percent of initial blood glucose was calculated for all time points.

**Plasma and Pancreatic Insulin Content**

For plasma insulin content, blood was collected at 0 and 30 minutes after glucose injection during an IPGTT from either the saphenous veins or retro-orbital plexus. For saphenous venous blood collection, the mouse was restrained, the distal-lateral portion of the leg was shaved, and the saphenous vein was punctured using a 25 5/8 G needle. Blood was collected into heparanized microvette tubes (Sarstedt), which were then placed on ice. For retro-orbital plexus blood collection, the mouse was anesthetized using isoflurane, the plexus was punctured using heparinized Natelson Blood Collecting Tubes (Fisher), and blood was then transferred to 1.5 ml tubes. All samples were centrifuged at 2,000 x g for 15 minutes at 4°C, and the plasma supernatant was transferred and stored at -80°C. At least 25 µl of each sample was analyzed for insulin content at the Hormone Assay and Analytical Services Core at Vanderbilt University by liquid-phase radioimmunoassay (RIA) using the Rat Insulin RIA Kit (Linco/Millipore). Plasma samples required longer incubation time with diluted antibody for increased sensitivity.

For pancreatic insulin content, pancreatic tissue was harvested from the mouse, weighed, homogenized in acid-alcohol (1 ml HCl in 110 ml 95% ethanol), and extracted in this solution for 3 days at 4°C with agitation (Brissova *et al*., 2002). The homogenate was then centrifuged at 800 x g for 30 minutes at 4°C, and the supernatant was transferred and stored at -20°C. Samples were analyzed for insulin content at the Hormone Assay and Analytical Services Core at Vanderbilt University by liquid-phase
RIA using the Rat Insulin RIA Kit (Linco/Millipore). Samples required dilution 1:1,000 in buffer prior to an analysis. Pancreatic insulin content was normalized to pancreas weight.

**Body Fat Mass Analysis**

Body composition analysis was performed in the Mouse Metabolic Phenotyping Center at Vanderbilt University with the Minispec mq7.5 (Bruker Instruments), which utilizes nuclear magnetic resonance (NMR) spectroscopy to assess percentage of body weight composed of fat, lean muscle, and free fluid.

**60% Partial Pancreatectomy (PPx)**

Mice were anesthetized using isoflurane. A midline abdominal incision allowed exteriorization of the splenic lobe of the pancreas (between the gastro-duodenal junction and the spleen). 60% PPx was performed by gently denuding the pancreatic tissue from the splenic lobe using cotton-tipped swabs soaked in 0.9% normal saline, leaving the main pancreatic duct and splenic artery intact. For Sham operations, the splenic lobe was isolated using cotton-tipped swabs and gently rubbed with a moistened gloved finger for 1 minute. Abdominal muscles were sutured using 5-0 vicryl (Ethicon), and the skin was stapled using 9.0 mm staples (Reflex Skin Closure Systems). Following the operation, 0.1 mg/kg buprenorphine-HCl in 0.9% normal saline was injected subcutaneously for analgesia, and 0.8 mg/ml bromo-deoxyuridine (BrdU; Sigma-Aldrich) was administered in the drinking water in a light-safe bottle and was replaced on the 4th day. Mice were sacrificed 1 week post-operation by cervical dislocation, and the splenic and duodenal...
lobes of the pancreas were harvested and analyzed separately. One day prior to and 7 days after the operation, IPGTTs were performed.

**Tamoxifen Injection**

The shoulder and nape of the neck area were shaved, and then 8 mg of a 20 mg/ml solution of tamoxifen (Sigma-Aldrich) in filter-sterilized corn oil was injected subcutaneously. The injection site was glued with Vetbond tissue adhesive (3M) to prevent leakage. Mice were injected every other day for a total of one, two, or three injections. Control mice were injected with an equal volume of filter-sterilized corn oil.

**Islet Isolation**

All islet isolations were performed in the Islet Procurement and Analysis Core at Vanderbilt University. Mice were anesthetized via an intraperitoneal injection of 0.15 mg/g ketamine-HCl and 0.04 mg/g xylazine (Henry Schein), the abdominal cavity was exposed, and 3-4 ml of 0.6% collagenase P (Roche) in Hank’s Balanced Salt Solution (HBSS) containing calcium and magnesium (Gibco) was injected into the common bile duct. The pancreas was then harvested and digested in 6.5 ml of the collagenase P solution for 4 minutes at 37°C followed by 1.5 minutes at room temperature, with shaking. Islets were hand-picked using at least 4 passages to reach 98% purity.
**Islet Perfusion**

Islets were cultured overnight in Roswell Park Memorial Institute (RPMI) Media 1640 (Gibco) supplemented with 1% penicillin-streptomycin and 10% heat-inactivated FBS at 37°C in the presence of 5% CO₂. The following day, islets were collected and loaded into the perifusion column, and islet equivalent (IEQ) of each sample was measured based on islet number and size. Islets were perifused with perifusion media (Dulbecco’s Modified Eagle’s Medium [DMEM] supplemented with 4.7 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid [HEPES], 38 mM NaHCO₃, 4.0 mM L-glutamine, 1.0 mM sodium pyruvate, 15.05 µM bovine serum albumin [BSA], and 0.0015% phenol red) + 5.6 mM glucose for 39 minutes (baseline) prior to sequential stimulation with the following secretagogues in perifusion media: 16.7 mM glucose, 100 µM isobutylmethylxanthine (IBMX) + 16.7 mM glucose, 300 µM tolbutamide, and 20 mM KCl. Each secretagogue was applied for 9 minutes, followed by 21 minutes of perifusion media + 5.6 mM glucose to return to baseline prior to subsequent stimulation. Perifusate was collected at a rate of 1 ml/min into 3 ml fractions. Insulin content in each fraction was measured using the Rat Insulin RIA Kit (Millipore/Linco) according to manufacturer’s protocol.

**RNA Isolation and Quantitative Real-Time RT-PCR (qRT-PCR)**

RNA was extracted from freshly-isolated islets or transiently-transfected HeLa cells using the RNAqueous kit (Ambion) and DNase-treated using the TURBO DNA-free kit (Ambion). Concentrations of all samples, A₆₀₀/A₂₈₀ ratios, and A₆₀₀/A₂₃₀ ratios were assessed using the ND-1000 Spectrophotometer (NanoDrop). Islet RNA was analyzed by
the Microarray Shared Resource at Vanderbilt University, where RNA quality was further assessed using the 2100 Electrophoresis Bioanalyzer (Agilent).

For qRT-PCR, cDNA was generated from 20 ng of islet RNA using the Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen). Real-time PCR was performed using the iQ5 Real-Time PCR Detection System (Bio-Rad) with iQ Real-Time SYBR Green PCR Supermix (Bio-Rad) and the following mouse primer sets: 

- **Foxm1** forward 5'-CAC TTG GAT TGA GGA CCA CTT-3' and reverse 5'-GTC GTT TCT GCT GTG ATT CC-3',
- **Plk1** forward 5'-TTG TAG TTT TGG AGC TCT GTC G-3' and reverse 5'-AGT GCC TTC CTC CTC TTG TG-3',
- **Cenp-a** forward 5'-CAA GGA GAC CCT CCA G-3' and reverse 5'-GTC TTC TG C GCA GTG TCT GA-3',
- **Birc5/Survivin** forward 5'-CCG ATG ACA ACC CGA TAG A-3' and reverse 5'-CAT CTG CTT CTT GAC AGT GAG G-3',
- **Ccna2** forward 5'-TTT GGC TGC ACC AAC AGT AA-3' and reverse 5'-CAA ACT CAG TTC TCC CAA AAA CA-3',
- **Skp2** forward 5'-GTA TGT TAG GGA ACC ATT TGC GAG-3' and reverse 5'-TTA GAA GGG CAC TTG GAA GAG TT-3',
- **Aurkb** forward 5'-CCC TAC GGC TCA AAG ACG-3' and reverse 5'-AGC AAG CGC AGA TGT CGT-3',
- **Cdc25b** forward 5'-CCC TTC CCT GTT TTC TTT TC-3' and reverse 5'-ACA CAC ACT CCT GCC ATA GG-3',
- **Ccnd2** forward 5'-CAC CGA CAA CTC TGT GAA GC-3' and reverse 5'-TCC ACT TCA GCT TAC CCA ACA-3',
- **Hprt1** (internal control) forward 5'-AGT CAA CGG GGG ACA TAA AA-3' and reverse 5'-TGC ATT GTT TTA CCA GTG TCA A-3'.

The following human primers were also
used: \textit{FoxM1} forward 5’-GGA GGA AAT GCC ACA CTT AGC G-3’ and reverse 5’-TAG GAC TTC TTG GGT CTT GGG GTG-3’. Samples were assessed in duplicate, and results were quantitated using the comparative \(C_T\) method (Schmittgen and Livak, 2008) and normalized to control samples.

Custom TaqMan Low Density Arrays (Applied Biosystems) were designed to assess expression of 48 transcripts (Table 2). cDNA was generated from 40-50 ng of islet RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). TaqMan-based qRT-PCR was performed according to manufacturer’s instructions using a 7900HT Real-Time PCR System (Applied Biosystems). Samples were assessed in duplicate, and results were quantitated using the comparative \(C_T\) method and normalized to control samples.

\textbf{Tissue Preparation and Histology}

For paraffin embedding, tissue was fixed in 4\% paraformaldehyde in PBS, pH 7.4 for 1-4 hours at 4\(^\circ\)C, washed in PBS at 4\(^\circ\)C, stored in 70\% ethanol at 4\(^\circ\)C, dehydrated in an ascending ethanol series at room temperature, cleared twice with xylene at room temperature, infiltrated with xylene:paraffin (1:1, v/v) and then 100\% paraffin at 56\(^\circ\)C, embedded in paraffin, and sectioned at 5 \(\mu\)m. Sections were then deparaffinized in xylene, rehydrated in a descending ethanol series, and washed in PBS.

For frozen embedding, tissue was fixed in 4\% paraformaldehyde in PBS, pH 7.4 for 1-4 hours at 4\(^\circ\)C, washed in PBS, partially dehydrated with 30\% [w/v] sucrose overnight at 4\(^\circ\)C, embedded in Tissue-Tek \textit{Optimal Cutting Temperature} (OCT) compound (Sakura) on dry ice, and sectioned at 7 \(\mu\)m. Frozen blocks and sections were
Table 2. Transcripts assessed by Custom TaqMan Low Density Array. Hs indicates *homo sapiens*. Mm indicates *Mus musculus*. g1 indicates that primers may detect genomic DNA. m1 indicates that primers span an intron and will not detect genomic DNA. s1 indicates that transcript consists of only one exon and thus primers will detect genomic DNA. mH indicates that intron-spanning primers were designed to detect a transcript belonging to a family with high sequence homology. gH indicates that the primers were designed to detect a transcript belonging to a family with high sequence homology and may detect genomic DNA.

<table>
<thead>
<tr>
<th>Common Name</th>
<th>Gene Symbol</th>
<th>Assay ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>18S</td>
<td>18s</td>
<td>Hs99999901_s1</td>
</tr>
<tr>
<td>Arx</td>
<td>Arx</td>
<td>Mm00545903_m1</td>
</tr>
<tr>
<td>Aurora B kinase</td>
<td>Aurkb</td>
<td>Mm01718146_g1</td>
</tr>
<tr>
<td>Survivin</td>
<td>Birc5</td>
<td>Mm00599749_m1</td>
</tr>
<tr>
<td>Cyclin A2</td>
<td>Ccna2</td>
<td>Mm00438064_m1</td>
</tr>
<tr>
<td>Cyclin B1</td>
<td>Ccnb1</td>
<td>Mm00838401_g1</td>
</tr>
<tr>
<td>Cyclin B2</td>
<td>Ccnb2</td>
<td>Mm00432351_m1</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>Ccnd1</td>
<td>Mm00432359_m1</td>
</tr>
<tr>
<td>Cyclin D2</td>
<td>Ccnd2</td>
<td>Mm00438071_m1</td>
</tr>
<tr>
<td>Cdc25A</td>
<td>Cdc25a</td>
<td>Mm00483162_m1</td>
</tr>
<tr>
<td>Cdc25B</td>
<td>Cdc25b</td>
<td>Mm00499136_m1</td>
</tr>
<tr>
<td>Cdk4</td>
<td>Cdk4</td>
<td>Mm00726334_s1</td>
</tr>
<tr>
<td>p21Cip1</td>
<td>Cdkn1a</td>
<td>Mm00432448_m1</td>
</tr>
<tr>
<td>p27Kip1</td>
<td>Cdkn1b</td>
<td>Mm00438167_g1</td>
</tr>
<tr>
<td>p57Kip2</td>
<td>Cdkn1c</td>
<td>Mm00438170_m1</td>
</tr>
<tr>
<td>p16INK4a</td>
<td>Cdkn2a</td>
<td>Mm00494449_m1</td>
</tr>
<tr>
<td>CenpA</td>
<td>Cenpa</td>
<td>Mm00483252_m1</td>
</tr>
<tr>
<td>Ctgf</td>
<td>Ctgf</td>
<td>Mm00515790_g1</td>
</tr>
<tr>
<td>Perk</td>
<td>Eif2ak3</td>
<td>Mm00438708_m1</td>
</tr>
<tr>
<td>FoxA2</td>
<td>Foxa2</td>
<td>Mm00839704_mH</td>
</tr>
<tr>
<td>FoxD3</td>
<td>Foxd3</td>
<td>Mm02384867_s1</td>
</tr>
<tr>
<td>Common Name</td>
<td>Gene Symbol</td>
<td>Assay ID</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>FoxM1</td>
<td>Foxm1</td>
<td>Mm00514924_m1</td>
</tr>
<tr>
<td>FoxO1</td>
<td>Foxo1</td>
<td>Mm00490672_m1</td>
</tr>
<tr>
<td>Glucagon</td>
<td>Gcg</td>
<td>Mm00801712_m1</td>
</tr>
<tr>
<td>Hnf4a</td>
<td>Hnf4a</td>
<td>Mm00433964_m1</td>
</tr>
<tr>
<td>Insulin 1</td>
<td>Ins1</td>
<td>Mm01259683_g1</td>
</tr>
<tr>
<td>Insulin 2</td>
<td>Ins2</td>
<td>Mm00731595_gH</td>
</tr>
<tr>
<td>Isl1</td>
<td>Isl1</td>
<td>Mm00627860_m1</td>
</tr>
<tr>
<td>MafA</td>
<td>Mafa</td>
<td>Mm00845209_s1</td>
</tr>
<tr>
<td>MafB</td>
<td>Mafb</td>
<td>Mm00627481_s1</td>
</tr>
<tr>
<td>Men1</td>
<td>Men1</td>
<td>Mm00484963_m1</td>
</tr>
<tr>
<td>Myosin 5a</td>
<td>Myo5a</td>
<td>Mm00487823_m1</td>
</tr>
<tr>
<td>Neurogenin 3</td>
<td>Neurog3</td>
<td>Mm00437606_s1</td>
</tr>
<tr>
<td>Nkx2.2</td>
<td>Nkx2-2</td>
<td>Mm00839794_m1</td>
</tr>
<tr>
<td>Nkx6.1</td>
<td>Nkx6-1</td>
<td>Mm00454962_m1</td>
</tr>
<tr>
<td>Hnf6</td>
<td>Onecut1</td>
<td>Mm00839394_m1</td>
</tr>
<tr>
<td>Pax4</td>
<td>Pax4</td>
<td>Mm01159036_m1</td>
</tr>
<tr>
<td>Pax6</td>
<td>Pax6</td>
<td>Mm00443072_m1</td>
</tr>
<tr>
<td>Pdx1</td>
<td>Pdx1</td>
<td>Mm00435565_m1</td>
</tr>
<tr>
<td>Plk1</td>
<td>Plk1</td>
<td>Mm00440924_g1</td>
</tr>
<tr>
<td>Rab27a</td>
<td>Rab27a</td>
<td>Mm00469997_m1</td>
</tr>
<tr>
<td>Rab3a</td>
<td>Rab3a</td>
<td>Mm00725988_s1</td>
</tr>
<tr>
<td>Skp2</td>
<td>Skp2</td>
<td>Mm00449925_m1</td>
</tr>
<tr>
<td>Glut2</td>
<td>Slc2a2</td>
<td>Mm00446224_m1</td>
</tr>
<tr>
<td>Sox9</td>
<td>Sox9</td>
<td>Mm00448840_m1</td>
</tr>
<tr>
<td>Granuphilin</td>
<td>Sytl4</td>
<td>Mm00489110_m1</td>
</tr>
<tr>
<td>Munc13-1</td>
<td>Unc13b</td>
<td>Mm00498847_m1</td>
</tr>
<tr>
<td>Vamp2</td>
<td>Vamp2</td>
<td>Mm00494118_g1</td>
</tr>
</tbody>
</table>
stored at -80°C. Sections were then thawed at room temperature for 15-30 minutes, permeabilized in PBS with 0.1% (v/v) Triton-X-100 for 45 minutes or in PBS with 0.2% (v/v) Triton-X-100 for 10 minutes, and washed in PBS.

The following primary antibodies were incubated with 5% normal donkey serum (NDS) and 1% BSA in PBS at 4°C overnight: guinea pig anti-insulin (1:1,000; Linco), guinea pig anti-glucagon (1:1,000; Linco), rabbit anti-cytokeratin (1:1,000; DakoCytomation), rabbit anti-phospho-histone H3 (1:250; Upstate Cell Signaling Solutions), rabbit anti-Cre (1:10,000; Novagen), and chicken anti-β-galactosidase (1:1,000; AbCam). The rat anti-BrdU primary antibody (1:400; Accurate Chemical & Scientific) was incubated with 5% NDS and 1% BSA in PBS at room temperature overnight. The mouse anti-Neurogenin3 primary antibody (Ngn3; 1:100; Developmental Studies Hybridoma Bank, The University of Iowa) was incubated in 1% blocking solution (Invitrogen TSA Kit #2) at 4°C overnight. The anti-Cre and anti-β-galactosidase antibodies were used exclusively on cryosections.

The following secondary antibodies were incubated with 1% BSA in PBS for 1 hour at room temperature: peroxidase-conjugated donkey anti-guinea pig (1:250; Jackson Laboratories), Cy2-conjugated donkey anti-guinea pig, Cy2-conjugated donkey anti-rabbit, Cy3-conjugated donkey anti-guinea pig, Cy3-conjugated donkey anti-rabbit, Cy3-conjugated donkey anti-rat, Cy3-conjugated donkey anti-chicken (all 1:500; Jackson Laboratories). For Ngn3 labeling, peroxidase-conjugated goat anti-mouse secondary antibody (1:100; Invitrogen) was incubated in 1% blocking solution (Invitrogen) for 1 hour at room temperature.
Detection of cytokeratin required pre-treatment with 20 µg/ml Proteinase-K (DakoCytomation) in PBS for 5 minutes at room temperature. Detection of Ngn3 required slow-boil microwave antigen retrieval with Tris-EGTA (TEG) buffer, pH 9.0 (10 mM Tris, 500 µM ethylene glycol tetraacetic acid [EGTA]) and tyramide signal amplification with TSA Kit #2 (Invitrogen). Detection of phospho-histone H3 required microwave antigen retrieval at 1200 W in 10 mM sodium citrate, pH 6.5 for 4 minutes and permeabilization with 0.2% (v/v) Triton-X-100 in PBS for 10 minutes. Detection of BrdU required pre-treatment with 1.5 N HCl for 20 minutes at 37°C, sodium borate buffer (0.85% [w/v] boric acid, 0.15% [w/v] sodium borate) for 1 minute at room temperature, and 0.005 mg/ml trypsin (Sigma-Aldrich) with 0.005 mg/ml CaCl$_2$ in 0.5 M Tris-HCl, pH 7.5 for 3 minutes at 37°C.

For screening of mouse anti-FoxM1 sera (Vanderbilt Monoclonal Antibody Core) by immunohistochemistry (IHC), the HistoMouse-SP Kit (Zymed) was used according to manufacturer’s protocol. Sera was incubated overnight at 4°C at dilutions ranging from 1:50 to 1:250 in PBS with 5% NDS and 1% BSA. The TSA Kit #2 (Invitrogen) was also used for screening, following manufacturer’s protocol. In some cases, microwave antigen retrieval was performed with 10 mM sodium citrate, pH 6.5 or with TEG buffer, pH 9.0.

Coverslips were mounted with Permount (Fisher) for bright-field microscopy or with anti-fade mounting media (50% glycerol [v/v] and 2% N-propylgalate [w/v] in PBS, pH 7.4) for fluorescent microscopy. Nuclei were fluorescently labeled with 1.5 µg/ml 4,’6’-diamidino-2-phenylindole (DAPI; Molecular Probes) in mounting media.
5-bromo-4-chloro-3-indolyl-B-D-galactoside (X-gal) staining was performed on paraformaldehyde-fixed tissue or whole embryos. After washing with PBS, samples were permeabilized for 30 minutes at 4°C and again for 30 minutes at room temperature with permeabilization solution (2 mM MgCl₂, 0.01% [w/v] sodium deoxycholate, and 0.02% [v/v] NP-40 in PBS). Samples were then incubated overnight at room temperature in X-gal staining solution (0.1% [w/v] X-gal, 2 mM MgCl₂; 5 mM potassium ferricyanide; 5 mM potassium ferrocyanide; 20 mM Tris, pH 7.4).

**In Situ Hybridization**

*Foxm1* probes were generated from a fragment of rat *Foxm1* cDNA (*Eco*RI-**Pst**I sub-clone, 500 bp) in the pGEM-1 vector, a generous gift from Robert H. Costa (University of Illinois at Chicago) (Ye *et al.*, 1997). The anti-sense probe was generated using SP6 RNA polymerase and *Eco*RI-digested plasmid DNA, while the sense probe was generated using T7 RNA polymerase and *Hind*III-digested plasmid DNA. Probes were labeled with non-radioactive digoxigenin-UTP (DIG) using the DIG RNA Labeling Kit (Roche) and purified using G-50 sephadex columns (Amersham). Labeling efficiency was determined by spot-testing according to instructions in the DIG RNA Labeling Kit.

Paraffin sections were deparaffinized in xylene, rehydrated in a descending ethanol series, and washed in PBS. Sections were then post-fixed in 4% paraformaldehyde in PBS, pH 7.4 for 20 minutes on ice, treated with 15 μg/ml Proteinase K in PBS for 7 minutes at room temperature, post-fixed again in 4% paraformaldehyde in PBS, pH 7.4 for 20 minutes on ice, and treated with acetylation
agent (86 mM triethanolamine, 26 mM acetic anhydride) for 10 minutes at room temperature. Tissue was then hybridized with an appropriate dilution of each probe in hybridization solution (40% [v/v] formamide, 20X SSC, 50X Denhardt’s reagent [Fisher], 250 µg/ml heparin [Sigma], 1 mg/ml tRNA [Sigma]) at 65°C overnight. Slides were then washed in 5X SSC for 5 minutes at 60°C, 0.2X SSC for 1 hour at 60°C and then 5 minutes at room temperature, and maleic acid buffer, pH 7.5 (100 mM maleic acid, 150 mM NaCl, 175 mM NaOH) for 5 minutes at room temperature. Slides were then blocked in 1% blocking reagent (Roche) in maleic acid buffer for 1 hour at room temperature and incubated with anti-DIG primary antibody (1:5,000; Roche) in maleic acid buffer for 1 hour at room temperature. Slides were then washed two times for 15 minutes each in maleic acid buffer at room temperature and in Tris solution (100 mM Tris, pH 9.5; 100 mM NaCl, 5 mM MgCl₂) for 5 minutes at room temperature. Slides were then developed in detection buffer, pH 9.5 (2 mM Tris, 2 mM NaCl) with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) tablets (Roche) for 4 hours to overnight at room temperature, followed by serial washes in deionized H₂O and Tris-EDTA (TE) buffer, pH 8.0 (10 mM Tris-HCl, 1 mM EDTA) before mounting.

β Cell Mass Analysis

Sections 250 µm apart (3-15 sections per tissue sample, depending on tissue size) were incubated with anti-insulin primary antibody followed by peroxidase-conjugated anti-guinea pig secondary antibody, which was visualized using the DAB Peroxidase Substrate Kit (Vector Laboratories). Sections were counterstained with eosin, and a
digital image was created using a Nikon Coolscan 9000 and NikonScan v4.0.2. MetaMorph v6.1 software (Molecular Devices) was used to measure the total insulin+ area and the total pancreatic area of each section. β cell mass was calculated by dividing the total insulin+ area of all sections by the total pancreatic areas of all sections and multiplying this ratio by the pancreatic wet weight.

**Proliferation Analyses**

For adult β cell proliferation analyses, evenly-spaced sections (250-1250 µm apart, 2-8 sections per tissue sample, depending on tissue size) were labeled with anti-insulin and anti-BrdU primary antibodies and DAPI. Images of all insulin+ cells on each section were captured at 400X magnification on an Olympus BX41 microscope with a digital camera using Magnafire (Optronics), and cells were counted using MetaMorph v6.1. Percent proliferating β cells was calculated by dividing the number of insulin/BrdU double-positive cells by the total number of insulin+ cells. α cells were identified by glucagon labeling, and proliferation was measured in the same manner. Ductal cells were identified by cytokeratin labeling on sections 250-750 µm apart, and images were captured at 200X magnification. Acinar cells were identified by morphological characteristics on 200X images from sections 750 µm apart.

For embryonic β cell proliferation analyses sections 125 µm apart (6-9 sections per tissue sample) were labeled with anti-insulin and anti-phospho-histone H3 primary antibodies, and nuclei were labeled with DAPI in mounting media.
Islet Size, β cell Size, and β cell Nucleus Size Analyses

Using the same pictures analyzed for β cell proliferation, the cross-sectional area of each insulin+ cell group was circumscribed and measured using MetaMorph. Average cross-sectional β cell size per islet was calculated by dividing the total area of the islet by the number of β cell nuclei within it. β cell nuclear size was measured by circumscribing the DAPI+ cross-sectional area within insulin+ cells.

β cell Apoptosis Analysis

Apoptotic β cells were identified on sections 750-1250 µm apart (2-4 sections per tissue sample) by terminal deoxynucleotidyl transferase-mediated dUTP nick-end-labeling (TUNEL) using the BD ApoAlert DNA Fragmentation Assay Kit (BD Biosciences-Clontech), followed by labeling with anti-insulin primary antibody and DAPI. Images of all insulin+ cells on each section were captured at 400X magnification. Percentage of apoptotic β cells was calculated by dividing the number of insulin/TUNEL double-positive cells by the total number of insulin+ cells.

R2δR Recombination Analysis

Evenly-spaced cryosections (2-3 sections per tissue sample, 250-750 µm apart, depending on tissue size) were labeled with anti-β-galactosidase and anti-insulin primary antibodies. Nuclei were labeled with DAPI in mounting media. Images of all insulin+ cells on each section were captured at 400X magnification, and cells were counted using MetaMorph v6.1. The percent of recombined β cells was calculated by dividing the
number of β-galactosidase/insulin double-positive cells by the total number of insulin+ cells.

**Generation of an Anti-FoxM1 Monoclonal Antibody**

**Sub-cloning of Foxm1 cDNA Fragments**

Full-length murine Foxm1 cDNA in pYX-Asc in DH5α E. coli was obtained from Open Biosystems (clone 6417436, accession number BC065067) (Figure 20). The DH5α E. coli were grown on Luria Broth (LB)-Ampicillin agar plates overnight at 37°C, and isolated colonies were cultured overnight in Terrific Broth (TB; 1.2% [w/v] tryptone, 2.4% [w/v] yeast extract, 0.4% [v/v] glycerol, 17 mM KH₂PO₄, 72 mM K₂HPO₄) with 100 μg/ml Ampicillin at 37°C with shaking at 225 rpm prior to plasmid purification.

Three fragments of the Foxm1 cDNA were amplified by PCR, using primers that added a BamHI restriction site and start (ATG) codon to the 5’ end and a stop (TAG) codon and SalI restriction site to the 3’ end of each amplicon. The following primer sets were used: Fragment 1 forward 5’-GGA TCC ATG AGA ACC AGC CCC C-3’ and reverse 5’-GTC GAC CTA CTC AGA CAC AGA GTC CTG CTG-3’, Fragment 2 forward 5’-GGA TCC ATG AAT CGC TAC TTG ACA TTG GA C C-3’ and reverse 5’-GTC GAC CTA CTC AGG GCA GCT GAG-3’, Fragment 3 forward 5’-GGA TCC ATG GAA GAG GGA GGA CCT TTC-3’ and reverse 5’-GTC GAC CTA CTC AGG GAT GAA CTG AGA CCA G-3’. Fragment 1 primers amplified a 714 bp product, consisting of bp 172-870 of the Foxm1 cDNA (NM_008021). Fragment 2 primers amplified an 849 bp product, consisting of bp 1108-1938 of the Foxm1 cDNA. Fragment 3 primers amplified
Figure 20. **pYX-Asc vector.** Murine *Foxm1* cDNA was obtained from OpenBiosystems in the pYX-Asc vector. Figure from OpenBiosystems website.
a 522 bp product, consisting of bp 1939-2445 of the Foxm1 cDNA. Each 50 µl PCR reaction included 1 µg DNA, 200 nM of each primer, 10X PCR Buffer with 15 mM MgCl₂ (Takara), 400 µM dNTP mix, and 2.5 U Taq DNA Polymerase (Takara). The following conditions were used for amplification: 95°C for 2 minutes (hot-start); 30 cycles of 95°C for 30 seconds (denature), 61°C for 30 seconds (anneal), and 72°C for 1 minute (elongation); and 72°C for 10 minutes. PCR products were separated on a 0.8% [w/v] agarose gel with 50 ng/ml ethidium bromide and 1 mM guanosine and extracted using the QIAquick Gel Extraction Kit (Qiagen). DNA was stored at -20°C.

Each PCR-amplified Foxm1 fragment was cloned into the pCR2.1-TOPO vector using the TOPO-TA Cloning Kit (Invitrogen) (Figure 21). Transformed OneShot TOP10 E. coli (Invitrogen) were grown overnight on LB-Ampicillin agar plates at 37°C. Isolated colonies were then cultured overnight in TB with 50 µg/ml Kanamycin at 37°C with shaking at 225 rpm prior to plasmid purification. Positive clones for each Foxm1 fragment were identified by restriction digest with EcoRI followed by gel electrophoresis, which produced a vector band at 4 kb and Foxm1 Fragment 1-, 2-, and 3-specific bands at 714, 849, and 522 bp, respectively. Clones were verified by sequencing using M13 reverse and T7 primers (Vanderbilt DNA Sequencing Facility).

Verified clones were cultured in TB with 50 µg/ml Ampicillin overnight at 37°C with shaking at 225 rpm prior to plasmid purification. Each Foxm1 fragment was excised from pCR2.1-TOPO with BamHI and SalI, gel extracted, and sub-cloned into the maltose binding protein (MBP)-tagged expression vector pAT107b, provided by the Vanderbilt Monoclonal Antibody Core (Figure 22). Transformed DH5α E. coli were grown on LB-Kanamycin agar plates overnight at 37°C, and isolated colonies were cultured in TB
Figure 21. **pCR-TOPO2.1 vector.** Murine Foxm1 cDNA fragments generated by PCR were sub-cloned into the pCR-TOPO2.1 vector and then excised using restriction digest with EcoRI. Figure from Invitrogen website.
Murine Foxm1 cDNA fragments were sub-cloned into the multiple cloning site of the pAT107b expression vector, via ligation at the EcoRI and NotI restriction sites. The pAT107b vector adds an MBP tag and an 8X polyhistidine tag to each cDNA clone, which can be cleaved by digestion with 3C protease.

Figure 22. pAT107b vector. Murine Foxm1 cDNA fragments were sub-cloned into the multiple cloning site of the pAT107b expression vector, via ligation at the EcoRI and NotI restriction sites. The pAT107b vector adds an MBP tag and an 8X polyhistidine tag to each cDNA clone, which can be cleaved by digestion with 3C protease.
with 50 µg/ml Kanamycin overnight at 37°C with shaking at 225 rpm prior to plasmid purification. Positive clones for each *Foxm1* fragment were identified by restriction digest with *BamHI* and *NotI* followed by gel electrophoresis, which produced a vector band at 6.5 kb and *Foxm1* Fragment 1-, 2-, and 3-specific bands at 722, 857, and 529 bp, respectively. Putative *Foxm1* Fragment 1 clones were verified by restriction digest with *SalI* and *EcoRV*, which produced bands of 6780 and 452 bp. Putative *Foxm1* Fragment 2 clones were verified by restriction digest with *BamHI* and *PvuII*, which produced bands at 6528 and 831 bp. Putative *Foxm1* Fragment 3 clones were verified by restriction digest with *SalI* and *PstI*, which produced bands of 6869 and 168 bp.

Verified clones were used to transform BL21 CodonPlus (DE3)-RIPL *E. coli* (Stratagene), which were then grown on LB-Kanamycin agar plates overnight at 37°C.

**Plasmid Purification**

Plasmid mini-preps were performed on 1 ml overnight cultures. Cultures were pelleted by centrifugation at 1,000 x g for 1 minute, resuspended/lysed in 100 µl Alkaline Lysis Solution I (50 mM glucose; 25 mM Tris-HCl, pH 8.0; 10 mM EDTA, pH 8.0), and mixed with 200 µl of Alkaline Lysis Solution II (0.2 N NaOH, 1% [w/v] sodium dodecyl sulfate [SDS]). Then 150 µl Alkaline Lysis Solution III (3 M potassium acetate, 11.5% [v/v] glacial acetic acid) was added to each sample, and samples were vortexed. Lysate was cleared by centrifugation at high speed (16,000 x g) for 10 minutes, and then transferred to 900 µl of 95% ethanol. Precipitated DNA was pelleted by centrifugation at high speed (16,000 x g) for 5 minutes, washed with cold 70% ethanol, and resuspended in
55 µl TE buffer with 200 ng/µl RNase A. For sequencing, plasmid mini-preps were performed using the Plasmid Mini Kit (Qiagen) according to manufacturer’s protocol.

Plasmid maxi-preps were performed using the Plasmid Maxi Kit (Qiagen) according to manufacturer’s protocol. DNA was resuspended in 100 µl TE buffer with 200 ng/µl RNase A.

**Spectrophotometry**

DNA concentration was measured by optical density (OD) absorption at 260 nm ($A_{260}$) using a SmartSpec 3000 spectrophotometer (Bio-Rad) and a quartz cuvette. A conversion factor of 50 µg/ml dsDNA per absorption unit (AU) was used. Nuclease-free water was used as a blank and to dilute the samples appropriately to attain $A_{260}$ between 0.1 and 1.5 for accuracy.

Bacterial growth was determined by OD absorption at 600 nm ($A_{600}$) using a SmartSpec 3000 spectrophotometer (Bio-Rad) and disposable polystyrene cuvettes. A conversion factor of $5 \times 10^8$ cells/ml per AU was used. LB (1% [w/v] tryptone, 0.5% [w/v] yeast extract, 171 mM NaCl) was used as a blank and to dilute the cultures appropriately to attain $A_{600}$ between 0.1 and 1.5 for accuracy.

**Restriction Digests**

Restriction enzymes were obtained from New England Biolabs and used according to the manufacturer’s instructions. Restriction digests were performed in 20 µl reactions using 10 µg DNA, 2 µl each restriction enzyme (4 U per µg DNA),
2 µl appropriate 10X buffer, 0.2 µl BSA if necessary, and nuclease-free H₂O. Reactions were incubated at 37°C for 2 hours to overnight.

**DNA Ligation**

Ligations of insert and vector were performed using the Quick Ligation Kit (New England Biolabs). Each ligation step consisted of two control reactions (vector alone, insert alone) and two ligation reactions (1:1 [v/v] vector:insert, 1:7 [v/v] vector:insert). Each 20 µl reaction contained 1 µl Quick Ligase, 10 µl 2X Quick Ligase Buffer, appropriate volume of vector and insert, and nuclease-free H₂O. Reactions were incubated at room temperature for 5 minutes and chilled on ice prior to use. Ligation products were stored at -20°C.

**Bacterial Transformation**

DH5α *E. coli* were transformed by adding 2 µl purified plasmid or 10 µl ligation products to 100 µl cells in 14 ml round-bottom tubes (Falcon) on ice, mixing gently, incubating on ice for 2 minutes, incubating at 42°C for 1 minute, and incubating again on ice for 2 minutes. Transformed cells were then spread onto LB agar plates with appropriate antibiotic.

OneShot TOP10 *E. coli* were transformed according to manufacturer’s protocol (Invitrogen). Transformed cells were then spread onto LB agar plates with appropriate antibiotic.
BL21 CodonPlus (DE3)-RIPL E. coli were transformed according to manufacturer’s protocol (Stratagene). 200 µl transformed cells were then spread onto LB agar plates with appropriate antibiotic.

**Induction of Recombinant FoxM1 Expression in Bacteria**

Transformed BL21 CodonPlus (DE3)-RIPL E. coli were cultured in LB with 50 µg/ml Kanamycin and 50 µg/ml Chloramphenicol overnight at 37°C with shaking at 225 rpm. The cultures were then diluted to an OD A 600 of 0.1-0.2 AU with LB with 50 µg/ml Kanamycin and 50 µg/ml Chloramphenicol and cultured at 37°C with shaking at 225 rpm until the OD A 600 reached ~0.5 AU. Bacteria were induced to express recombinant FoxM1 by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and culturing for 2-6 hours with shaking at 225 rpm at 37°C, 32°C, 29°C, or 25°C.

Small samples of each culture prior to and after induction were collected, centrifuged at high speed (16,000 x g) for 2 minutes to remove media, and resuspended in protein gel sample buffer (50 mM Tris, pH 6.8; 1% [w/v] SDS; 5% [w/v] sucrose; 0.004% [w/v] bromophenol blue; 120 mM β-mercaptoethanol) for SDS-polyacrylamide gel electrophoresis (PAGE) analysis. Bacteria (pellets and resuspended) were stored at -20°C.

**Purification of Recombinant FoxM1 Antigen**

Bacterial cultures induced to express recombinant FoxM1 were centrifuged at 5,000 x g for 10 minutes at 4°C to remove media. Cells were resuspended/lysed in
Bacterial Protein Extraction Reagent (B-PER; Pierce Biotechnology) with NaCl (final concentration 150 mM), EDTA (final concentration 2 mM), and 2.5% (v/v) Protease Inhibitor Cocktail (Sigma-Aldrich) for use with bacterial cell extracts (Sigma-Aldrich), vortexed, and mixed for 10 minutes at 4°C. The insoluble fraction was pelleted by centrifugation at 15,000 x g for 15 minutes at 4°C. Soluble and insoluble fractions were stored at -20°C.

FoxM1 fragment-MBP fusion proteins were purified from soluble lysate by binding to Amylose Resin (New England Biolabs) and eluting with Maltose Monohydrate (Supelco). The amylose resin was prepared for binding by brief centrifugation at low speed to remove the ethanol in which it was stored, washed twice with 2 volumes of column buffer (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 2 mM EDTA; 0.1% [v/v] NP-40), resuspended in 1 volume of column buffer, and stored at 4°C. Soluble lysate was mixed 20:1 with prepared amylose resin at 4°C for 1 hour, then briefly centrifuged at <6,000 x g, and the unbound fraction was removed. Pelleted bound resin was washed five times with 2 volumes of column buffer. MBP-bound proteins were eluted by resuspending pellet in 10 mM maltose in column buffer, mixing for 10 minutes at 4°C, and centrifuging briefly at <6,000 x g. The eluted fraction was removed and stored at -20°C.

Small samples of crude lysate, insoluble fraction, soluble fraction, unbound fraction, bound fraction, eluted fraction, and non-eluted fraction were collected, mixed with 2X protein gel sample buffer for SDS-PAGE analysis of induction and purification efficiencies, and stored at -20°C.
**Mice in Vanderbilt Monoclonal Antibody Core**

Balb/c and A/J mice were injected with purified MBP-tagged FoxM1 fragments. A total of 50 µg of FoxM1 Fragment 1-MBP and Fragment 3-MBP were mixed with sterile PBS in a final volume of 100 µl. Two injections of 50 µl each were injected per mouse, one subcutaneous and the other intraperitoneal. Mice were injected approximately once every 30 days. Prior to the initial injection and two weeks after the second and consecutive boosts, blood was collected from either the tail vein or the retro-orbital plexus. Serum was collected after coagulation and centrifugation. **Enzyme-linked immunosorbent assay (ELISA)** was performed by the Monoclonal Antibody Core to assess sera reactivity with MBP, Fragment 1-MBP, and Fragment 3-MBP.

**Transient Transfection of Mammalian Cells**

Full-length murine Foxm1 cDNA was sub-cloned from the pYX-Asc vector to the pcDNA3.1+ vector by digestion with EcoRI and NotI. DH5α E. coli were transformed with ligation products and grown on LB-Ampicillin agar plates overnight at 37°C. Isolated colonies were cultured in TB with 200 µg/ml Ampicillin overnight at 37°C prior to plasmid purification. Positive clones were identified by restriction digest with EcoRI and NotI, which produced bands of 5,428 and 4,390 bp; restriction digest with EcoRV, which produced bands of 9,938 and 420 bp; and restriction digest with Nhel, which produced bands of 7,279 and 2,539 bp. Clones were verified by sequencing using T7 primer (Vanderbilt DNA Sequencing Facility).

Verified clones were used to transiently transfect HeLa cells, generously provided by Shuangli Guo, Post-Doctoral Fellow in Dr. Roland Stein’s laboratory (Vanderbilt...
University). 4 μg plasmid prep was complexed with Lipofectamine Reagent (Invitrogen) by mixing 1:4 (w/v) DNA:Lipofectamine in Opti-MEM I Reduced Serum Medium (Invitrogen) and incubating for 30 minutes at room temperature. Negative controls lacked DNA. HeLa cells were transfected at ~50% confluence, after washing twice with Dulbecco’s PBS and incubating for 10-15 minutes with Opti-MEM at 37°C. DNA:Lipofectamine complexes in Opti-MEM were incubated with cells for 5 hours at 37°C, then growth medium was added, and the cells were incubated for 20 hours at 37°C prior to RNA and protein extraction.

**Protein Extraction**

Total protein was extracted from mouse tissue (embryonic liver, embryonic heart and lungs, embryonic whole body, or adult islets). Tissue was homogenized in lysis buffer (20 mM HEPES, 400 mM NaCl, 752 μM spermidine, 250 μM EDTA, 2 mM EGTA, 1% [v/v] NP-40, 25% [v/v] glycerol, 2 mM dithiothreitol [DTT], 1 mM phenylmethylsulphonyl fluoride [PMSF], 0.04% [v/v] protease inhibitor cocktail), then centrifuged at high speed (16,000 x g) for 10 minutes at 4°C. Supernatant was stored at -80°C.

Nuclear and cytoplasmic protein fractions were extracted from transfected HeLa cells. Cells were incubated with lysis buffer (100 mM Tris-HCl, pH 8.0; 0.5% [v/v] NP-40) for 5 minutes on ice with vortexing, then centrifuged at high speed (16,000 x g) at 4°C for 5 minutes. The supernatant (cytoplasmic fraction) was collected and stored at -80°C. The pellet was resuspended in nuclear extraction buffer (20 mM HEPES, pH 7.5; 400 mM NaCl; 1 mM DTT; 2 mM Na₃VO₄; 1 mM EDTA;
1 mM EGTA, pH 8.0; 1 mM PMSF), incubated for 20 minutes on ice with vortexing, then centrifuged at high speed (16,000 x g) at 4°C for 5 minutes. The supernatant (nuclear fraction) was collected and stored at -80°C.

**Protein Quantification**

Extracted protein samples were quantitated using the DC Protein Assay Kit (Bio-Rad). Samples and BSA standards were assessed in duplicate using a microplate reader to measure A750.

**SDS-PAGE, Western Immunoblotting**

Protein samples were mixed with 4X NuPAGE LDS Sample Buffer (Invitrogen), boiled at 95-100°C for 5 minutes, chilled, and subjected to denaturing electrophoresis on NuPAGE Novex 4-12% Bis-Tris Mini Gels using 3-morpholinopropanesulfonic acid, 3-(N-morpholino) propanesulfonic acid (MOPS) SDS Running Buffer, and the Xcell SureLock Mini cell electrophoresis system (all from Invitrogen) according to manufacturer’s protocol. SeeBlue Plus2 Pre-Stained Standard (Invitrogen) was used as a molecular weight marker.

For analysis of recombinant protein induction and purification, gels were stained with Bio-Safe Coomassie G250 Stain (Bio-Rad) according to manufacturer’s protocol.

For western immunoblotting, protein was transferred from gel to Hybond-P polyvinylidene difluoride (PVDF) membrane (Amersham) using the Xcell II Blot Module (Invitrogen), following manufacturer’s protocol. Membranes were then blocked in 5% [w/v] non-fat milk in Tris-buffered saline, pH 7.4 (TBS; 20 mM Tris, 137 mM NaCl).
for 1 hour at room temperature and incubated with primary antibody in 3% [w/v] non-fat milk overnight at 4°C, washed for 30 minutes in TBS with 0.1% (v/v) Tween 20 (TBS-T) at room temperature, and incubated with species-specific peroxidase-conjugated secondary antibody in 3% non-fat milk for 1 hour at room temperature. Following 30 minutes to 1 hour of washing in TBS-T, antibody detection was performed using ECL Western Blotting Detection Reagents (Amersham) and BioMax or X-Omat scientific imaging film (Kodak).

Primary antibodies used for western immunoblotting included: rabbit anti-FoxM1 (1:1,000; a gift from Robert H. Costa [University of Illinois at Chicago]) (Wang et al., 2005), rabbit anti-MPP2 (C-20) (1:200; Santa Cruz Biotechnology), mouse anti-FoxM1 sera (1:1,000; Vanderbilt Monoclonal Antibody Core). Secondary antibodies included: peroxidase-conjugated goat anti-mouse IgG (1:5,000; Promega) and peroxidase-conjugated goat anti-rabbit IgG (1:5,000; Promega).

**Statistical Analyses**

Data were analyzed by unpaired t-test, one-way ANOVA with Bonferroni’s post-tests, or two-way ANOVA with Bonferroni’s post-tests, as appropriate, using GraphPad Prism v5.01. P<0.05 was considered significant. Specific analyses performed and sample sizes are included in the figure legends.
CHAPTER III

INVESTIGATING THE ROLE OF FOXM1 IN β CELL REGENERATION AND EXPANSION FOLLOWING 60% PARTIAL PANCREATECTOMY

Introduction

As type I and type II diabetes result from an absolute or relative deficiency in β cell number, respectively, understanding how β cell number is determined and can be manipulated may lead to new therapeutic options. While transplantation of cadaveric islets remains promising, additional sources of islets or β cells are required to make this treatment more widely available (Shapiro et al., 2006). Diabetic patients would also benefit from in vivo manipulation of their β cell population. Although β cells proliferate slowly after birth (Finegood et al., 1995), increased β cell proliferation can be stimulated under various conditions, including obesity, pregnancy, injury, and growth factor over-expression. In adult rodents and humans, β cell replication is the primary mechanism by which new β cells are formed (Dor et al., 2004; Teta et al., 2007; Meier et al., 2008), and there is much debate regarding whether and how new β cells arise de novo in the adult. However, a recent study in mice has conclusively shown that new β cells are generated from facultative adult progenitor cells (neogenesis) in response to pancreatic injury, in a manner reminiscent of embryonic endocrine cell differentiation (Xu et al., 2008). Additionally, lineage tracing studies using the duct marker carbonic anhydrase II (CAII) showed that duct ligation stimulates differentiation of both acinar and endocrine cells from duct cells in adult mice, similar to what occurs during development (Bonner-Weir et al., 2008). Furthermore, patients with type I diabetes exhibit evidence for continued β
cell production in the face of immune destruction (Meier et al., 2005; Meier et al., 2006), providing support for the ability of human β cells to regenerate.

Partial pancreatectomy (PPx) has been used by several groups as a method of pancreatic injury that stimulates regeneration (Bonner-Weir et al., 1983; Leahy et al., 1988; De Leon et al., 2003; Lee et al., 2006; Peshavaria et al., 2006; Joglekar et al., 2007; Teta et al., 2007). However, there are important differences in the actual techniques used in these studies, with tissue removal ranging from 50-90% and the process of tissue removal being either excision (including removal of the main pancreatic duct and splenic artery) or denuding (leaving the main pancreatic duct and splenic artery relatively intact). Although it is difficult to directly compare results among such studies, it seems that the greater amount of tissue removed creates a stronger stimulus for regeneration, and that denuding the tissue results in more de novo differentiation than is observed following pure excision of tissue, although both techniques stimulate proliferation. Additionally, removal of 90% of pancreatic tissue results in hyperglycemia (Bonner-Weir et al., 1983; Sharma et al., 1999), which is an independent stimulus for β cell proliferation, while 60% PPx does not induce hyperglycemia (Leahy et al., 1988; Peshavaria et al., 2006). This study aimed to determine FoxM1’s role in β cell proliferation and regeneration under normoglycemic conditions using 60% PPx, in which tissue from the splenic lobe of the pancreas is denuded from the main pancreatic duct and splenic artery.

FoxM1 is an important regulator of postnatal β cell proliferation, but loss of FoxM1 in Foxm1\textsuperscript{flox/flox}\cdotPdx1\textsuperscript{5.5kb-Cre} (FoxM1\textsuperscript{Δpanc}) mice does not affect embryonic pancreas or β cell development (Zhang H et al., 2006). These outcomes mirror those
reported for widespread deletion of other cell cycle regulators (Cdk4, Cyclin D), with postnatal endocrine cell-specific effects causing diabetes (Rane et al., 1999; Georgia and Bhushan, 2004; Kushner et al., 2005a). Female FoxM1\textsuperscript{Apanc} mice remain glucose tolerant despite significantly reduced β cell mass and thus are the focus of this study, allowing for analysis of β cell proliferation and regeneration without the confounding effects of hyperglycemia.

To determine whether FoxM1 is required for new β cell formation during regeneration, 60% PPx was performed on adult female FoxM1\textsuperscript{Apanc} mice and Control (Foxm1\textsuperscript{floxt/floxt}) littermates (Figure 23A,B). Importantly, Foxm1 and some of its transcriptional targets were up-regulated within islets following PPx during the period of peak regeneration, and endocrine cell proliferation and regeneration of β cell mass following PPx were specifically impaired in FoxM1\textsuperscript{Apanc} mice. Furthermore, loss of FoxM1 did not impair islet neogenesis but did impair islet growth after PPx.

**Results**

60% PPx up-regulated Foxm1 and select targets within islets while maintaining normoglycemia.

FoxM1 mRNA and protein are relatively low in adult islets (Figure 24A) (Zhang H et al., 2006), but it was unknown whether up-regulation occurs upon stimulation of endocrine cell proliferation. Indeed, Foxm1 expression was up-regulated 2-fold in Control islets 6 days after PPx versus Sham (Figure 24B), suggesting that FoxM1 plays a role in the regenerative response of endocrine cells. Importantly, Foxm1 up-regulation
Figure 23. 60% partial pancreatectomy (PPx).  (A) Exocrine and endocrine tissue were removed from the splenic lobe of the pancreas, leaving the main pancreatic duct intact. The splenic (regenerating) and duodenal (expanding) lobes were analyzed separately. It was expected that the regenerating lobe would undergo both proliferation and neogenesis, while the expanding lobe would undergo only proliferation.  (B) Eight week old female mice underwent either a PPx or a Sham operation, in which no tissue was removed. One day prior to the operation, IPGTT was performed. Mice recovered for one week, during which they were given BrdU in the drinking water. After 7 days, IPGTT was performed again, and the mice were sacrificed for tissue harvest.
Figure 24. Expression of Foxm1 and targets in Control islets. (A) qRT-PCR revealed that Foxm1 expression was relatively low in adult islets, compared to postnatal day 4 (P4) whole pancreas. (B) After 60% PPx, expression of Foxm1 (blue) and several of its targets (green) were up-regulated within islets compared to after a Sham operation. Other FoxM1 targets were not up-regulated after PPx (red), nor were cell cycle regulators that are not FoxM1 targets (black). Results were normalized to Hprt1 levels and then to control samples. Error bars represent SEM. Unpaired t-test with Welch’s correction was used in A, and with no corrections in B, to measure significance. *P<0.05, **P<0.01. n=3-4 per group in A, 4-6 per group in B.
corresponded with the peak of β cell proliferation following PPx (Peshavaria et al., 2006).

Other transcripts of interest were then screened for differences in expression after 60% PPx versus Sham, using Custom TaqMan Low-Density Arrays. Although preliminary, these screens revealed that many transcripts were up-regulated within islets following PPx, most notably *Aurkb, Birc5/Survivin, Ccna2, Ccnb1, Ccnb2, Cenp-a, Plk1,* and *Sox9* (Figure 25). Other transcripts, including *Cdc25b, Ctgf, Nkx2.2,* and *Skp2* were up-regulated to a similar extent as was *Foxm1.* qRT-PCR was used to validate these findings, and this analysis confirmed that several of FoxM1’s known transcriptional targets were up-regulated, including *Plk1, Cenp-a, Birc5/Survivin,* and *Ccnb1* (Figure 24B). Other targets, including *Skp2, Cks1,* and *Cdc25b,* displayed a trend of up-regulation following PPx versus Sham but were not significantly altered. A similar trend was observed for *Ccna2* but not for *Ccnb2,* both of which have been linked to β cell proliferation (Georgia and Bhushan, 2004; Inada et al., 2005; Kushner et al., 2005a), but neither of which is a known FoxM1 target.

To determine whether FoxM1 is necessary for endocrine cell regeneration following pancreatic injury, FoxM1\textsuperscript{Δpanc} and Control female littermates underwent PPx or Sham operation at 8 weeks of age. In agreement with previous reports showing that 60% PPx does not induce hyperglycemia (Leahy et al., 1988; Peshavaria et al., 2006), IPGTTs performed 7 days following 60% PPx or Sham confirmed that Control and FoxM1\textsuperscript{Δpanc} female mice remained glucose tolerant, although there was a trend toward slightly higher glucose levels in both genotypes after PPx versus Sham (Figure 26A,B).
Figure 25. Analysis of transcript expression in Control islets after 60% PPx or Sham operation using Custom TaqMan Low Density Arrays. Error bars represent SEM. n=2 Sham, 3 PPx.
Figure 26. Glucose tolerance was maintained in Control and FoxM1Δpanc mice following 60% PPx. (A) IPGTTs were performed in FoxM1Δpanc and Control female mice 1 week after 60% PPx or a Sham operation. (B) Area under the curve (AUC) for glucose was calculated based on blood glucose levels during IPGTT in FoxM1Δpanc and Control female mice 1 week after 60% PPx or a Sham operation. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=5-7 per group.
Regeneration of β cell mass within the splenic lobe was specifically impaired in FoxM1Δpanc mice.

Similar to FoxM1Δpanc male mice (Zhang H et al., 2006), FoxM1Δpanc female mice also exhibited ~40% reduced β cell mass at 9 weeks of age compared to littermate Controls (1.07 mg versus 1.62 mg), although FoxM1Δpanc female mice remained normoglycemic. This ~40% reduction in β cell mass was unchanged after a Sham operation (Figure 27A), but was specifically due to a reduction in β cell mass within the splenic, not duodenal, pancreatic lobe (Figure 27C,E). Furthermore, the reduction in β cell mass was specific to the endocrine compartment of the pancreas, as neither total pancreatic weight nor weights of the individual lobes was different between Control and FoxM1Δpanc mice (Figure 27B,D,F). There was also no significant difference in total pancreatic area on sections (data not shown). Consistent with previous findings (Spooner et al., 1970), a significant majority of β cell mass was located within the splenic lobe of Control mice after a Sham operation versus the duodenal lobe (Figure 27C,E) (P<0.01).

PPx effectively eliminated most of the tissue from the splenic lobe, although a relatively small amount of acinar and endocrine tissue remained attached to the main pancreatic duct after the procedure (Figure 27D, 28A,C). Within 7 days, a significant and equivalent amount of tissue regenerated in both FoxM1Δpanc and Control mice (Figure 27D, 28B,D), suggesting that overall pancreas regeneration during this time period was not impaired by Foxm1 deletion. β cell mass regeneration within the splenic lobe, however, was impaired in FoxM1Δpanc mice, as β cell mass in these mice did not significantly increase within 7 days following PPx, in contrast to Control littermates (Figure 27C). There were no significant alterations in tissue weight or β cell mass within the duodenal lobe of Control or FoxM1Δpanc mice following 60% PPx (Figure 27E,F).
Figure 27. β cell mass and pancreas weight in Control and FoxM1<sup>Δpanc</sup> mice after 60% PPx or a Sham operation. (A) Total β cell mass and (B) pancreas weight. (C) Splenic lobe β cell mass and (D) weight. (E) Duodenal lobe β cell mass and (F) weight. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. ns=not significant. n=4-6 per group.
Figure 28. Regeneration of the splenic lobe was observed within 7 days after 60% PPx in Control and FoxM1ΔpAnc mice. Sections through the splenic lobe of Control (A, B) and FoxM1ΔpAnc pancreata (C, D) at either Day 0 (A, C) or Day 7 (B, D) following PPx were labeled with anti-insulin antibody (brown) and counterstained with eosin. The majority, but not all, of the endocrine and exocrine tissue was removed by the PPx operation, and an increased amount of tissue was observed 7 days later in both groups of mice. Larger islets were observed in Control mice than in FoxM1ΔpAnc mice, and in both groups of mice there was evidence of islet neogenesis within newly-differentiating portions of the splenic lobe (arrowheads, insets). Scale bar = 1 mm.
β cell proliferation was reduced in FoxM1^{Δpanc} mice compared to Controls after 60% PPx.

Because β cells are replenished primarily by self-replication (Dor et al., 2004), and FoxM1 is important for postnatal β cell proliferation (Zhang H et al., 2006), it seemed likely that reduced β cell proliferation contributed to the impaired β cell mass regeneration observed in FoxM1^{Δpanc} mice. Indeed, PPx dramatically stimulated β cell proliferation in both pancreatic lobes of Control mice, and these effects were significantly blunted in FoxM1^{Δpanc} mice (Figure 29A-F). Moreover, β cell proliferation within the duodenal lobe of FoxM1^{Δpanc} mice did not significantly increase after PPx.

β cell proliferation in the splenic lobe of FoxM1^{Δpanc} mice did increase significantly following PPx versus Sham, despite Foxml deletion (Figure 29E), due to increased proliferation of β cells within small endocrine cell clusters (8 or fewer insulin^{+} cells) and definitive islets (9 or more insulin^{+} cells) (Figure 30A,C). However, β cell proliferation within definitive islets was significantly reduced in FoxM1^{Δpanc} versus Control mice (Figure 30C). Because there was no significant impairment in β cell proliferation in small endocrine cell clusters in FoxM1^{Δpanc} mice, we hypothesized that these represented newly-formed β cells that did not require FoxM1 for proliferation. This hypothesis was supported by the finding that embryonic β cell proliferation did not require FoxM1 (Figure 31A,B). Additionally, proliferation of β cells within small endocrine cell clusters after PPx was specifically stimulated in the regenerating splenic lobe (Figure 30A), but not duodenal lobe (Figure 30B). These data suggest that just as perinatal β cells can proliferate in the absence of FoxM1, newly-differentiated β cells in the adult can undergo several rounds of FoxM1-independent replication prior to switching to FoxM1-dependent proliferation.
Figure 29. β cell proliferation was reduced in FoxM1Δpanc mice after 60% PPx. Low levels of β cell proliferation were observed in the splenic lobes of Control (A) and FoxM1Δpanc (C) mice after a Sham operation. PPx enhanced BrdU incorporation into all pancreatic cell types within the splenic lobe of Control mice (B), but incorporation into endocrine cells was reduced in FoxM1Δpanc mice (D). β cell proliferation was quantified for both the splenic (E) and duodenal (F) pancreatic lobes. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. ns=not significant. n=4-5 per group
Figure 30. β cell proliferation was only reduced in definitive islets, but not small endocrine cell clusters, in FoxM1^{αpnc} versus Control mice after 60% PPx. β cell proliferation within small endocrine cell clusters (≤8 β cells) after PPx versus Sham was similarly enhanced in the splenic lobes of FoxM1^{αpnc} and Control mice (A), but was not significantly altered in the duodenal lobes (B). β cell proliferation within definitive islets (≥9 β cells) after PPx was enhanced in the splenic lobe of Control mice, and this effect was partially inhibited in FoxM1^{αpnc} mice (C). PPx also significantly stimulated β cell proliferation within definitive islets in the duodenal lobe of Control, but not FoxM1^{αpnc}, mice (D). Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. ns=not significant. n=4-5 per group
Table 3. Summary of β cell proliferation results for Control and FoxM1\(^\text{A}_{\text{pance}}\) mice after Sham versus PPx.

<table>
<thead>
<tr>
<th></th>
<th>β Cell Proliferation in Clusters</th>
<th>β Cell Proliferation in Islets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Control PPx vs. Sham</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenic Lobe</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Duodenal Lobe</td>
<td>←→</td>
<td>↑</td>
</tr>
<tr>
<td><strong>FoxM1(^\text{A}_{\text{pance}}) PPx vs. Sham</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenic Lobe</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Duodenal Lobe</td>
<td>←→</td>
<td>←→</td>
</tr>
<tr>
<td><strong>FoxM1(^\text{A}_{\text{pance}}) Sham vs. Control Sham</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenic Lobe</td>
<td>←→</td>
<td>←→</td>
</tr>
<tr>
<td>Duodenal Lobe</td>
<td>←→</td>
<td>←→</td>
</tr>
<tr>
<td><strong>FoxM1(^\text{A}_{\text{pance}}) PPx vs. Control PPx</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Splenic Lobe</td>
<td>←→</td>
<td>↓</td>
</tr>
<tr>
<td>Duodenal Lobe</td>
<td>←→</td>
<td>↓</td>
</tr>
</tbody>
</table>
Figure 31. β cell proliferation was unaffected in FoxM1^{Δpanc} embryos versus Control littermates. Phospho-histone H3 labeling at e17.5 (A) and e18.5 (B) was used to measure β cell proliferation. Error bars represent SEM. Unpaired t-test was used to measure significance. n=2-3 per group.
PPx stimulated β cell proliferation within definitive islets of Control mice to the same extent (7-fold) in both the splenic and duodenal lobes versus Sham (Figure 30C,D). In contrast, proliferation in the splenic lobe of FoxM1<sup>∆panc</sup> mice increased only 5-fold, while the increase within the duodenal lobe was not significant, suggesting that proliferation of pre-existing β cells was impaired in the absence of FoxM1. The increased BrdU incorporation within definitive islets in the splenic lobe of FoxM1<sup>∆panc</sup> mice 7 days after PPx versus Sham (Figure 30C) may represent proliferation that occurred at an earlier stage of new islet development. These results are summarized in Table 3.

Similar to the results observed for the β cell population, α cell proliferation was also stimulated by PPx in Control mice, and this effect was significantly blunted in FoxM1<sup>∆panc</sup> mice (Figure 32A). In contrast, acinar (Figure 32B) and ductal cell (Figure 32C) proliferation were not impaired in FoxM1<sup>∆panc</sup> mice compared to Control mice after PPx. In fact, acinar proliferation was enhanced in FoxM1<sup>∆panc</sup> mice, perhaps in part as a compensatory mechanism due to reduced islet regeneration. However, no differences in gross splenic lobe weight nor acinar cell number were apparent between the two genotypes (Figure 27D and data not shown). These results indicate that FoxM1 is specifically required for endocrine cell proliferation in the pancreas following PPx.

**FoxM1<sup>∆panc</sup> mice exhibited increased β cell and nucleus size compared to Controls.**

Sham-operated FoxM1<sup>∆panc</sup> mice exhibited larger average β cell size in both pancreatic lobes (Figure 33A,B) versus Control littermates, due in part to increased β cell nucleus size (Figure 33C,D). However, enlarged nuclei alone could not account for the
Figure 32. α cell proliferation was reduced in FoxM1^Δpance mice after 60% PPx, but acinar and ductal cell proliferation were not impaired. BrdU incorporation into α cells (A), acinar cells (B), and duct cells (C) was measured in Control and FoxM1^Δpance mice after PPx or Sham. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=3-5 per group.
Figure 33. FoxM1^{Δ}panc mice exhibited increased β cell and nucleus size. After a Sham operation, FoxM1^{Δ}panc mice exhibited increased β cell size in both the splenic (A) and duodenal (B) pancreatic lobes. Increased β cell size was also observed after PPx in the splenic lobe of FoxM1^{Δ}panc mice versus Controls but was significantly reduced compared to after a Sham operation. The average β cell size in Control pancreata was unchanged by PPx. FoxM1^{Δ}panc mice also exhibited increased β cell nucleus size in the splenic (C) but not duodenal (D) lobe, which was unchanged by PPx. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=4-5 per group.
total increase in β cell size observed. Thus, cellular hypertrophy also contributed, likely as a compensatory measure due to reduced β cell number. Although PPx did not alter β cell size in Control mice, average β cell size was significantly reduced specifically within the splenic lobe of FoxM1Δpanc mice after PPx, likely due to new β cell formation.

**Islet size in FoxM1Δpanc mice was reduced compared to Control mice following 60% PPx.**

Although PPx reduced total β cell number within the splenic lobe, islets present within this lobe 7 days after PPx were of the same average size as after a Sham operation in Control mice (Figure 34A). However, FoxM1Δpanc islets were significantly smaller 7 days after PPx compared to Sham. There was also a trend for the average islet size within the duodenal lobe of Control mice to increase following PPx versus Sham, but no islet expansion was observed in the duodenal lobe of FoxM1Δpanc mice (Figure 34B). These data suggest that Foxm1 deletion impairs islet growth after PPx. Of note, islets within the splenic lobe of Control mice after Sham operation were approximately twice as large as islets within the duodenal lobe (P<0.05), which may be due to a greater proportion of small endocrine cell clusters versus definitive islets normally found in the duodenal versus splenic lobe (P<0.05) (Figure 34C,D). Interestingly, after PPx FoxM1Δpanc mice exhibited an increased proportion of small endocrine cell clusters versus definitive islets within their splenic lobe in comparison to Control mice (Figure 34C), which likely contributed to their reduced average islet size. No differences were observed in the proportion of small endocrine cell clusters between Control and FoxM1Δpanc mice after Sham operation or within the duodenal lobe under any condition (Figure 34D). These data are consistent with the hypothesis that new insulin+ cell
Figure 34. FoxM1\textsuperscript{Apnc} mice exhibited impaired islet growth after 60\% PPx. There was no significant difference in average islet size between Control and FoxM1\textsuperscript{Apnc} mice after a Sham operation or PPx in either the splenic (A) or duodenal (B) pancreatic lobes. Following PPx, the average islet size in the splenic lobe of Control pancreata was similar to that observed in Sham-operated mice, but FoxM1\textsuperscript{Apnc} islets were significantly reduced in size. Within the duodenal lobe, Control mice trended toward increased average islet size after PPx, but no increase was observed in FoxM1\textsuperscript{Apnc} mice. (C) FoxM1\textsuperscript{Apnc} mice specifically exhibited an increased proportion of small insulin\textsuperscript{+} cell clusters (1-8 β cells) within the splenic lobe after PPx, but (D) no differences were observed within the duodenal lobe. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=4-5 per group.
clusters form in the splenic/regenerating lobes after PPx, and that subsequent growth of these clusters is impaired by loss of FoxM1.

**β cell neogenesis following 60% PPx was not impaired in FoxM1Δpanc mice.**

Islet density was significantly less in the splenic lobe of FoxM1Δpanc mice versus Controls after a Sham operation (Figure 35A), but no differences were observed in the duodenal lobe between the two genotypes (Figure 35B). Interestingly, the density of insulin+ cell groupings in the splenic lobe of both FoxM1Δpanc and Control mice trended toward an increase 7 days after PPx versus Day 0 (Figure 35A), and insulin+ cells were observed within foci of regeneration in the splenic lobes of both groups of mice (Figure 28B,D). However, islet density in the duodenal lobe was unchanged by PPx in either genotype. These data suggest that generation of new insulin+ cell groups, or neogenesis, occurs specifically in the splenic lobe after PPx and is not impaired in FoxM1Δpanc mice. In support of these findings, Ngn3, a marker of endocrine progenitor cells (Gradwohl et al., 2000), was observed in ductal epithelial cells in both Control (Figure 35C) and FoxM1Δpanc (Figure 35D) mice following PPx. Importantly, Ngn3 expression was only observed in ductules within the regenerating portion of the splenic lobe, but not within differentiated pancreas tissue. Furthermore, no difference in the number of Ngn3+ ductal epithelial cells was detected between Control and FoxM1Δpanc mice following PPx.

*FOXM1c over-expression did not enhance β cell mass regeneration following 60% PPx.*

To determine whether FoxM1 over-expression affects pancreas and β cell regeneration following PPx, *Rosa26-FOXM1c* Tg mice were used, which constitutively
Figure 35. FoxM1<sup>Δ</sup>panc mice did not exhibit impaired β cell neogenesis after 60% PPx. (A) The number of insulin<sup>+</sup> cell groupings per section (islet density) was reduced within the splenic lobe of FoxM1<sup>Δ</sup>panc mice compared to Control littermates after a Sham operation, but at Day 0 and Day 7 following PPx, the number of insulin<sup>+</sup> cell groupings per section was equivalent between FoxM1<sup>Δ</sup>panc and Control mice. 7 days after PPx, there was a trend in both groups of mice to show increased numbers of insulin<sup>+</sup> cell groupings per section within the splenic lobe compared to Day 0. (B) No differences in islet density were observed between any groups of mice in the duodenal lobe. (C) Ngn3 expression was detected only after PPx within cytokeratin<sup>+</sup> (CK<sup>+</sup>) ductal epithelial cells located within foci of regeneration in the splenic lobes of both Control and (D) FoxM1<sup>Δ</sup>panc mice. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=4-5 per group.
and ubiquitously over-express human FOXM1c (Kalinichenko et al., 2003). Despite FOXM1c over-expression within islets (Figure 36A), Tg mice exhibited no significant differences in glucose tolerance (Figure 36B) nor β cell mass following PPx (Figure 37A) compared to wild-type (WT) littermates. Furthermore, no differences in pancreatic tissue weight (Figure 375B), average islet size (Figure 37C), or islet density (Figure 37D) were observed between Tg and WT mice in either lobe. Preliminary analyses also revealed no obvious differences in β cell proliferation within the splenic/regenerating lobe of Tg and WT mice after PPx (Figure 37E). Additionally, no significant changes in transcript levels of the FoxM1 targets Plk1 or Cenp-a, or of the cell cycle regulator Ccnd2, were observed in Rosa26-FOXM1c Tg versus Control islets (data not shown).

Discussion

FoxM1 is highly expressed within pancreatic endocrine cells during embryogenesis and is down-regulated with age (Figure 14A-C) (Zhang H et al., 2006), corresponding with reduced β cell proliferation. Our laboratory previously showed that mice with Foxm1 deleted throughout the pancreatic epithelium (FoxM1∆panc) exhibit impaired growth and maintenance of postnatal β cell mass secondary to reduced postnatal β cell proliferation, associated with increased nuclear-localized p27Kip1 and premature cellular senescence (Zhang H et al., 2006). Several of FoxM1’s direct transcriptional targets inhibit p27Kip1 by promoting its ubiquitination and subsequent degradation (Skp2, Cks1) (Wang et al., 2005) or its nuclear export (KIS) (Petrovic et al., 2008). The study presented here showed that FoxM1∆panc mice have impaired β cell mass regeneration.
Figure 36. Over-expression of FOXM1C had no effect on glucose tolerance. (A) Real-time qRT-PCR with primers specific to human FOXM1c was performed on RNA extracted from isolated islets from 9 week old WT and Rosa26-FOXM1c Tg mice. (B) Tg mice did not display any significant differences in glucose tolerance after a sham operation or PPx. Error bars represent SEM. Unpaired t-test was used to measure significance for A. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance for B. n=2-3 WT, 4-5 Tg.
Figure 37. Over-expression of FOXM1C had no effect on β cell regeneration after 60% PPx. No differences were observed in β cell mass (A), pancreas weight (B), average islet size (C), or average number of insulin+ cell groupings per section (islet density) (D) after PPx in either the splenic or duodenal pancreatic lobes of Rosa-FOXM1c Tg mice compared to WT littermates. Islet size and number were obtained from the same images used to measure β cell mass. (E) β cell proliferation in the splenic lobe after PPx was also similar between Rosa-FOXM1c Tg and WT mice. Error bars represent standard error of the mean (SEM). Unpaired t-test was used to measure significance. n=2-3 WT, 4-5 Tg for A-D. n=2 per group for E.
following PPx, due to reduced β cell proliferation, but there was no evidence that neogenesis was affected by loss of FoxM1.

60% PPx is a normoglycemic pancreatic injury model that stimulates regeneration by (1) differentiation and proliferation and (2) hyperplasia of pre-existing tissue. This study revealed that Foxm1 and some of its targets were up-regulated within islets following PPx during a period of enhanced α and β cell proliferation, leading to the hypothesis that FoxM1 is required for injury-stimulated endocrine cell proliferation. Indeed, FoxM1Δpanc mice exhibited impaired α and β cell proliferation and impaired β cell mass regeneration following PPx. PPx stimulated β cell proliferation in both the splenic (regenerating) and duodenal (expanding) lobes of Control mice, but not in the duodenal lobe of FoxM1Δpanc mice. Thus, hyperplasia of pre-existing β cells after injury requires FoxM1.

Interestingly, PPx-stimulated β cell proliferation was blunted but not completely inhibited within the splenic lobe of FoxM1Δpanc mice, due at least in part to impaired proliferation of β cells in definitive islets, but not small endocrine cell clusters, in the absence of FoxM1. Of course, small clusters of insulin+ cells are not necessarily newly-formed, as a certain amount of such clusters are normally present in the adult pancreas. Furthermore, because islet size and insulin+ cell number were quantified using two-dimensional histology, it is possible that some of the clusters included in these analyses were in fact the edges of larger islets. However, because Control and FoxM1Δpanc mice were analyzed in a similar manner, it is unlikely that this method skewed the data based on genotype, although comparisons between Sham, Day 0, and Day 7 may have been
affected. To avoid this caveat, three-dimensional analyses of re-constituted confocal z-stacks could be used to more accurately determine cluster and islet size.

The proliferation data presented here suggest that another pathway(s), which may mimic that utilized during embryonic pancreas development, compensates for loss of FoxM1 during regeneration, as FoxM1 was also not required for embryonic β cell proliferation. Thus, pre-existing β cells seemingly exhibit a stronger requirement for FoxM1 than do new β cells formed by neogenesis. Although it is currently unclear which factors are required for β cell proliferation during embryogenesis and following islet neogenesis, this study supports the hypothesis that neogenesis in the adult is similar to embryonic β cell development, both with regard to re-expression of Ngn3 and initial FoxM1-independent proliferation.

Because BrdU was administered over 7 days, this study may have underestimated the effects of Foxm1 deletion on endocrine cell proliferation. Previous studies have shown that Foxm1−/− cells can undergo multiple rounds of DNA synthesis without karyo- or cytokinesis (endoreduplication), resulting in polyploid nuclei (Krupczak-Hollis et al., 2004). Evidence of polyploid β cells and exocrine cells were observed in FoxM1Δpanc mice, and these cells would have been counted as proliferating cells in this study, but would not have actually resulted in increased cell number. This phenomenon could partially explain the increased BrdU incorporation in β cells without significant β cell mass regeneration within the splenic lobe of FoxM1Δpanc mice after PPx compared to Sham, although it most likely would not be restricted to one lobe. Labeling with phospho-histone H3 may yield different results, as this protein is specifically phosphorylated during mitosis (Dai et al., 2005), and such labeling would be a useful
addition to these experiments. However, it may be necessary to analyze phospho-histone H3 labeling at multiple time points following PPx, as the time course of stimulated β cell proliferation may vary between Control FoxM1^Δpanc mice.

Additionally, incomplete Foxm1 recombination could have resulted in mosaic expression, allowing some β cells to continue proliferating in FoxM1^Δpanc mice. However, this is unlikely because Pdx1^5.5kb-Cre was previously shown to recombine the Rosa26-LacZ reporter allele within all endodermally-derived pancreatic cells and to yield a significant reduction in FoxM1 protein by e15.5 (Zhang H et al., 2006). Additionally, Foxm1 transcripts were significantly reduced in FoxM1^Δpanc neonatal pancreas (Figure 38A) and even more dramatically in adult islets (Figure 38B). These tissues contain non-endodermally-derived mesenchymal, endothelial, and neuronal cells, which would not undergo Foxm1 recombination, and thus likely account for remaining transcript expression. Verification of FoxM1 protein expression, or the lack thereof, could not be performed because antibodies to detect FoxM1 protein in mouse tissue do not currently exist.

Proliferation of α and β cells, but not acinar or ductal cells, was reduced in FoxM1^Δpanc mice versus Control littermates following PPx, suggesting that FoxM1 is required specifically within endocrine cells. These data concur with other studies showing that endocrine cells are particularly susceptible to perturbations in cell cycle regulation (Georgia and Bhushan, 2004; Kushner et al., 2005a; Mettus and Rane, 2003; Rane et al., 1999). The current study utilized qRT-PCR on islet RNA to assess changes in Foxm1 expression following PPx. Lack of an anti-FoxM1 antibody precludes precise identification of the cell population(s) in which FoxM1 expression or localization
Figure 38. *Foxm1* transcript levels were dramatically reduced in FoxM1\(^{\Delta\text{panc}}\) mice versus Control littermates. Real-time qRT-PCR was performed on RNA isolated from postnatal day 4 FoxM1\(^{\Delta\text{panc}}\) and Control pancreata (A) and from isolated islets from 9 week old mice (B). *Foxm1* transcript levels were reduced by 63% in postnatal day 4 FoxM1\(^{\Delta\text{panc}}\) pancreata and by 77% in adult FoxM1\(^{\Delta\text{panc}}\) islets. Error bars represent SEM. Unpaired t-test with Welch’s correction was used to measure significance. n=3-5 per group.
changes with time and after PPx. Such studies will in the future allow for better understanding of cell type-specific requirements for FoxM1 and may help to explain the differing effects of FoxM1 absence that were observed between endocrine and exocrine cells following PPx. However, the expression analyses described here identified several potentially important regulators of pancreatic endocrine cell proliferation and regeneration that are themselves regulated by FoxM1 (Plk1, Cenp-a, Birc5/Survivin, Ccnb1).

This study also presented evidence of β cell neogenesis following 60% PPx, including Ngn3+ duct cells, insulin+ cells within regenerating tissue, and increased islet density. Although each finding alone is not sufficient to support neogenesis, all pieces of data together strongly indicate the occurrence of neogenesis. Importantly, these findings were equivalent between Control and FoxM1Δpanc mice, revealing that β cell neogenesis in the adult mouse does not require FoxM1. Because neither β cell mass at birth (Zhang H et al., 2006) nor embryonic β cell proliferation were altered in FoxM1Δpanc mice, it is clear that β cell neogenesis during development also does not require FoxM1. Peshavaria et al. (Peshavaria et al., 2006) showed increased small endocrine cell clusters by 2 days post-PPx, which normalized by 7 days. Although the definition of “cluster” in that work was based on insulin+ area, while here “cluster” was defined by number of insulin+ cells (in order to avoid confounding effects of β cell size on cluster area), the data presented here are consistent the findings of Peshavaria et al., as Control mice at 7 days post-PPx exhibited a normal proportion of small endocrine cell clusters. However, FoxM1Δpanc mice had an increased proportion of small endocrine cell clusters at 7 days post-PPx, indicating that formation of these clusters is not impaired in the absence of FoxM1, but
significant growth is. These data support the hypothesis that initial proliferation of newly-differentiated β cells does not require FoxM1, but that these cells later switch to a FoxM1-dependent state. Unfortunately, current technology precludes real-time monitoring of β cell proliferation and islet growth. However, this study highlights the importance of β cell proliferation as a mechanism of β cell mass regeneration, as neogenesis, without adequate proliferation, was not sufficient to regenerate a significant amount of β cell mass in FoxM1^△panc mice after 60% PPx.

As β cell regeneration after partial duct ligation mimics embryonic β cell differentiation with Ngn3 re-expression (Xu et al., 2008), it is not surprising that similar processes occur following 60% PPx, although perhaps to a lesser extent. In comparison to results published for ductal ligation (Xu et al., 2008), relatively few ductule cells were found to express Ngn3 at 7 days after PPx (0-3 positive cells per 200X field of view). However, analysis at an earlier timepoint, such as 1-2 days after PPx when there is a significant increase in small insulin^+ cell clusters (Peshavaria et al., 2006), would likely reveal more Ngn3^+ cells, as Ngn3 expression is transient in endocrine progenitors.

This is the first study to show Ngn3 re-expression following PPx, in contrast to several previous studies that concluded that after PPx, neogenesis and Ngn3 re-expression did not occur. However, the partial pancreatectomy procedures used in these studies were performed in a manner that likely precluded true regeneration. Lee et al. performed 50% PPx, in which the entire splenic lobe and pancreatic duct were surgically excised, and they reported no re-expression of Ngn3 in the remaining tissue by immunohistochemistry and Ngn3-EGFP knock-in analyses (Lee et al., 2006). As we only observed Ngn3 expression in foci of regeneration within the splenic lobe after 60%
PPx, these results are not surprising. The data presented here and by others (Bonner-Weir et al., 1993; Sharma et al., 1999) reveal the importance of leaving the main pancreatic duct and splenic artery in order to stimulate differentiation of new pancreas tissue. Teta et al. also utilized 50% PPx, in conjunction with sequential thymidine analog labeling to assess proliferation, and they concluded that no specialized progenitors gave rise to new β cells in the adult because individual β cells only rarely incorporated more than one thymidine analog after PPx (Teta et al., 2007). Again, complete removal of the splenic lobe and main pancreatic duct likely precluded differentiation of new pancreas tissue in this model. Furthermore, our results do not indicate that newly-formed β cells (in small clusters) undergo more proliferation than do pre-existing β cells (in definitive islets) in Control mice after 60% PPx. Dor et al. performed 60-70% PPx in a manner similar to that described here, but they did not analyze the splenic and duodenal lobes separately (Dor et al., 2004). Based on β cell lineage labeling results, in which β cells were labeled with a heritable marker prior to PPx and no significant dilution of this label was observed after PPx, they concluded that neogenesis did not give rise to new β cells. Because the splenic lobe comprises only a small percentage of total pancreas weight and β cell mass after PPx (~20% after 7 days), and because the contribution of neogenesis and regeneration to new β cell formation is relatively small following PPx, it would be unlikely to detect any significant changes in the β cell lineage label using this technique without analyzing the splenic and duodenal lobes separately. The current study removed tissue from the splenic lobe, leaving the main pancreatic duct intact. This lobe was analyzed separately, and only specific foci of regeneration within the splenic lobe exhibited evidence of neogenesis. In contrast, the duodenal lobe, which was the sole or
primary source of tissue analyzed in the aforementioned studies, exhibited significant hyperplasia with no evidence of neogenesis after 60% PPx, in agreement with these other published works. Thus, this study does not contradict but adds to the current knowledge regarding the potential for pancreas regeneration and β cell neogenesis.

FOXM1C over-expression did not affect β cell regeneration following PPx, which could have been due to differences in activity between human FOXM1C and murine FoxM1, although both are transactivators. Rosa26-FOXM1c Tg mice were used for these experiments because mice over-expressing murine Foxm1 or the more closely-related human FOXM1b have not yet been generated. However, these results suggest that over-expression of FoxM1 is not sufficient to elevate β cell proliferation, emphasizing that the β cell cell cycle is under tight negative regulatory control, even after injury. As reviewed (Cozar-Castellano et al., 2006a), β cells express all of the cell cycle “brakes” studied thus far, but only some “accelerators”. Thus, it may be more difficult than initially anticipated to stimulate β cell proliferation in vivo or in vitro as a therapeutic option for diabetic patients. Because FoxM1 positively regulates cell cycle accelerators and negatively regulates cell cycle brakes, it is of particular interest. However, because over-expression of FOXM1C did not seem up-regulate target genes in mouse islets in vivo, FoxM1 may not be a limiting factor for β cell proliferation. Alternatively, it may be necessary to directly activate FoxM1 in addition to over-expressing it in order to stimulate β cell proliferation. Thus, better understanding of post-translational and inhibitory regulators of FoxM1 will be essential for successful manipulation of FoxM1 activity in β cells.
CHAPTER IV

INVESTIGATING THE ROLE OF FOXM1 IN β CELL HYPERPLASIA IN RESPONSE TO DIET-INDUCED OBESITY

Introduction

Obesity is a primary risk factor for developing Type II diabetes (Staff, 2007), and it has been well-characterized that increased adiposity leads to insulin resistance, as reviewed in (Kahn et al., 2006). Insulin resistance is known to stimulate β cell compensation via enhanced insulin secretory function and expansion of β cell mass in order to produce more insulin in an attempt to maintain normoglycemia. Genetic mouse models of insulin resistance have been generated by deletion of the insulin receptor (IR) (Okada et al., 2007; Cohen et al., 2007), Irs1 (Tamemoto et al., 1994; Araki et al., 1994), or Irs2 (Withers et al., 1998; Kubota et al., 2000; Kubota et al., 2004). Spontaneous mutations in the genes encoding leptin (ob/ob) (Lindstrom, 2007) or the leptin receptor (db/db) (Chen et al., 1996) also resulted in obesity and insulin resistance. Additionally, mouse models of diet-induced obesity have been shown to exhibit insulin resistance. In particular, high-fat diets cause the most dramatic effects on body weight and insulin resistance, and the C57Bl/6 mouse strain is most susceptible to these effects (Collins et al., 2004).

In rodents, β cell mass expansion in response to insulin resistance occurs primarily via increased proliferation (Zhong et al., 2007) and secondarily via β cell hypertrophy (Lingohr et al., 2002). C57Bl/6 mice fed a high-fat diet exhibit 2.2-fold increases in β cell mass and proliferation within four months compared to mice fed a
control diet (Sone and Kagawa, 2005). Rodent studies have shown that both hyperglycemia and hyperlipidemia stimulate β cell proliferation, both under acute and chronic conditions (Bonner-Weir et al., 1989; Steil et al., 2001). Furthermore, hyperinsulinemia stimulated by peripheral insulin resistance can act through the insulin/IGF-1 receptor on β cells to stimulate proliferation and promote survival (Bernal-Mizrachi et al., 2001). Additionally, incretins, such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP), which are secreted by intestinal cells after feeding, can promote β cell proliferation and survival (Drucker, 2006). All of these stimuli also enhance β cell insulin secretory function. However, chronic exposure to these stimuli eventually results in β cell failure, characterized by apoptosis and senescence, reduced proliferation and β cell mass, and diabetes.

In contrast, obese humans undergo only an approximate 50% expansion of β cell mass compared to lean individuals (Butler et al., 2003). Such expansion is primarily due to β cell neogenesis, with β cell proliferation being difficult to observe under any condition, which is consistent with the low replicative capacity of human versus rodent β cells, as discussed in (Butler et al., 2007). Although Type II diabetes in humans progresses in a similar manner as in obese rodents (Rhodes, 2000), the majority of obese humans do not develop Type II diabetes (Mokdad et al., 2001; Kahn et al., 2006) suggesting that diet alone is not responsible, and that primary β cell dysfunction may play a role in pre-disposing some people to developing the disease. Type II diabetes, although a complex multifactorial disorder, is subject to high genetic risk and has been linked to several gene mutations, some of which likely affect β cell function (Permutt et al., 2005; Sladek et al., 2007; The Wellcome Trust Case Control Consortium, 2007). Thus,
identification of factors that play a role in regulating β cell mass expansion may give some insight into the pathogenesis of Type II diabetes, as well as provide putative therapeutic targets.

While FoxM1 has been identified as an important regulator of β cell proliferation and β cell mass growth after weaning in mice under normal conditions (Zhang H et al., 2006), it was unknown whether FoxM1 was similarly required for β cell proliferation and β cell mass expansion stimulated by diet-induced obesity and insulin resistance. To address this question, FoxM1^Apanc mice were placed on a high-fat/high-carbohydrate diet, and their physiological and islet responses were analyzed in comparison to Control littermates and to mice on a chow diet with moderate fat content (Figure 39).

In response to the high-fat diet, FoxM1^Apanc female mice became obese to the same extent as did Control female littermates. Both Control and FoxM1^Apanc mice on the high-fat diet displayed glucose intolerance, which was more prominent in FoxM1^Apanc mice, but all mice on the chow diet remained glucose tolerant. FoxM1^Apanc mice on the high-fat diet displayed reduced insulin secretion in response to glucose. Part of this impairment was explained by reduced β cell mass in FoxM1^Apanc mice, which was also observed in chow-fed mice. However, no expansion of β cell mass was observed in Control mice in response to the high-fat diet, despite their ability to increase insulin secretion. Thus, the impaired insulin secretion observed in FoxM1^Apanc mice may be due at least in part to β cell dysfunction rather than just reduced β cell number. Unfortunately, the failure of Control mice to under β cell mass expansion, and the lack of a significant increase in β cell proliferation, in response to the high-fat diet rendered this study inconclusive as to the role of FoxM1 in obesity-induced β cell mass compensation.
Figure 39. Diet-induced obesity. (A) High-fat/high-carbohydrate diets induce obesity, which causes insulin resistance in insulin target tissues such as liver, muscle, and fat. Insulin resistance results in an increased demand for insulin, which stimulates increased β cell insulin secretory function and β cell mass expansion. (B) Four week old mice were placed on either a high-fat/high-carbohydrate diet or a moderate-fat chow diet for 12 weeks. IPGTTs were performed at the start of the study and every 4 weeks thereafter. Insulin secretion was measured at 0 and 30 minutes during the IPGTT at 8, 12, and 16 weeks of age. At 15 weeks old, mice were subjected to IPITT and NMR body composition analysis and then given BrdU in the drinking water for 1 week. Mice were sacrificed at 16 weeks of age, after 12 weeks on the respective diets, and whole pancreas tissue was harvested.
The most likely reason this study failed was because the FoxM1\textsuperscript{Δpanc} and Control mice were on a mixed strain background. Therefore, a pilot study was performed to determine whether isogenic C57Bl/6 mice responded in the predicted ways to diet-induced obesity, and then FoxM1\textsuperscript{Δpanc} and Control mice were backcrossed to the C57Bl/6 background in order to repeat the study. These experiments verified that female mice on the C57Bl/6 strain background underwent β cell mass expansion in response to the high-fat diet.

Despite these setbacks, several interesting findings came from these studies that will be interesting to investigate further. First, a potential insulin secretory defect in FoxM1\textsuperscript{Δpanc} mice was identified by measuring plasma insulin levels before and after a glucose challenge. Preliminary results from islet perifusion and transcript expression analyses suggest that loss of FoxM1 may have other β cell effects in addition to regulating proliferation. Second, preliminary analysis of islet transcript expression suggested that Foxm1 and some of its transcriptional targets were up-regulated within islets in response to the high-fat diet. Thus, follow-up of these studies is likely to yield interesting and important results regarding FoxM1’s function in β cell adaptation.

Results

FoxM1\textsuperscript{Δpanc} and Control Mice on a Mixed Background

High-fat diet induced obesity in mixed background FoxM1\textsuperscript{Δpanc} and Control mice.

FoxM1\textsuperscript{Δpanc} and Control female littermates weighed the same amount at the outset of the study at 4 weeks of age (Figure 40A), prior to randomization into the two diet
Figure 40. High-fat diet induced obesity in FoxM1Δpanc and Control littermates. (A) Absolute body weight increased more dramatically in FoxM1Δpanc and Control mice fed the high-fat diet versus the chow diet over the 12 week study period, from age 4 weeks (after weaning) to age 16 weeks. (B) Average fold-change in body weight over the 12 week study period was significantly greater in FoxM1Δpanc and Control mice fed the high-fat diet versus the chow diet. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. **P<0.01, ***P<0.001 HFD vs Chow. n=10-12 per group.
groups. However, feeding of the high-fat diet (HFD; 58.7% fat) induced obesity in both Control and FoxM1Δpanc mice versus mice on a chow diet (mouse diet 5015, 25.3% fat), with body weights of the high-fat diet fed groups diverging from the chow-fed groups as early as 8 weeks of age, after being on the diet for 4 weeks. By the end of the study period, both Control and FoxM1Δpanc mice on the high-fat diet exhibited significantly increased body weights versus chow-fed mice (Figure 40A), and total weight high-fat diet-fed mice was ~30% greater than that of mice fed the chow diet (Figure 40B). Importantly, no significant differences in weight gain were observed between Control and FoxM1Δpanc mice, regardless of diet or gender.

To confirm that increased weight gain in mice on the high-fat diet versus chow was associated with increased adiposity, body composition analysis was performed at the end of the study period, after 12 weeks on the respective diets. In comparison to the chow diet, high-fat diet resulted in significantly increased body fat mass in both Control and FoxM1Δpanc mice (Figure 41A). In addition, percent body weight composed of fat was also significantly increased by the high-fat diet, at the expense of lean muscle mass (Figure 41B). Again, these changes were similar between Control and FoxM1Δpanc mice.

*High-fat diet induced glucose intolerance in mixed background FoxM1Δpanc and Control mice.*

At four weeks of age, all mice were glucose tolerant (Figure 42A). However, after being fed the high-fat diet for only four weeks, both Control and FoxM1Δpanc mice began to exhibit glucose intolerance, defined as significantly higher blood glucose levels during IPGTT compared to mice on the chow diet (Figure 42B). Additionally, FoxM1Δpanc mice displayed significantly higher blood glucose levels at the later
Figure 41. High-fat diet induced increased adiposity in FoxM1^{apanc} and Control littermates. (A) NMR spectroscopy revealed that absolute weight of body fat was significantly greater in FoxM1^{apanc} and Control mice fed the high-fat diet versus the chow diet at the end of the 12 week study period. Lean mass (muscle) and weight of free fluid were not significantly altered. (B) Percent total body weight composed of fat was significantly increased in FoxM1^{apanc} and Control mice fed the high-fat diet versus the chow diet at the end of the 12 week study period, while percent body weight composed of lean mass was reduced. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=8-9 per group.
Figure 42. High-fat diet induced glucose intolerance in FoxM1^{∆panc} and Control littermates. (A) IPGTT at 4 weeks of age showed that all mice at the beginning of the study displayed similar glucose tolerance. (B) IPGTT at 8 weeks of age, after being fed either the high-fat or chow diet for 4 weeks, showed that high-fat diet-fed mice displayed significant glucose intolerance, while mice fed the chow diet remained glucose tolerant. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. **P<0.01, ***P<0.001 HFD vs Chow; †P<0.05, ††P<0.01 FoxM1^{∆panc} HFD vs Control HFD. n=10-12 per group.
timepoints during IPGTT, indicating that loss of FoxM1 within the pancreas exacerbates high-fat diet-induced glucose intolerance. However, because glucose tolerance is determined by a combination of \(\beta\) cell function and peripheral insulin sensitivity, it was unclear what was affected by diet and what was affected by genotype.

**High-fat diet induced insulin resistance in mixed background FoxM1\(^{\Delta\text{panc}}\) and Control mice.**

To assess peripheral insulin resistance, IPITTs were performed after 11 weeks on the respective diets. Surprisingly, no differences in insulin tolerance were observed between Control and FoxM1\(^{\Delta\text{panc}}\) mice on either diet and high-fat diet did not significantly alter insulin tolerance in either group of mice (Figure 43A). However, use of the Homeostasis Model Assessment (HOMA) (fasting plasma insulin \(\times\) fasting blood glucose / 22.5), an indirect measure of insulin sensitivity (Matthews *et al.*, 1985), revealed a trend for both Control and FoxM1\(^{\Delta\text{panc}}\) mice to display insulin resistance as early as 4 weeks on the high-fat diet (Figure 43B). Importantly, no differences in IPITT or HOMA were observed between Control and FoxM1\(^{\Delta\text{panc}}\) mice on either diet.

**FoxM1\(^{\Delta\text{panc}}\) mice on a mixed background exhibited impaired insulin secretion on the high-fat diet.**

In order to better assess \(\beta\) cell function, insulin secretion was measured during IPGTTs at 0 and 30 minutes after glucose injection. In agreement with published results, Control mice displayed an approximate 2-fold increase in plasma insulin levels at 30 minutes versus 0 minutes after glucose injection after both 4 weeks (Figure 44A) and 12 weeks (Figure 44B) on the chow diet. At the 4 week timepoint, no significant differences
Figure 43. High-fat diet did not induce significant insulin resistance. (A) IPITT at 15 weeks of age showed no significant differences in insulin tolerance between Control or FoxM1\textsuperscript{Δ\text{panc}} mice fed the high-fat diet for 11 weeks versus those fed the chow diet. However, (B) HOMA calculation at 8 weeks of age, after being fed either a high-fat or chow diet for 4 weeks, revealed a trend for the high-fat diet-fed mice to display insulin resistance. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=7-9 per group.
Figure 44. FoxM1Δpanc mice fed the high-fat diet exhibited impaired insulin secretion. (A) Insulin secretion in Control mice on either diet and in FoxM1Δpanc mice on the chow diet increased two-fold by 30 minutes after glucose injection during IPGTT at 8 weeks of age, after 4 weeks on the respective diets. However, FoxM1Δpanc mice on the high-fat diet did not secrete more insulin at 30 minutes after glucose injection than at baseline. (B) After 12 weeks on the high-fat diet, Control mice exhibited increased fasting and 30-minute plasma insulin levels versus mice fed the chow diet, but no such increase was observed in FoxM1Δpanc mice. (C) Calculation of the insulinogenic index revealed a trend for high-fat diet-fed FoxM1Δpanc mice to display reduced β cell insulin secretory function after 4 weeks and (D) 8 weeks on the diet. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. †P<0.05, ††P<0.01, †††P<0.001 FoxM1Δpanc HFD vs Control HFD. n=10-12 per group.
were observed between Control and FoxM1^Δpanc mice on the chow diet at 0 or 30 minutes, nor on the high-fat diet at 0 minutes (Figure 44A). However, FoxM1^Δpanc mice, after 4 weeks on the high-fat diet, exhibited impaired insulin secretion in response to glucose, with no significant increase in plasma insulin levels at 30 minutes versus 0 minutes, resulting in the 30 minute plasma insulin level in these mice being significantly reduced compared to Control mice on the high-fat diet. This impairment in insulin secretion worsened by 12 weeks on the high-fat diet, as plasma insulin levels in FoxM1^Δpanc mice at this timepoint were only 50% of those of Control mice at both 0 and 30 minutes after glucose injection (Figure 44B). In comparison to mice on the chow diet, Control mice on the high-fat diet exhibited higher plasma insulin levels at both 0 and 30 minutes, whereas FoxM1^Δpanc mice did not secrete more insulin on the high-fat versus chow diet.

Comparing the results for blood glucose levels and plasma insulin levels at 0 and 30 minutes after glucose injection allowed for calculation of the insulinogenic index (change in plasma insulin / change in blood glucose), which is a measure of β cell secretory function (Wareham et al., 1995). After both 4 weeks (Figure 44C) and 12 weeks (Figure 44D) on the high-fat diet, FoxM1^Δpanc mice displayed reduced insulinogenic indices compared to Control mice, although these differences were not statistically significant. Thus, based on insulin secretion and insulinogenic index calculations, FoxM1^Δpanc mice appear to exhibit defective insulin secretion when placed on the high-fat diet.
FoxM1Δpanc mice on a mixed background exhibited reduced β cell mass compared to Controls, and high-fat diet did not stimulate β cell mass expansion.

As obesity-induced insulin resistance and hyperglycemia have been shown to stimulate β cell proliferation and expansion of β cell mass, it was of interest to determine whether FoxM1 was required for these processes. Additionally, it was possible that FoxM1Δpanc mice displayed reduced insulin secretion on the high-fat diet because of impaired β cell mass compensation. At 16 weeks of age, although pancreas weight was similar to that of Control mice (Figure 45A), FoxM1Δpanc mice displayed an approximate 40% reduction in β cell mass on both the chow and high-fat diets (Figure 45B). Surprisingly, high-fat diet did not significantly alter pancreas weight or β cell mass in either genotype.

As a corollary to β cell mass, pancreatic insulin content was assessed in Control and FoxM1Δpanc mice after 12 weeks on the chow and high-fat diet. Indeed, pancreatic insulin content results were similar to those of β cell mass, with FoxM1Δpanc mice exhibiting a 40% reduction versus Control mice when on the chow diet (Figure 45C). Additionally, high-fat diet had no effect on pancreatic insulin content in either group of mice.

High-fat diet did not stimulate significant β cell proliferation or apoptosis.

To determine whether high-fat diet had any effects on β cell proliferation that were not appreciated by analysis of β cell mass, BrdU incorporation into β cells was assessed during the 12th week on the diet. No significant differences in β cell proliferation were observed between Control and FoxM1Δpanc mice fed the chow diet, but β cell proliferation was significantly reduced in FoxM1Δpanc mice compared to Controls.
Figure 45. FoxM1Δpanc mice exhibited reduced β cell mass and pancreatic insulin content compared to Controls, and neither was altered by high-fat diet. (A) Pancreas weight did not significantly differ between Control and FoxM1Δpanc mice on either diet. However, (B) β cell mass and (C) pancreatic insulin content in FoxM1Δpanc mice at 16 weeks of age were reduced by ~40% compared to Control mice on either diet. High-fat diet did not cause any changes in β cell mass or pancreatic insulin content in either genotype. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=10-12 per group for A, n=5-6 per group for B and C.
when fed the high-fat diet (Figure 46A). Additionally, there was a trend for Control mice on the high-fat diet to exhibit increased β cell proliferation, whereas no such trend was observed for FoxM1\textsuperscript{Δpnc} mice on the high-fat versus chow diet.

It was surprising that high-fat diet did not stimulate significant β cell proliferation in Control mice, but it was possible that such stimulation occurred at an earlier timepoint, and that by 12 weeks on the diet, significant β cell compensation could no longer be observed. Therefore, BrdU incorporation into β cells was assessed during the 5\textsuperscript{th} week on the diet, but again no differences in β cell proliferation between Control mice fed the high-fat diet versus the chow diet were apparent (Figure 46B). Additionally, it was possible that the high-fat diet stimulated β cell apoptosis that counter-balanced any hyperplasia or expansion that occurred. To this end, TUNEL labeling of β cells after 12 weeks on the diets was measured, but very few TUNEL\textsuperscript{+} β cells were observed in any group of mice (Figure 46C). Thus, high-fat diet did not appear to increase β cell apoptosis.

Together, these results suggested that mice on a mixed C57Bl/6 strain background do not exhibit β cell hyperplasia or β cell mass expansion in response to diet-induced obesity.

\textit{FoxM1\textsuperscript{Δpnc} mice on a mixed background displayed enlarged β cell size but reduced islet size.}

Although this set of experiments did not allow for assessment of FoxM1’s involvement in β cell hyperplasia and β cell mass expansion in response to diet-induced obesity, several interesting results were observed when comparing Control and FoxM1\textsuperscript{Δpnc} mice on either diet. Similar to what was reported in Chapter III, FoxM1\textsuperscript{Δpnc}
Figure 46. FoxM1Δpanc mice exhibited reduced β cell proliferation after 12 weeks on the high-fat diet, but high-fat diet did not significantly stimulate β cell proliferation in Control mice. (A) BrdU incorporation into β cells was significantly reduced in FoxM1Δpanc mice compared to Control mice after 12 weeks on the high-fat, but not chow, diet. High-fat diet did not significantly stimulate β cell proliferation in Control mice compared to chow diet, but did result in decreased β cell proliferation in FoxM1Δpanc mice. (B) BrdU incorporation into β cells of Control and FoxM1Δpanc mice after 5 weeks on the high-fat diet was similar to results observed after 12 weeks. (C) TUNEL labeling identified only a small number of β cells undergoing apoptosis in either Control or FoxM1Δpanc mice after 12 weeks on either the high-fat or chow diet. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance for A and C. n=5-6 per group for A, n=3 Controls and 1 FoxM1Δpanc for B, n=2-3 per group for C.
mice exhibited enlarged β cell size compared to Control mice on both the chow and high-fat diets (Figure 47A). Interestingly, high-fat diet did not result in significant increases in β cell size in either genotype. As discussed in Chapter III, FoxM1Δpanc mice on the chow diet display enlarged nuclei due to endoreduplication, which partially accounts for the observed increase in cell size. Although β cell nucleus size was not directly measured in this study, it is likely that similar results would be obtained.

Despite having larger β cells, however, average islet size in FoxM1Δpanc mice was reduced compared to Controls on both diets, and high-fat diet did not cause any changes in islet size versus chow diet (Figure 47B). The reduction in average islet size observed in FoxM1Δpanc mice could in part be attributed to an increased proportion of small endocrine cell clusters versus definitive islets in these mice compared to Controls (Figure 47C). Additionally, islet density was significantly reduced in FoxM1Δpanc mice compared to Controls after being fed the high-fat diet (Figure 47D).

**Isogenic C57Bl/6 Mice Pilot Study**

To confirm that isogenic C57Bl/6 female mice would undergo β cell hyperplasia and β cell mass expansion in response to the high-fat diet used in the above studies, and to determine whether a chow diet with reduced fat content would serve as a better control, pilot studies were performed using C57Bl/6JBom mice fed three different diets for 12 weeks: rodent diet 5001 (13.5% fat), mouse diet 5015 (25.3% fat), or high-fat/high-carbohydrate mouse diet F3282 (58.7% fat).
Figure 47. FoxM1<sup>Δpanc</sup> mice exhibited enlarged β cell size but reduced islet size and density compared to Control littermates. (A) β cell size was significantly larger, while (B) islet size was significantly smaller, in FoxM1<sup>Δpanc</sup> mice compared to Control mice after 12 weeks on either the chow or high-fat diet. High-fat diet did not significantly alter β cell or islet size versus chow diet. (C) The proportion of small endocrine cell clusters versus definitive islets was greater in FoxM1<sup>Δpanc</sup> mice than Controls after 12 weeks on either the high-fat or chow diet and was not significantly altered by high-fat diet. (D) Islet density was significantly reduced in FoxM1<sup>Δpanc</sup> mice compared to Controls after 12 weeks on the high-fat, but not chow diet. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=5-6 per group.
High-fat diet induced obesity and glucose intolerance in C57Bl/6 mice.

Female C57Bl/6JBom littermates were weaned at four weeks of age, at which time their weights were similar (Figure 48A), prior to being placed on one of the three study diets. As early as four weeks after being fed the high-fat diet, the mice began to diverge in weight, which was exacerbated with age. While no significant differences in weight gain were observed between mice on the two chow diets, mice on the low-fat 5001 chow diet displayed a consistent trend towards less weight gain than mice on the moderate-fat 5015 chow diet.

In accordance with body weight, mice on the high-fat diet exhibited glucose intolerance as early as eight weeks of age, after only four weeks on the diet. Area under the curve (AUC) calculations, utilizing blood glucose levels during IPGTT, revealed that, despite all mice initially being normoglycemic, mice fed the high-fat diet displayed significantly higher blood glucose levels during IPGG than mice in either chow diet group at later timepoints (Figure 48B). Again, no significant differences were observed in AUC measurements between mice on the two chow diets.

High-fat diet stimulated β cell mass expansion in C57Bl/6 mice.

Mice fed the high-fat diet had larger pancreata than mice on either chow diet (Figure 49A), and these pancreata contained an increased percentage of insulin+ tissue (Figure 49B). Together, these two phenomena resulted in mice on the high-fat diet exhibiting increased β cell mass versus mice on the chow diets (Figure 49C). Again, no differences in these parameters were apparent between mice on the two chow diets, although they did follow the body weight results, with mice on the low-fat 5001 chow
Figure 48. High-fat diet induced obesity and glucose intolerance in C57Bl/6 female mice. (A) Fasting body weight was measured every four weeks during the study, beginning at 4 weeks of age after weaning. All mice weighed approximately the same amount at 4 weeks of age, and subsequently the high-fat diet-fed group gained weight more rapidly and to a greater extent than either of the chow diet-fed groups. (B) Area under the curve (AUC) for glucose during IPGTT was calculated every four weeks during the study. While mice fed either chow diet maintained a stable AUC at all timepoints, high-fat diet-fed mice displayed glucose intolerance at 8, 12, and 16 weeks of age. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. *P<0.05, **P<0.01, ***P<0.001 vs HFD. n=4-5 per group.
Figure 49. High-fat diet stimulated pancreas growth and β cell mass expansion in C57Bl/6 female mice. Although sample size was too small to reach significance, mice fed the high-fat diet exhibited a consistent trend towards increased (A) pancreas weight, (B) percent insulin+ area within the pancreas, (C) β cell mass, and (D) BrdU incorporation into β cells. Error bars represent SEM. One-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=2 per group.
diet demonstrating the lowest values for pancreas weight, insulin$^+$ area, and β cell mass. A similar trend was observed for β cell proliferation, with mice on the high-fat diet displaying increased BrdU incorporation into β cells than mice on either chow diet (Figure 49D).

*High-fat diet stimulated Foxm1 expression in C57Bl/6 islets.*

qRT-PCR was used to assess whether diet-induced obesity altered Foxm1 expression within islets. Indeed, Foxm1 transcript levels mirrored the changes observed in β cell mass and proliferation, with mice fed the high-fat diet expressing a higher level of Foxm1 transcripts compared to mice fed either of the chow diets (Figure 50). Additionally, enhanced expression of the FoxM1 targets Plk1 and Aurkb was also observed, while there was no change in Ccnd2, which is not a known FoxM1 target.

Despite the small sample size for some of the analyses performed in this pilot study, it demonstrated that the high-fat diet used in the previous studies could elicit changes in β cell mass, β cell proliferation, and islet Foxm1 expression in isogenic C57Bl/6 female mice. Additionally, this study suggested that the low-fat 5001 chow diet may be a better control diet to use in future studies. Thus, it was deemed worthwhile to pursue investigating FoxM1’s role in β cell hyperplasia in response to diet-induced obesity, using mice on a congenic C57Bl/6 background.

*Foxm1$^{flox/flox}$ Mice on a C57Bl/6 Background*

Based on the results of the two aforementioned studies, Foxm1$^{flox}$ and $Pdx1^{5.5kb-Cre}$ mice were backcrossed eight generations to the C57Bl/6JBo strain, and
Figure 50. High-fat diet up-regulated Foxm1 and some of its targets in C57Bl/6 female mice. Foxm1, Plk1, and Aurkb, but not Ccnd2, transcripts were up-regulated in mice fed the high-fat diet compared to mice fed either of the control diets. Error bars represent SEM. n=1-2 per group.
the original study of FoxM1’s role in β cell adaptation to diet-induced obesity was repeated with a shorter end-point of eight weeks, as prior studies had demonstrated that many parameters were altered by high-fat diet feeding within this time period.

Unfortunately, during the course of the study, it was discovered that the \( Pdx1^{5.5kb-Cre} \) transgene had been silenced in the mouse colony prior to the beginning of the study. This was confirmed for the mice in this study, which had genotyped positive for the \( Cre \) transgene (Figure 51A) but still had the full-length floxed \( Foxm1 \) allele and no null allele upon genotyping pancreas tissue from sections (Figure 51B). Additionally, Cre expression was undetectable in islet nuclei (Figure 51C). Thus, FoxM1\(^\text{Apanc} \) mice were actually not included in the experiment, and all results reported here represent \( Foxm1^{\text{flox/flox}} \) mice on either the high-fat diet or the low-fat 5001 chow diet.

**High-fat diet induced obesity and glucose intolerance in Foxm1\(^{\text{flox/flox}} \) mice on the C57Bl/6 background.**

At four weeks of age, after weaning, \( Foxm1^{\text{flox/flox}} \) female mice on the C57Bl/6 background were randomized into either the high-fat diet or low-fat chow diet groups. All mice has similar body weights at the beginning of the study, but within eight weeks mice fed the high-fat diet gained significantly more weight than did mice fed the chow diet (Figure 52A). Similarly, all mice exhibited similar glucose tolerance at four weeks of age (Figure 52B,C), but eight weeks of high-fat diet feeding resulted in glucose intolerance compared to mice fed the chow diet, evidenced by increased blood glucose levels after glucose injection during IPGTT (Figure 52B,D).
Figure 51. *Foxm1*<sup>flox/flox;Pdx1<sup>5.5kb-Cre</sup> mice on the C57Bl/6 background did not undergo Cre-mediated recombination of *Foxm1*. (A) Despite approximately half of the mice included in the study genotyping positive for the Cre transgene, (B) floxed *Foxm1* alleles were still present in pancreas tissue from all mice, while *Foxm1* null alleles were undetectable, and (C) Cre expression was undetectable in endocrine cell nuclei.
Figure 52. High-fat diet induced obesity and glucose intolerance in *Foxm1*\textsuperscript{flox/flox} C57Bl/6 female mice. (A) Fasting body weight at 4 weeks of age was similar between all mice, but the high-fat diet-fed group subsequently gained more weight than the chow-fed group. (B) Area under the curve (AUC) for glucose during IPGTT increased over the 8 week study period to a greater extent in high-fat diet-fed mice versus chow-fed. (B) IPGTT at 4 weeks of age revealed no differences in glucose tolerance between the mice at the beginning of the study, (C) but after 8 weeks on the high-fat diet, *Foxm1*\textsuperscript{flox/flox} C57Bl/6 mice exhibited hyperglycemia versus chow-fed mice. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. **P<0.01, ***P<0.001. n=11-12 per group.
High-fat diet stimulated β cell mass expansion in Foxm1^{floxed} mice on the C57Bl/6 background.

Although pancreas weight was not significantly different in mice on the high-fat versus chow diet (Figure 53A), the percent of pancreas tissue composed of β cells was significantly increased in high-fat diet-fed mice versus chow diet-fed mice (Figure 53B). This resulted in an approximate 50% increase in β cell mass in Foxm1^{floxed} female mice on the high-fat diet compared to chow diet within eight weeks (Figure 53C).

Investigating Insulin Secretory β Cell Function in FoxM1^{dp} Mice on a Mixed Background

Because FoxM1^{dp} mice fed a high-fat diet exhibited reduced plasma insulin levels after a glucose challenge, it was of interest to determine whether this was due to a primary β cell defect associated with loss of FoxM1. To this end, a preliminary islet perfusion study was performed on isolated islets from nine week old female FoxM1^{dp} and Control littermates. Comparison of islet responses to various secretagogues (high glucose, tolbutamide, IBMX, and KCl) revealed an approximate 50% reduction in insulin secretion from FoxM1^{dp} islets compared to Control islets (Figure 54). Of course, this study compared islets from only one FoxM1^{dp} mouse and one Control littermate, necessitating the need for further study. Unfortunately, the aforementioned silencing of the Pdx1^{5.5kb-Cre} transgene has precluded such studies from being performed as of yet.

An additional approach used to determine whether FoxM1^{dp} islets exhibited non-proliferative defects was islet transcript expression analysis. For these analyses, a combination of routine qRT-PCR and higher-throughput arrays were utilized. Again, islet RNA was isolated from nine week old female FoxM1^{dp} and Control littermates.
Figure 53. High-fat diet stimulated β cell mass expansion in Foxm1<sup>fl/fl</sup> C57Bl/6 female mice. (A) High-fat diet did not alter pancreas weight versus chow diet. However, (B) percent insulin<sup>+</sup> area within the pancreas and (C) β cell mass were significantly increased in high-fat diet-fed mice versus chow-fed mice. Error bars represent SEM. Unpaired t-tests were used to measure significance. n=7-9 per group.
Figure 54. Preliminary analysis revealed a possible insulin secretory defect in FoxM1\textsuperscript{△}panc islets. 50.05 IEQ of each genotype were loaded onto perifusion columns and exposed to either 5.6 mM glucose (baseline) or one of four secretagogues (16.7 mM glucose, 16.7 mM glucose + IBMX, Tolbutamide, or KCl). Insulin concentration in the perifusate was measured by RIA. Insulin secretion in response to all secretagogues was reduced in FoxM1\textsuperscript{△}panc islets compared to Control islets. n=1 per group.
qRT-PCR revealed no significant differences in expression of the islet hormones *Insulin1, Insulin2, or Glucagon*, or of the mature islet transcription factors *Pdx1, MafA,* or *Arx* (Figure 55). However, FoxM1Δpanc islets expressed reduced levels of the transcription factor *Pax4*. Additionally, the FoxM1 target *CenpA* was reduced in FoxM1Δpanc islets, although other proliferation markers (*Plk1, Aurora B kinase,* and *Cyclin D2*) were not significantly altered. Thus, FoxM1Δpanc islets do not express less insulin than Control islets, so the putative insulin secretory defect was likely due to downstream defects in insulin secretion.

To further investigate this hypothesis, Custom TaqMan Low Density Arrays were utilized to analyze expression of many targets, including islet hormones, transcription factors, cell cycle regulators (including some FoxM1 targets), and factors involved in insulin vesicle secretion. These analyses confirmed the reduced *CenpA* expression in FoxM1Δpanc islets identified by qRT-PCR, but contradicted the *Pax4* results, with *Pax4* transcript levels being higher in FoxM1Δpanc islets analyzed by the arrays (Figure 56). In fact, *CenpA* and *Pax4* were the most dramatically-altered transcripts using this technique. Additionally, the Cdk inhibitors *p16INK4a* and *p21Cip1* were up-regulated in FoxM1Δpanc islets, concurring with a proliferative defect. The array data also suggested that some factors involved in insulin secretion (*Vamp2, Rab3a, Rab27a,* and *Myosin5a*) may be down-regulated in FoxM1Δpanc islets, while *Munc13b* may be up-regulated. However, because of technical issues several RNA samples could not be analyzed, and thus, these studies need to be repeated before any conclusions can be drawn from the array data.
Figure 55. Real-time qRT-PCR analysis of transcript expression in FoxM1$^{\Delta_{\text{panc}}}$ and Control islets. Error bars represent SEM. Unpaired t-tests were used to measure significance. ***P<0.001. n=4-5 per group.
Figure 56. Analysis of transcript expression in FoxM1\(\Delta\)panc and Control islets using Custom TaqMan Low Density Arrays. Error bars represent SEM. n=3 Control, 1 FoxM1\(\Delta\)panc.
Discussion

Diet-induced obesity has been utilized in many rodent studies as a means to stimulate β cell proliferation. However, not all mouse strains are affected in the same manner by a high-fat diet, and the C57Bl/6 strain is particularly susceptible to weight gain, glucose intolerance, and β cell compensation (Black et al., 1998; Funkat et al., 2004; Andrikopoulos et al., 2005). Some of these distinctions may be due to significant differences in islet mass, number, and function that have been identified among various mouse strains (Bock et al., 2005; Andrikopoulos et al., 2005). Therefore, it is not entirely surprising that Control mice on a mixed background (129SvJ, ICR, CBA, C57Bl/6) did not undergo significant β cell mass expansion in response to the high-fat diet. However, these mice were outbred from the C57Bl/6 strain, and other groups have observed diet-induced β cell mass expansion in mouse strains other than C57Bl/6 (Gupta et al., 2007).

In addition, different responses to high-fat diet are observed between male and female mice on the same genetic background. In general, male rodents are more susceptible to obesity and diabetes than are female rodents, due at least in part to estrogenic effects on body weight regulation, insulin sensitivity, and β cell mass and function (Geary et al., 2001; Louet et al., 2004; Choi et al., 2005; Contreras et al., 2002). Thus, many published studies regarding effects of high-fat diet utilized only male mice. However, the majority of FoxM1^Δpanc^ male mice develop glucose intolerance and diabetes under normal conditions by six to nine weeks of age, associated with islet necrosis and fatty infiltration of the pancreas (Zhang H et al., 2006), which could mask any diet-induced effects. Despite these concerns, FoxM1^Δpanc^ and Control male mice
were included in the aforementioned high-fat studies. However, the majority of male mice, regardless of genotype, displayed glucose intolerance or diabetes when fed the high-fat diet, and FoxM1\textsuperscript{Δpanc} male mice consistently displayed impaired insulin secretion, regardless of diet. Therefore, only results from the female arm of the study were included here, as they are representative of both groups of data but lack the confounding effects of pre-existing hyperglycemia. Interestingly, Control male mice did undergo β cell mass expansion (2-fold) in response to the high-fat diet, revealing that β cell compensation occurred in male, but not female, mice on this particular mixed background.

To circumvent this conundrum, FoxM1\textsuperscript{Δpanc} mice were backcrossed onto the C57Bl/6 strain background before repeating the study. However, an alternative approach would be to use FoxM1\textsuperscript{Δislet} male mice (\textit{Foxm1}\textsuperscript{floxed},\textit{Pdx1}\textsuperscript{Pb-CreER}\textsuperscript{TM}), in which Foxm1 is specifically deleted within islet endocrine cells (primarily β cells) after injection of tamoxifen (Zhang H \textit{et al.}, 2005). By delaying Foxm1 deletion until just before the start of the study and restricting Foxm1 deletion to islets, the confounding effects of pre-existing hyperglycemia and exocrine defects (Zhang H \textit{et al.}, 2006) could be avoided, which may allow for better analysis of FoxM1’s role in β cell mass expansion in response to diet-induced obesity. These studies have not yet been undertaken, but the necessary mice are readily available.

Another caveat to this study is that the high-fat and chow diets used were not matched for micronutrients. Thus, it is possible that some of the effects observed in response to the diets (or lack thereof) were due to differences in components of the diets other than fat. Additionally, it is becoming clearer that different types of fat sources have
different effects on body composition and insulin resistance (Rivellese et al., 2002). Although the fat source in both the high-fat diet and mouse diet #5015 was lard, which is known to induce insulin resistance, it is possible that this fat source does not stimulate β cell compensation in the same manner as other fat sources. Future studies should aim to use matched diets with optimal fat sources in order to avoid these potential confounding factors, although the high-fat diet used in this study did stimulate β cell mass expansion in C57Bl/6 mice, and such effects would need to be verified for other diets.

When considering the use of other diets or other mouse models for diet-induced obesity studies, it will be important to verify that obesity actually correlates with insulin resistance, as the studies presented here have shown that obesity alone is not sufficient to stimulate β cell mass expansion. To this end, it may be worthwhile in future experiments to utilize hyperinsulinemic-euglycemic clamps to assess insulin resistance, rather than IPITTs or HOMA calculations. Although HOMA has been shown to correlate well with clamp-determined insulin sensitivity (Lee et al., 2008), hyperinsulinemic-euglycemic clamps are considered the reference standard in humans and rodents (Ayala et al., 2006). However, the clamps are technically difficult and would need to be an end-point analysis, as opposed to HOMA, which can be assessed repeatedly in the same mouse and relatively easily. Additionally, consideration should be given to administering glucose for IPGTTs based on lean body mass, rather than total body mass, as glucose levels in high-fat diet-fed mice were likely inflated in this study due to increased adiposity.

Although preliminary results presented here suggest that Foxm1 transcript levels are up-regulated in mouse islets after exposure to a high-fat diet, these results will need to be confirmed, and ideally up-regulation within β cells specifically will need to be
assessed. Such studies have not yet been performed because of the lack of an acceptable anti-FoxM1 antibody. Once such an antibody is available, immunohistochemistry could be used to assess FoxM1 expression within particular cell types, both under normal and high-fat diet-fed conditions. Additionally, because nuclear localization of FoxM1 is essential for its transcriptional activity, and phosphorylation has been shown to regulate such localization and activity (Ma et al., 2005), it will be important to determine whether sub-cellular localization of FoxM1 in different cell types is altered under various conditions. Importantly, mice fed diets with differing fat contents exhibit altered sub-cellular localization of another forkhead transcription factor, FoxD3 (Dr. Trish Labosky, Vanderbilt University; personal communication), and nuclear exclusion of FoxO is associated with insulin resistance (Okada et al., 2007). Therefore, localization of FoxM1 may also change in response to a high-fat diet, and an antibody will be necessary in order to detect such a change. Chapter VI discusses the ongoing efforts to generate a monoclonal anti-FoxM1 antibody for use in western immunoblotting and/or immunohistochemistry in order to perform these experiments.

This study aimed to determine whether FoxM1 was required for β cell proliferation and β cell mass expansion in response to diet-induced obesity and insulin resistance, using mice with a pancreas-wide deletion of Foxm1 (FoxM1^∆panc) fed a high-fat diet. However, Control mice failed to exhibit β cell mass expansion or increased β cell proliferation after being fed the high-fat diet, preventing any conclusions from being made regarding FoxM1’s role in these processes. This series of studies revealed that female mice on a congenic C57Bl/6 strain background, but not those on a mixed background, responded to the high-fat diet as expected. Although FoxM1^∆panc mice were
backcrossed to the C57Bl/6 background, the *Pdx1-Cre* transgene became silenced, and new mice will have to be backcrossed before the experiments can be repeated. The mechanism of gene silencing has not yet been determined, but it occurred in two different colonies of mice, on both the original and backcrossed strain backgrounds, during a similar timeframe. Thus, perhaps after a certain number of generations, the transgene underwent epigenetic modification, chromatin remodeling, and/or RNAi-mediated silencing.

Additionally, these studies indicated that FoxM1Δpanc mice suffered from reduced insulin secretion when fed the high-fat diet, suggesting that FoxM1 may be important for the compensatory enhancement of β cell function that normally occurs in response to diet-induced obesity and insulin resistance. Importantly, the impairment in insulin secretion was not due to reduced *Insulin* gene transcription or reduced Insulin protein expression per β cell mass. Together with preliminary islet perifusion experiments that showed reduced insulin secretion in response to all secretagogues, these results suggest that loss of FoxM1 impairs general insulin secretion. These results are intriguing, particularly because mice with a global deletion of Skp2 (*Skp2*−/−), which is a direct FoxM1 transcriptional target, also exhibited reduced insulin secretion in response to glucose without a reduction in insulin protein expression per β cell mass, as well as impaired β cell mass expansion in response to diet-induced obesity (Zhong *et al.*, 2007). Therefore, FoxM1 may regulate β cell mass expansion and β cell function through Skp2, although loss of FoxM1 may produce more dramatic effects than observed in *Skp2*−/− mice, as other transcriptional targets are likely affected as well. Thus, further study of FoxM1’s role(s) in β cell compensation is justified.
CHAPTER V

UTILIZING PDX1<sup>PB-<span style='font-variant: normal'>CRE-ER</span><sup>TM MICE FOR ISLET-SPECIFIC DELETION OF FOXM1 AND LINEAGE TRACING

Introduction

There is much interest in generating new β cells both in vivo and in vitro in order to enhance or replace a patient’s own β cell population. However, a definitive source of new β cells in the adult pancreas, and indeed whether new β cells can even be derived from adult human tissue, has not been conclusively determined. Several studies have shown that replication of pre-existing β cells is the primary mechanism by which β cell mass expansion and regeneration occurs during adulthood (Dor et al., 2004; Teta et al., 2007; Meier et al., 2008) (Chapter III). However, because β cells differentiate from Ngn3<sup>+</sup> precursors located within the ductal epithelium during development (Gradwohl et al., 2000; Gu et al., 2002), it is hypothesized that β cells may be able to be derived from duct cells in the adult. In support of this hypothesis, several groups have found that after pancreatic injury there are increased numbers of insulin<sup>+</sup> cells within or directly adjacent to ducts (Bonner-Weir et al., 1993; Hayashi et al., 2003); the pancreatic progenitor and β cell marker, Pdx1, is up-regulated in duct cells (Sharma et al., 1999); and Ngn3 is up-regulated (Xu et al., 2008) (Chapter III). Furthermore, ductal epithelium isolated from mice and humans has been induced to differentiate into insulin-producing cells in vitro (Ramiya et al., 2000; Heremans et al., 2002).

In hopes of identifying a definitive β cell precursor population in the adult mouse, lineage tracing studies have been performed in which a particular cell population is
labeled with a heritable marker that will distinguish it and its progeny at a later timepoint upon histological analysis. Such studies have been performed using conditional Cre expression to recombine a marker, such as the Rosa26 reporter (Soriano, 1999) (Figure 18), in particular cell populations during development in order to determine into which cell types they differentiate. For adult lineage tracing, it is often necessary to use inducible, conditional Cre-mediated recombination to label a cell population at a specific timepoint. For this purpose, CreERTM-expressing mouse lines are used, in which Cre recombinase is fused to a mutated form of the estrogen receptor ligand binding domain that renders it responsive to tamoxifen, but not endogenous estrogen (Littlewood et al., 1995). Binding of CreERTM to tamoxifen disrupts its interaction with heat shock proteins that sequester it in the cytoplasm, allowing for nuclear translocation of the fusion protein and Cre-mediated recombination of floxed target alleles (Figure 16B).

Several distinct CreERTM mouse lines have been utilized for lineage tracing after pancreatic injury, although interpretation of the results are somewhat unclear. Most recently, adult duct cells were labeled by CreERTM-mediated recombination of the Rosa26 reporter locus, under the control of the carbonic anhydrase II (CAII) promoter, and labeled islet cells were observed following duct ligation (Bonner-Weir et al., 2008). Thus, duct cells can contribute to formation of new islet cells, but the frequency of such occurrence was not reported, and no images were provided in the manuscript for interpretation. Interestingly, lineage tracing of acinar cells using the elastase I promoter driving expression of CreERTM showed that acinar cells did not give rise to endocrine cells after 70-80% partial pancreatectomy (PPx), treatment with exendin-4, cerulein-induced pancreatitis, or duct ligation (Desai et al., 2007). Finally, β cells themselves
have been lineage-labeled using the rat *insulin* promoter (RIP) to drive CreER<sup>TM</sup>-mediated recombination of the Z/AP reporter (Dor *et al.*, 2004). In this study, a pulse-chase experiment was performed, in which β cells were labeled in adult mice by tamoxifen injection (pulse), and maintenance or dilution of this label within the β cell population over time and after 70% PPx (chase) was assessed (Figure 57A). In both cases, the percent of labeled β cells remained constant, indicating that non-β cells (unlabeled) do not give rise to β cells.

However, several caveats existed in the Dor *et al.* (2004) study that could have confounded the results. First, tamoxifen-induced recombination of the Z/AP reporter was significantly less than 100% (ranging from 30-60%, depending on the dose of tamoxifen administered), requiring extrapolation of the results to conclude that no new β cells are derived from non-β cells. Second, because the actual portion of the pancreas that undergoes regeneration is quite small in comparison to the remaining portion of the pancreas, which undergoes expansion of pre-existing tissue (see Chapter III), and because the regenerating portion was not analyzed separately, it is possible that the results were skewed by including only pre-existing islets and no new islets. Third, it was unclear whether tamoxifen was still present during the “chase” periods, as no pharmacokinetic studies have been performed in rodents using doses as high as used in this study. Because the RIP would be activated in newly-differentiated β cells, regardless of their origin, these cells would express CreER<sup>TM</sup>, and if tamoxifen had not yet been cleared from the bloodstream, the fusion protein would be translocated to the nucleus, recombination of the reporter allele would occur, and expression of the marker would have been interpreted as the cell being derived from a pre-existing β cell. Although the
Figure 57. Pulse-chase lineage labeling of β cells.  (A) Lineage labeling of β cells is accomplished by CreER-mediated recombination of a heritable reporter label (pulse) that can be assessed over a period of time (chase).  (B) Experimental design of β cell lineage labeling experiments in Pdx1Pβ-CreERTm,R26R mice.  Part A of figure is adapted from Dor et al. (2004).
contribution of neogenesis would most likely be small and would be restricted to or more prevalent in regenerating tissue, this study did not conclusively show that β cell neogenesis fails to occur after PPx or under normal conditions in the adult.

To address some of the above concerns, these studies were repeated with some modifications, seeking to determine whether β cell neogenesis occurred following 60% PPx, and, if so, to determine whether FoxM1 participated in this process. Pdx1\(^{PB}\)-CreER\(^{TM}\) mice were used rather than RIP-CreER\(^{TM}\) mice, as the Pdx1\(^{PB}\) promoter is also endocrine cell- (primarily β cell-) specific but is less leaky than the RIP (Jeanelle Kantz and Dr. Al Powers, Vanderbilt University; personal communication). 60% PPx was used as the method of pancreatic injury to induce regeneration, and the regenerating portion of the pancreas was separated from the remaining portion for analysis, as this portion is most likely to undergo neogenesis (see Chapter III). Five week old mice were injected subcutaneously with 3 injections of 8 mg tamoxifen each, and 60% PPx was performed 2 weeks after the final injections (Figure 57B), as it was hypothesized that tamoxifen would be cleared from the system within this time period.

**Results**

The original experimental design included Foxm1\(^{floc/-};\)Pdx1\(^{PB}\)-CreER\(^{TM};\)R26\(^{R}\) and Foxm1\(^{flox/+};\)Pdx1\(^{PB}\)-CreER\(^{TM};\)R26\(^{R}\) mice, in order to address both aims of this study with one set of experiments. However, despite multiple breeding schemes, there was no success in obtaining mice with a Foxm1\(^{n}\) allele on the R26\(^{R}\) background, suggesting that the Foxm1 and Rosa26 loci were linked. In fact, both loci are located 13.3 centimorgans (cM) apart on mouse chromosome 6 (Figure 58A). Although this distance confers an
**Rosa26 locus**
Chrom 6; 48.7cM; 113,012,092-113,026,574bp

**Foxm1 locus**
Chrom 6; 62.0cM; 128,328,595-128,341,500bp

---

**Figure 58.** The Foxm1 and Rosa26 loci are closely located on mouse chromosome 6. (A) Chromosomal locations of Rosa26 (Thumpd3) and Foxm1 loci, provided by the University of California Santa Cruz (UCSC) Genome Browser. (B) Recombination efficiency of Cre recombinase diminishes with distance between loxP sites. The approximate distance and recombination efficiency between Rosa26 and Foxm1 are noted in red. Adapted from Zheng et al. (2000).
approximate 13% chance of recombination between the loci, no appropriate mice were generated after 6 litters and 47 pups. Even if these mice were generated, though, the presence of loxP sites within both the Foxm1 and Rosa26 loci presents the potential problem of Cre-mediated excision of the intervening sequence between the two loci, which includes multiple genes as well as the LacZ knock-in and could confound the results. Although rare, Cre-mediated recombination can occur between distant loxP sites (Zheng et al., 2000) (Figure 58B).

To avert these concerns, R26R mice were replaced with Z/EG mice, which were generated by random transgenic insertion of a floxed LacZ coding sequence upstream of an EGFP coding sequence, driven by a ubiquitous CMV enhancer/chicken β-actin promoter (Novak et al., 2000) (Figure 19). Unfortunately, Z/EG mice on the C57Bl/6 strain background, which was the background of the Foxm1flox/- and Pdx1PB-CreERTM mice used in these studies, often displayed delayed growth and failure to thrive, which has also been observed by Jackson Laboratories, from which the mice were procured. This phenotype would have confounded assessment of physiological parameters and β cell mass, rendering these mice unusable for these experiments as well.

Finally, it was determined that Pdx1PB-CreERTM,R26R mice would be used for lineage tracing analysis to assess whether β cell neogenesis occurs following 60% PPx, while Foxm1flox/-,Pdx1PB-CreERTM and Foxm1flox/-,Pdx1PB-CreERTM mice would be used to assess FoxM1’s role in β cell neogenesis following 60% PPx.
Efficiency of Pdx1\textsuperscript{PB-CreER\textsuperscript{TM}}-Mediated Recombination of R26\textsuperscript{R}

The protocol of 3 subcutaneous injections of 8 mg tamoxifen into 5 week old Pdx1\textsuperscript{PB-CreER\textsuperscript{TM},R26\textsuperscript{R}} female mice resulted in ~90% recombination of R26\textsuperscript{R} in β cells by 9 weeks of age, assessed by double-labeling with anti-insulin and anti-β-galactosidase antibodies. At 8 weeks old, mice were subjected to either 60% PPx or Sham, and one week later the percentage of total β cells that were β-galactosidase\textsuperscript{+} was compared. Preliminary analyses of the percentage of β-galactosidase\textsuperscript{+} β cells in the splenic pancreatic lobe of mice that underwent 60% PPx versus a Sham operation revealed no obvious difference in β cell labeling (Figure 59A-C). These results may indicate that non-β cells (unlabeled) did not give rise to new β cells after 60% PPx, although further analysis is necessary.

Longevity of Cre Nuclear Localization Following Tamoxifen Injection

Although tamoxifen injection is often used to perform “pulse-chase” experiments, the particular nature of this lineage labeling study requires that the “pulse” time frame be very well defined to ensure that any β cells that may differentiate from unlabeled precursors during the “chase” period do not undergo CreER-mediated recombination and express the lineage label. Because CreER nuclear localization correlates with recombination activity and is dependent on tamoxifen presence, anti-Cre antibody labeling was performed in order to assess Cre protein sub-cellular localization after tamoxifen injection, as an indirect assessment of tamoxifen presence. The PPx experiments were designed to account for slow clearing of tamoxifen, with Pdx1\textsuperscript{PB-CreER\textsuperscript{TM},R26\textsuperscript{R}} mice subjected to PPx or Sham two weeks after tamoxifen
Figure 59. Pdx1<sup>PB-CreER<sup>TM</sup> mediated high levels of recombination of R26<sup>R</sup> in β cells. Pdx1<sup>PB-CreER<sup>TM</sup>;R26<sup>R</sup></sup> mice were injected 3 times with 8 mg tamoxifen and underwent a Sham operation or 60% PPx. (A) Cryosections of the splenic lobe of Sham and (B) PPx-operated mice were labeled for Insulin (green), β-galactosidase (red), and DAPI (blue). Inset shows an additional islet. (C) Approximately 90% of β cells were β-galactosidase<sup>+</sup> at 7 days after either a Sham operation or 60% PPx. All images were captured at 400X magnification. n=1 per group.
injection and then sacrificed one week after the operation. Surprisingly, even after this three week “chase” period, Cre protein was localized primarily to the nuclei of the majority of β cells (Figure 60A,A’). In contrast, Pdx1^{PB-CreER_{TM};R26^{R}} mice injected with vehicle (corn oil) alone did not display any significant amount of nuclear-localized Cre (Figure 60B,B’). These findings suggested that tamoxifen was still present in injected animals for much longer than anticipated. Thus, lineage labeling experiments were postponed until the time frames of tamoxifen and Cre activity were better characterized.

To determine whether there was a time point by which Cre was no longer localized to the nucleus, time course experiments were performed in which Pdx1^{PB-CreER_{TM};R26^{R}} mice were administered 3 injections of 8 mg tamoxifen each, and the mice were sacrificed at various time points thereafter for Cre labeling of pancreatic sections. This analysis revealed that the intensity of Cre labeling in individual nuclei, tended to decline over time, although a significant number of β cell nuclei were labeled strongly for Cre even 8 weeks after tamoxifen injection (Figure 61A,A’,B,B’).

To determine whether the relatively high dose of tamoxifen was responsible for the persistent Cre nuclear localization, the number of tamoxifen injections was reduced to either two injections of 8 mg tamoxifen each or a single injection of 8 mg tamoxifen. At five weeks after two injections, Pdx1^{PB-CreER_{TM};R26^{R}} mice displayed similar results as observed at three or five weeks after three injections, with the majority of β cells exhibiting strong nuclear Cre labeling (Figure 62A,A’). However, five weeks after a single tamoxifen injection, there were very few β cell nuclei labeled with Cre (Figure 62B,B’), implying that the dose of tamoxifen administered correlated with nuclear
Figure 60. Cre was primarily localized to islet nuclei 3 weeks after Pdx1<sup>Pb</sup>-CreER<sup>TM</sup>;R26<sup>R</sup> mice were injected 3 times with 8 mg tamoxifen. (A) Cryosections of the splenic lobe from Sham-operated mice previously injected with tamoxifen were labeled for Insulin (green), Cre (red), and DAPI (blue). The majority of β cells exhibited strong Cre labeling within the nucleus. (B) Pancreas cryosections from Pdx1<sup>Pb</sup>-CreER<sup>TM</sup>;R26<sup>R</sup> mice injected three times with vehicle (corn oil) alone showed strong cytoplasmic, but not nuclear, Cre labeling. All images were captured at 400X magnification.
Figure 61. Nuclear localization of Cre persisted until at least 8 weeks after tamoxifen injection. Pdx1\textsuperscript{PB}-CreER\textsuperscript{TM};R26\textsuperscript{R} mice were injected 3 times with 8 mg tamoxifen, and pancreatic tissue was harvested either 5 weeks (A) or 8 weeks (B) following tamoxifen injection. Pancreatic cryosections were labeled for Insulin (green), Cre (red), and DAPI (blue). Inset shows an additional islet. The intensity of Cre labeling appeared to decrease with time, although the majority of β cells continued to exhibit Cre labeling within the nucleus. All images were captured at 400X magnification.
Figure 62. Tamoxifen dose correlated with nuclear localization of Cre protein in $Pdx1^{Pb-} - CreER^{TM}; R26^{R}$ mice. $Pdx1^{Pb-} - CreER^{TM}; R26^{R}$ mice were administered either (A) 2 injections of 8 mg tamoxifen each or (B) a single injection of 8 mg tamoxifen. Five weeks later, pancreatic cryosections were labeled for Insulin (green), Cre (red), and DAPI (blue). Inset shows an additional islet. Five weeks after 2 injections, the majority of $\beta$ cells exhibited strong Cre labeling within the nucleus. However, after only a single injection, the majority of $\beta$ cells showed strong cytoplasmic, but not nuclear, Cre labeling, although there was substantial variation among islets. All images were captured at 400X magnification.
localization of Cre. Similarly, tamoxifen dose directly correlated with $R26^R$ recombination, assessed by $\beta$-galactosidase expression. $Pdx1^{PB-CreER^{TM}};R26^R$ mice after only one or two tamoxifen injections displayed a reduced percentage of $\beta$-galactosidase$^+$ $\beta$ cells compared to that observed after three injections (Figure 63A,A',B,B').

The persistence of Cre nuclear localization suggested that perhaps tamoxifen is not readily metabolized and cleared from the body. To directly address this issue, our laboratory in collaboration with Rachel Reinert and Dr. Al Powers (Vanderbilt University) are planning experiments to determine the pharmacokinetic profile of tamoxifen in mice and to determine whether $Pdx1^{PB-CreER^{TM}};R26^R$ islets will undergo recombination when transplanted into mice previously injected with tamoxifen.

**FoxM1$^{\text{Aislet}}$ Mice Subjected to 60% PPx**

Although lineage tracing experiments were inconclusive and were postponed due to possible confounding effects of tamoxifen longevity, data from studies performed on $Foxm1^{\text{flox/flox}};Pdx1^{5.5\text{kb-Cre}}$ (FoxM1$^{\text{Apanc}}$) and $Foxm1^{\text{flox/flox}}$ mice indicated that $\beta$ cell neogenesis occurred following 60% PPx and was not impaired in the absence of FoxM1 (see Chapter III). Supporting experiments were designed to determine whether FoxM1 is required in non-endocrine cells for the generation of new $\beta$ cells after 60% PPx, using $Foxm1^{\text{flox/}};Pdx1^{PB-CreER^{TM}}$ (FoxM1$^{\text{Aislet}}$) and $Foxm1^{\text{flox/+}};Pdx1^{PB-CreER^{TM}}$ female littermates. These mice were subjected to 60% PPx or a Sham operation, and regeneration of $\beta$ cell mass was evaluated. Additionally, the extent of $\beta$ cell mass regeneration in these mice was compared to that of FoxM1$^{\text{Apanc}}$ mice to determine
Figure 63. Tamoxifen dose directly correlated with β-galactosidase expression in Pdx1<sup>PB-CreER<sup>TM</sup>;R26<sup>R</sup></sup> mice. Pdx1<sup>PB-CreER<sup>TM</sup>;R26<sup>R</sup></sup> mice were administered either (A) 2 injections of 8 mg tamoxifen each or (B) a single injection of 8 mg tamoxifen. Five weeks later, pancreatic cryosections were labeled for Insulin (green), β-galactosidase (red), and DAPI (blue). In both cases, the percentage of β-galactosidase<sup>+</sup> β cells was less than 90%. Inset shows an additional islet. All images were captured at 400X magnification.
whether loss of FoxM1 in all pancreatic cells was more detrimental than islet-specific loss of FoxM1. If at 7 days after PPx, β cell mass in FoxM1\(^{\Delta_{\text{islet}}}\) mice was reduced compared to Control littermates, and if this reduction was proportionate to the reduced β cell mass observed in FoxM1\(^{\Delta_{\text{panc}}}\) mice compared to their Control littermates (Chapter III), then these results would suggest that FoxM1 was only required islet cells for β cell mass regeneration. In contrast, if at 7 days after PPx, β cell mass in FoxM1\(^{\Delta_{\text{islet}}}\) versus Control littermates was reduced to a lesser extent than observed in FoxM1\(^{\Delta_{\text{panc}}}\) versus Control littermates, then these results would suggest that both islet and non-islet cells required FoxM1 for regeneration of β cell mass. Both interpretations are dependent on high CreER-mediated recombination efficiency of the Foxm1\(^{\text{flox/flox}}\) locus.

Fourteen mice have thus far been included in the experiment, of which only six have been evaluated for β cell mass. Regardless of genotype or tamoxifen injection, all mice exhibited similar body weight (Figure 64A) and glucose tolerance 7 days after PPx (Figure 64B). Of the pancreata that have been analyzed to date, the weight of the splenic lobe 7 days after PPx was slightly reduced in FoxM1\(^{\Delta_{\text{islet}}}\) mice compared to Controls, whereas duodenal lobe weight was increased (Figure 65A). Furthermore, there appeared to be reduced regeneration of β cell mass in the splenic lobe of FoxM1\(^{\Delta_{\text{islet}}}\) mice compared to Controls (Figure 65C), which correlated with reduced percent insulin\(^+\) area on pancreatic sections (Figure 65B). In comparison to FoxM1\(^{\Delta_{\text{panc}}}\) female mice, however, FoxM1\(^{\Delta_{\text{islet}}}\) mice exhibited similar reductions in β cell mass regeneration compared to their respective Control littermates. One week after 60% PPx, β cell mass in FoxM1\(^{\Delta_{\text{panc}}}\) mice was ~50% that of Control littermates (0.057 mg versus 1.02 mg; Figure 27C), and FoxM1\(^{\Delta_{\text{islet}}}\) mice similar exhibited only ~50% the β cell mass of Control.
Figure 64. Foxm1^Aislet and Control mice exhibited similar body weights and glucose tolerance. Mice were injected with either vehicle (corn oil) or tamoxifen and then subjected to 60% PPx. 7 days after PPx, (A) body weight was measured, and (B) IPGTT was performed. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=2-3 per group for Corn Oil-injected, 4-5 per group for Tamoxifen-injected.
Figure 65. After 60% PPx, β cell mass in the regenerating splenic lobe of Foxm1Δislet mice was reduced compared to Control mice. Mice were injected with tamoxifen and then subjected to 60% PPx. (A) 7 days after PPx, splenic lobe weight was slightly reduced, while duodenal lobe weight was increased, in Foxm1Δislet mice versus Controls. (B) Percent insulin+ pancreatic area on sections was also reduced in the splenic, but not duodenal, lobe of Foxm1Δislet mice versus Controls. (C) Taking into account tissue weight and % insulin+ area, β cell mass in the splenic lobe was reduced, while that in the duodenal lobe was increased, in Foxm1Δislet mice versus Controls. Error bars represent SEM. Two-way ANOVA with Bonferroni’s post-tests was used to measure significance. n=1-3 per group.
littermates at the same time point (0.035 mg versus 0.077 mg; Figure 65C). The different mixed strain backgrounds of the two Cre-expressing mouse lines likely accounted for the different β cell mass results in the respective Control mice. Of course, additional analyses need to be performed on the remaining tissue samples before any conclusions can be drawn from these experiments.

**Discussion**

The field of β cell regeneration has been debated for quite some time regarding not only the source(s) and mechanism(s) of such regeneration, but also whether β cell neogenesis in fact occurs. There is also debate over whether neogenesis refers solely to progression from an undifferentiated cell to a differentiated one, or whether it can encompass such processes as de-differentiation and re-differentiation, and transdifferentiation. Regardless, it is clear that the type of pancreatic injury induced is paramount to the interpretations of the results, as is the precision with which analyses are performed. It is also clear that neogenesis is not the primary mechanism by which the β cell population regenerates or grows. However, the there is great potential for β cell neogenesis to influence future therapy for diabetic patients.

This study was begun before Xu *et al.* (2008) and Bonner-Weir *et al.* (2008) reported direct mechanistic and lineage tracing evidence for β cell neogenesis, respectively. These reports and the data presented in Chapter III substantiate the histological findings that have been reported by many groups in support of the occurrence of neogenesis. However, additional lineage tracing studies, particularly using other injury models, are vital to the field. Thus, these studies still merit completion.
Although the lineage tracing study has not yet been completed, it raised the possibility of an important caveat to time-sensitive CreER™-mediated lineage labeling systems, as nuclear-localized CreER protein was evident for many weeks after tamoxifen injection. Prior studies utilizing CreER lineage labeling suggested a 48 hour window of tamoxifen-induced CreER activity (Gu et al., 2002). However, these studies utilized intraperitoneal injections of pregnant moms and analyzed embryonic recombination, which may have produced different results than observed in this study using subcutaneous injections and adult analyses. In general, substances injected intraperitoneally are more readily introduced into the bloodstream than if injected subcutaneously.

Of course, maintenance of Cre nuclear localization does not necessarily correlate with tamoxifen presence. Although CreER is translocated to the nucleus by binding to tamoxifen, it is unclear whether CreER is shuttled out of the nucleus in the absence of tamoxifen, and if so, how quickly this occurs. The slow reduction in nuclear-localized Cre protein after tamoxifen injection observed in this study could be due to slow clearance of tamoxifen and/or to high perdurance of Cre protein in combination with slow nuclear exclusion. However, it would not be surprising if tamoxifen is cleared slowly from the body, as tamoxifen and its metabolites are extremely hydrophobic (Figure 66) and consequently are stored at relatively high concentrations in adipose tissue (Kisanga et al., 2003; Kisanga et al., 2005). Furthermore, tamoxifen metabolites in general exhibit greater activity than tamoxifen itself (Lim et al., 2005), meaning that extensive metabolism is required to clear tamoxifen activity. Therefore, pharmacokinetic
Figure 66. Tamoxifen metabolism pathways. Tamoxifen is extensively metabolized by the Cytochrome P450 (CYP) family in the liver. The metabolites 4-hydroxy-tamoxifen and N-desmethyltamoxifen have particularly high activity. Figure is from Kisanga et al. (2005).
profiling of tamoxifen, administered in the same manner (location and dose) used for lineage tracing studies is necessary for proper interpretation of results of such studies.

The study described in Chapter III suggested that FoxM1 is not required for β cell neogenesis following 60% PPx, utilizing FoxM1^{Δpanc} mice. The studies described here were designed to complement the original study, utilizing FoxM1^{Δislet} mice and lineage labeling of β cells. Preliminary results suggested that regeneration of β cell mass was not improved in FoxM1^{Δislet} versus FoxM1^{Δpanc} mice, indicating that FoxM1 was not required in non-endocrine cells for generation of new β cells. It is possible, however, that Foxm1 was not actually deleted in FoxM1^{Δislet} mice, as Foxm1 transcript levels have not yet been measured in these mice by our laboratory. Interestingly, despite ~90% recombination of the R26^R reporter in β cells using the same method of CreER induction (Figure 59C), Foxm1 transcript levels were only reduced by 27% in FoxM1^{Δislet} islets compared to Foxm1^{+/+};Pdx1^{P8-CreER} Control islets sent to a collaborating lab (Jeremy Lavine and Dr. Alan Attie, University of Wisconsin – Madison, personal communication). These conflicting results could be due to differing efficiencies of CreER-mediated recombination at the Rosa26 and Foxm1 loci. To avoid the possibility of inefficient recombination, future experiments could use Rip-Cre mice to delete Foxm1 in β cells. These mice may in fact provide a better comparison against FoxM1^{Δpanc} mice, as they would also undergo deletion of Foxm1 during development. FoxM1^{Δislet} mice were initially used in these experiments with the plan that they could be used for lineage tracing studies as well. However, combining these studies has been impossible, and the inherent difficulties and possible low efficiency of CreER-mediated recombination makes a constitutive Cre line preferable.
Another possible explanation for the lack of a difference in β cell mass regeneration between FoxM1^{Aislet} and FoxM1^{Apanc} mice is that, as Chapter III describes, the contribution of neogenesis to β cell mass recovery following 60% PPx is small in comparison to that of proliferation. Therefore, it may simply be difficult to detect a difference in neogenesis between FoxM1^{Aislet} and FoxM1^{Apanc} mice using the methods described here. However, direct lineage tracing using the recently-published duct-selective CAII-CreERTM (Bonner-Weir et al., 2008) or Cytokeratin (CK) 19-CreERTM (Means et al., 2008) mouse lines, in combination with Foxm1 deletion, could potentially produce more precise data regarding FoxM1’s role in β cell neogenesis.
CHAPTER VI

GENERATING A FOXM1 ANTIBODY

Introduction

FoxM1 was first identified in 1994 as an antigen for the MPM2 antibody, which recognizes a specific serine/threonine phosphorylation epitope in proteins phosphorylated during mitosis (Westendorf et al., 1994). However, this antibody recognizes many other M-phase phosphorylated proteins (MPPs), meaning it is not selective for FoxM1. Since then, many anti-FoxM1 antibodies have been generated by various companies and laboratory groups. However, many of these antibodies specifically react with human FOXM1, but not mouse FoxM1. Furthermore, several of these antibodies were generated against a peptide and have not been verified. In order to perform analyses of FoxM1 expression, cellular and sub-cellular localization, and post-translational modification, it is necessary to have a specific antibody that can be used for these specific applications.

Our laboratory first utilized a polyclonal anti-FoxM1 antibody generated against the N-terminus by Dr. Robert H. Costa’s laboratory (University of Illinois at Chicago) (Ye et al., 1997) to detect FoxM1 protein in embryonic, perinatal, and adult pancreatic sections (Zhang H et al., 2006). However, this antibody was only available for a short period of time, and results could not be replicated with other antibody preparations. Commercially-available antibodies from Santa Cruz Biotechnology that were generated against various fragments of the FoxM1 protein and have been used for immunocytochemistry on human cell lines (Ma et al., 2005) have not been shown to
work on mouse tissue, and our laboratory was unable to detect a specific signal using these antibodies for immunohistochemistry on mouse tissue sections. Furthermore, commercially-available antibodies from AbCam that were generated against a FoxM1-specific peptide have not been verified by other groups, and indeed, our laboratory did not obtain positive results using such antibodies for immunohistochemistry.

Generally, it is difficult to detect protein on tissue sections due to the fixation process involved and the quarternary structure of the protein of interest, which can mask the epitope recognized by the antibody. Although many antigen retrieval methods exist to aid in exposing the epitope of interest, they are not always sufficient. Despite using protease digestion and heat-denaturing in both acidic and basic solutions with the anti-FoxM1 antibodies mentioned above, our laboratory has been unable to detect FoxM1 protein on mouse tissue.

Western immunoblotting avoids the concerns mentioned above with regard to immunohistochemistry because the proteins are denatured prior to incubation with the antibody and are separated based on mass. Thus, all epitopes should be exposed, and specificity is not a primary concern because the protein of interest can be identified by its size. A polyclonal anti-FoxM1 antibody generated against the C-terminus by Dr. Robert H. Costa’s laboratory (University of Illinois at Chicago) (Wang et al., 2005) was used for western immunoblotting of mouse protein. However, our laboratory found that the signal produced by this antibody was not specific for FoxM1, despite appearing at an appropriate mass, because signals were observed in lanes containing both WT and Foxm1−/− protein (Figure 67A). Similar results were observed using a commercially-available polyclonal anti-C-terminal-FoxM1 antibody from Santa Cruz Biotechnology.
Figure 67. Available anti-FoxM1 antibodies are not specific. Western immunoblots were performed using protein extracted from embryonic liver from WT and Foxm1<sup>−/−</sup> littermates. (A) A polyclonal anti-C-terminal-FoxM1 antibody provided by Dr. Robert H. Costa’s laboratory bound to a protein at slightly higher than 83 kDa (arrow), but bands at this size were also observed in Foxm1<sup>−/−</sup> protein extracts, and consistent results were not observed between different WT protein samples. (B) A polyclonal anti-C-terminal-FoxM1 antibody from Santa Cruz Biotechnology also bound to a protein at slightly higher than 83 kDa (arrow) in WT protein extracts, but no difference was observed between WT and Foxm1<sup>−/−</sup> extracts.
(Figure 67B), and no published studies using either of these antibodies had included protein from Foxm1−/− tissue. To determine whether Foxm1 was actually deleted in Foxm1−/− mice, PCR was performed for the Foxm1WT and Foxm1null alleles (Figure 68A-D), and qRT-PCR was used to compare Foxm1 transcript levels in embryonic liver samples between WT and Foxm1−/− littermates (Figure 68E). These results confirmed that Foxm1−/− mice indeed contained the truncated Foxm1 gene but not the full-length gene, and that Foxm1 transcripts were nearly undetectable. Thus, we are confident that Foxm1−/− extract and tissue can be used to identify specific anti-FoxM1 antibodies, and that the antibodies tested to date do not specifically recognize FoxM1.

As described in Chapters III and IV, qRT-PCR specifically detects mouse Foxm1 or human FOXM1 transcripts. However, as with western immunoblotting, expression cannot be assessed on a cellular basis. In an attempt to identify Foxm1 transcript on tissue sections, in situ hybridization was performed. Radioactive in situ hybridization had previously shown widespread Foxm1 expression on whole-embryo sections, including within the pancreas (Ye et al., 1997). This finding was confirmed using non-radioactive in situ hybridization, which revealed that Foxm1 was found to be expressed at relatively high levels in the embryonic cords, along the ductal epithelium, at e15.5 (Figure 69A) and in embryonic liver (Figure 69B). These results were similar to those observed in the pancreas using an anti-N-terminus FoxM1 antibody on embryonic mouse sections (Zhang H et al., 2006) (Figure 14) and in the liver using radioactive in situ hybridization (Ye et al., 1997). However, because of the high levels of RNase proteins within the pancreas after birth, in situ hybridization failed to detect Foxm1 in adult tissues.
Figure 68. Confirmation of Foxm1−/− tissue. Embryos from Foxm1+/− inter-crosses were genotyped for Foxm1 (A) null and (B) WT alleles using DNA from tail tissue. Foxm1−/− embryos (#2, 6, and 8, asterisks) and Foxm1+/+ embryos (#1, 5, and 9, circles) were confirmed using DNA from pancreatic tissue sections by the presence of the (C) Foxm1 null allele and the absence of the (D) Foxm1 WT allele. Genotyping for IL-2 was used as a control. ns=non-specific. (E) Real-time qRT-PCR was used to assess Foxm1 transcripts in e15.5 liver samples in WT and Foxm1−/− littermates. n=1 per group.
Figure 69. *In situ* hybridization for *Foxm1*. (A) *Foxm1* mRNA was detected in endocrine cords (outlined) of WT pancreas at e15.5 and in (B) WT liver at e13.5.
Currently, no antibody exists that can specifically detect mouse FoxM1 using immunohistochemistry or western immunoblotting. Such analyses would enhance the studies presented in Chapters III-V and could be used in future studies by our laboratory and others. To this end, our laboratory decided to generate an anti-FoxM1 antibody. This chapter describes the processes of generating and screening a monoclonal anti-FoxM1 antibody, which was done in collaboration with the Vanderbilt Monoclonal Antibody Core. However, some of the methods used and reagents generated in this project could be used for future production of other antibodies, such as phospho-specific or peptide antibodies.

The choice to generate a monoclonal versus polyclonal antibody was made based on the need for a highly-specific antibody for use primarily in immunohistochemistry. Because monoclonal antibodies recognize an individual epitope, they are more specific than are polyclonal antibodies, which can recognize multiple epitopes. Although in many cases, the multiple epitopes recognized by polyclonal antibodies are still specific to the protein of interest, there is a greater risk of cross-reaction with epitopes on other proteins. Because FoxM1 is part of a large family of proteins that all share homology in the DNA binding domain, cross-reactivity is concerning. Additionally, monoclonal antibodies can be produced in unlimited quantity, and all lots have similar characteristics because they are produced from a clonal population of hybridoma cells. Polyclonal antibodies are collected from animal sera, which can vary greatly. Therefore, a monoclonal antibody would be useful for many future experiments and for other laboratory groups.
Progress to Date and Future Directions

Because FoxM1 is a rather large protein with multiple domains, and its three-dimensional structure is not known, it was decided that a protein antigen would be preferable to a peptide antigen for generation of a monoclonal antibody. However, because of FoxM1’s size and because of the concern regarding cross-reactivity with other Fox proteins mentioned above, it was decided that three fragments of the FoxM1 protein would be generated for immunization, none containing the DNA binding domain. These three fragments were generated from mouse Foxm1 cDNA (NM_008021) using PCR, with Fragment 1 consisting of bp 172-870 (amino acids 1-233), Fragment 2 consisting of bp 1108-1938 (amino acids 313-589), and Fragment 3 consisting of bp 1939-2445 (amino acids 590-757) (Figure 70A). These fragments were designed to specifically exclude the forkhead DNA binding domain because BLAST search indicated that FoxM1 shares little sequence homology with other proteins outside of this domain (Figure 70B).

The coding sequence for each FoxM1 fragment was sub-cloned into the pAT107b vector that contains an N-terminal high-molecular weight (43.2 kDa) MBP tag, which can be cleaved by 3C protease, and a C-terminal small 8x polyhistidine tag, which cannot be cleaved. These tags not only allow for identification of fusion proteins, but the MBP tag confers enhanced solubility and immunogenicity to each fusion protein (Dr. Robert Carnahan, Vanderbilt University, personal communication) (Bannantine et al., 2004). Additionally, this vector is a derivative of the pET vector, so expression of the fusion protein is driven by the T7 promoter, which is induced by IPTG but repressed in the absence of T7 RNA polymerase (Figure 71A).
Figure 70. Generation of FoxM1 fragments. (A) Three fragments of mouse FoxM1 were generated, corresponding to the N-terminal, middle, and C-terminal regions (Fragment 1, 2, and 3, respectively). The forkhead (FH) DNA binding domain was excluded from these fragments because (B) FoxM1 shares high sequence homology with other Fox proteins within this domain. B was obtained from NCBI BLAST search of mouse FoxM1 protein sequence (NP_032047) against mouse reference proteins (refseq_protein). Search was performed on August 12, 2008.
Figure 71. T7 expression system. (A) The pET vector and its derivatives, such as pAT107b, consist of a T7 RNA polymerase-responsive promoter ($P_{T7}$) upstream of a lac operon ($lacO$), a polylinker site ($p\text{Link}$) into which a sequence of interest can be inserted, and a lac repressor gene ($lacI$). In the absence of T7 polymerase and lactose (or IPTG), expression of the gene of interest is repressed. (B) The host chromosome of BL(DE3) E. coli contains the coding sequence for T7 RNA polymerase under control of the lac operator system. Presence of lactose or IPTG de-represses expression of T7 RNA polymerase, and the combined presence of these factors promotes expression of the gene of interest.
Each FoxM1 fragment-MBP fusion protein was expressed in BL21-CodonPlus (DE3)-RIPL E. coli (Stratagene), which contain the coding sequence for T7 RNA polymerase, driven by an IPTG-inducible promoter (Figure 71B). These bacteria also contain plasmids that carry genes encoding the argU, ileY, leuW, and proL tRNAs, which are normally rarely expressed in E. coli and can limit translation of heterologous proteins.

Small-scale inductions were used to assess and optimize culture, induction, and purification conditions. Cultures were induced with IPTG for 2, 4, or 6 hours at 37°C, 32°C, 29°C, or 25°C. Initial analyses of bacterial lysates indicated that the Fragment 1-MBP fusion protein was efficiently induced at 37°C after 2 hours, while Fragments 2- and 3-MBP were recovered at much lower levels (bands at 68, 73, and 61, respectively; Figure 72). These results suggested that the Fragment 2-MBP and Fragment 3-MBP fusion proteins were relatively insoluble. Induction for longer periods of time at lower temperatures, which can improve solubility, did not produce dramatically different results for Fragment 2-MBP compared to induction at 37°C (Figure 73). However, a slight improvement in recovery was observed for Fragment 3-MBP after induction at 32°C for 2 hours. Comparison of insoluble (pelleted) and soluble (supernatant) fractions of the lysate confirmed that the majority of the Fragment 2- and 3-MBP fusion proteins were insoluble, and that Fragment 2-MBP was less soluble than Fragment 3-MBP (Figure 74).

Large-scale cultures were then induced with IPTG for 2 hours at 32°C, and lysate was purified under denaturing conditions using amylose resin, which bound to the MBP tag on each FoxM1 fragment and was then competed away by maltose. All three fragment-MBP fusion proteins were efficiently induced (crude lysate, Figure 75). However, only Fragment 1-MBP was efficiently purified, while the majority of Fragment
Figure 72. IPTG induced expression of FoxM1 Fragment 1-, 2-, and 3-MBP fusion proteins. Crude cell lysates were collected from transformed BL21-CodonPlus (DE3)-RIPL E. coli prior to or 2, 4, or 6 hours after induction with IPTG. Band at 43 kDa represents MBP (vector, 4), band at 68 kDa represents FoxM1 Fragment 1-MBP (1), band at 73 kDa represents FoxM1 Fragment 2-MBP (2), and band at 61 kDa represents FoxM1 Fragment 3-MBP (3). Bands at 26 and 38 kDa represent chloramphenicol acetyl transferase (5) and the streptomycin resistance gene product (6), respectively, which are inherent to BL21-CodonPlus (DE3)-RIPL E. coli.
Figure 73. Lower induction temperatures modestly improved FoxM1 Fragment 3-MBP solubility. Crude cell lysates from BL21-CodonPlus (DE3)-RIPL E. coli were collected either prior to or 2, 4, or 6 hours after induction at 32, 29, or 25°C. Band at 43 kDa represents MBP (vector, 4), band at 73 kDa represents FoxM1 Fragment 2-MBP (2), and band at 61 kDa represents FoxM1 Fragment 3-MBP (3). Band at 38 kDa represents the streptomycin resistance gene product (6), which is inherent to BL21-CodonPlus (DE3)-RIPL E. coli.
Figure 74. FoxM1 Fragment 2- and 3-MBP fusion proteins were highly insoluble. Crude cell lysates from BL21-CodonPlus (DE3)-RIPL *E. coli* were collected either prior to or 2 hours after induction with IPTG at 32°C, and then centrifuged to separate soluble (supernatant; sup.) and insoluble (pellet) fractions. Band at 43 kDa represents MBP (vector, 4), band at 73 kDa represents FoxM1 Fragment 2-MBP (2), and band at 61 kDa represents FoxM1 Fragment 3-MBP (3). Band at 38 kDa represents the streptomycin resistance gene product (6), which is inherent to BL21-CodonPlus (DE3)-RIPL *E. coli*.
Figure 75. Final purification of FoxM1 Fragment 1-, 2-, and 3-MBP fusion proteins. Small samples of crude cell lysates were collected from BL21-CodonPlus (DE3)-RIPL E. coli transformed with either FoxM1 Fragment 1-MBP, Fragment 2-MBP, or Fragment 3-MBP prior to induction (uninduced) or 2 hours after induction with IPTG at 32°C (induced). The remainder of the large-scale culture was then collected, and the lysate supernatant (soluble extract) was incubated with amylose resin. After pelleting of the resin and bound proteins, the supernatant (unbound) was collected. Bound proteins were then eluted from the resin (purified). Band at 68 kDa represents FoxM1 Fragment 1-MBP (1), band at 73 kDa represents FoxM1 Fragment 2-MBP (2), and band at 61 kDa represents FoxM1 Fragment 3-MBP (3). Band at 38 kDa represents the streptomycin resistance gene product (6), which is inherent to BL21-CodonPlus (DE3)-RIPL E. coli.
2- and 3-MBP were not bound or purified by the amylose resin. Additionally, none of the fragments were completely purified, as a number of contaminating proteins remained in each preparation after eluting from the amylose resin. Despite these difficulties, a sufficient amount of Fragment 1-MBP and Fragment 3-MBP were recovered for injection into recipient mice in the Vanderbilt Monoclonal Antibody Core.

Mice were injected with both Fragment 1- and Fragment 3-MBP fusion proteins simultaneously. Pre-immune and post-immune sera were collected from mice and screened for reactivity against mouse FoxM1 protein on embryonic mouse liver sections and protein extracted from mouse embryos. Specificity was analyzed by comparing tissue or protein from WT and Foxm1⁻/⁻ embryos. Sera collected after three total injections of Fragment 1-MBP and Fragment 3-MBP showed no specific reactions against FoxM1 using either screening method. However, after a fourth injection, sera from two mice reacted with protein at ~83 kDa, the predicted molecular weight of mouse FoxM1 (Figure 76). These bands were only observed in extracts from WT, but not Foxm1⁻/⁻, embryos, suggesting that these mice are producing antibodies specific to FoxM1. To confirm that this band likely represented FoxM1, HeLa cells were transfected with full-length mouse Foxm1 cDNA, and protein extracts were subjected to western immunoblotting with sera from mice injected with Fragment 1-MBP and Fragment 3-MBP. This screen showed that all injected mice were producing antibodies that reacted against a protein at ~83 kDa in transfected cells (Figure 77). This band was very weak in extracts from HeLa cells transfected with a negative control, likely representing relatively low levels of endogenous human FOXM1 expression. The fact that all serum samples reacted with FoxM1 in transfected HeLa cell extracts but only two
Figure 76. **Endogenous mouse FoxM1 was detected by sera from two antigen-injected mice.** Total protein extracts were collected from WT and Foxm1−/− embryos and used for western immunoblotting with sera from antigen-injected A/J and Balb/c mice. Sera from two mice produced bands at ~83 kDa (arrows) specifically in WT, but not Foxm1−/− extracts (arrows).
Figure 77. Recombinant FoxM1 was detected by sera from all antigen-injected mice. HeLa cells were transfected with no DNA (lane 1) or mouse Foxm1 cDNA in pcDNA3.1 (lanes 2 and 3). Nuclear proteins were then extracted and used for western immunoblotting with sera from seven different antigen-injected A/J or Balb/c mice (#1-7). All sera samples produced bands at ~83 kDa that were predominant in the transfected HeLa cell extracts (arrows).
serum samples reacted with endogenous FoxM1 in mouse embryo extracts was likely due to the relatively higher amount of FoxM1 being produced by the transfected HeLa cells in comparison to embryonic tissue, along with differences in antibody affinity. Based on these results, it is highly probable that the endogenous mouse protein bound by the sera from the two mice was indeed FoxM1. No specific reactions were observed using these sera for immunohistochemistry on mouse embryonic liver paraffin sections. Instead, several of the serum samples reacted with both WT and Foxm1/- tissue. However, there was not enough sera available to test using various antigen retrieval methods, on cryosections, or to otherwise optimize these experiments.

Because mice were injected with N-terminal (Fragment 1) and C-terminal (Fragment 3) regions of the FoxM1 protein, it is possible that some antibodies produced by these mice bind to the N-terminal portion of FoxM1, for which the coding sequence is not deleted by recombination of Foxm1^{flox/flox} alleles. qRT-PCR primers used to detect Foxm1 transcripts bind to sequences in exons 4-7, which are not present in the Foxm1^{null} allele. Therefore, it is currently unknown whether truncated FoxM1 mRNA or protein is produced after Cre-mediated recombination. The presence of an N-terminal truncated FoxM1 protein could yield false-positive results upon screening of Foxm1^{-/-} tissue. Thus, it is possible that some of the serum samples contain FoxM1-specific antibodies even though they react with Foxm1^{-/-} tissue, which may be why no specific reactivity was observed on tissue sections but was observed on western immunoblots.

Based on the positive western immunoblot results, the next step in generating a monoclonal antibody will involve isolating the antibody-producing B cells from a chosen mouse and fusing these cells with an immortal myeloma cell line to form hybridomas.
Hybridoma clones will then be identified and screened for anti-FoxM1 antibody production. Because conditioned media from these cells will be readily available, several screening techniques will likely be employed to detect one or more antibodies that can be used for western immunoblotting and/or immunohistochemistry, as these will be the primary uses for such an antibody in our laboratory. It is expected that an antibody will be identified that yields a positive result upon western immunoblotting, because crude sera produced such a result. However, it cannot be predicted whether or not any antibody generated will be able to be used for immunohistochemistry. Thorough screening using multiple antigen retrieval and signal amplification methods will likely be necessary. If after such screening a useful antibody has still not been identified, then efforts should be diverted to generating a polyclonal antibody against either a FoxM1 fragment or peptide. Because of the potential utility of a specific anti-FoxM1 antibody, this project remains a worthwhile endeavor.
Previous to this work, FoxM1 was known to activate transcription of multiple cell cycle regulators in several cell types outside of the pancreas. Its importance in cell cycle control was evident from global deletion studies, which resulted in late embryonic lethality (Krupczak-Hollis et al., 2004). Additionally, FoxM1 had been shown to play an important role in liver regeneration, using both deletion and over-expression experiments (Ye et al., 1999; Wang et al., 2002a; Wang et al., 2002b). Pancreas-selective deletion studies performed in our laboratory revealed that absence of FoxM1 resulted in reduced postnatal β cell mass and proliferation, associated with progressive diabetes (Zhang H et al., 2006). It was just becoming clear at this time that β cells exhibited several unique cell cycle characteristics: requirements for particular cell cycle regulators (Rane et al., 1999; Georgia and Bhushan, 2004; Kushner et al., 2005b), different requirements during embryogenesis versus neonatal versus adult timepoints (Krishnamurthy et al., 2006; Georgia and Bhushan, 2006; Rachdi et al., 2006; Zhang W et al., 2006), and altered expression of different cell cycle regulators in response to different proliferative stimuli (Uchida et al., 2005; Cozar-Castellano et al., 2006c; Friedrichsen et al., 2006). Thus, it was of great interest to determine whether FoxM1 is required for proper β cell proliferation at different ages and under different circumstances (Figure 78A). Additionally, we wanted to determine whether FoxM1 is involved in any of the other processes that regulate β cell mass (Figure 78B).
Figure 78. Summary of FoxM1’s role in β cell mass regeneration and expansion. (A) β cells are known to proliferate in response to pancreatic injury, growth factors, hormones, and metabolic stimuli. Our laboratory seeks to define FoxM1’s role in such stimulation of β cell proliferation. This dissertation revealed a role for FoxM1 downstream of 60% PPx. (B) Proliferation of pre-existing β cells was impaired in the absence of FoxM1, whereas proliferation of newly-differentiated (neogenic) β cells did not require FoxM1. β cell neogenesis and apoptosis were not affected by loss of FoxM1, but β cell hypertrophy was observed in FoxM1<sup>Δ</sup>panc mice. Check-marks indicate FoxM1’s involvement. X-marks indicate FoxM1 is not involved.
Mice with a pancreas-wide deletion of Foxml (FoxM1$^{\Delta\text{panc}}$) previously were shown to exhibit normal β cell mass at birth and relatively normal growth of β cell mass during the neonatal period (Zhang H et al., 2006). However, at 4 weeks of age and older, further growth of β cell mass was inhibited, and β cell proliferation was reduced in FoxM1$^{\Delta\text{panc}}$ mice compared to Control littermates. Findings presented in this dissertation revealed that β cell proliferation was not reduced in late-stage FoxM1$^{\Delta\text{panc}}$ embryos (Chapter III), indicating that FoxM1 is differentially required for β cell proliferation at different ages. An interesting follow-up experiment would be to analyze β cell proliferation during the neonatal period to determine whether, despite normal growth of β cell mass, there is defective β cell proliferation that is compensated for by enhanced β cell neogenesis, as neogenesis is known to normally occur during this period (Scaglia et al., 1997).

In an effort to determine whether FoxM1 is required for enhanced β cell proliferation in response to pancreatic injury or insulin resistance, euglycemic FoxM1$^{\Delta\text{panc}}$ female mice were subjected to 60% PPx or diet-induced obesity, respectively. Other members of our laboratory are investigating FoxM1’s role in β cell proliferation stimulated during pregnancy and in response to various growth factors. Unfortunately, experimental obstacles beyond our control precluded analysis of high-fat diet-induced β cell proliferation in FoxM1$^{\Delta\text{panc}}$ mice at this time, although these experiments are ready to be repeated in the future. With regard to injury-induced β cell proliferation, however, it was determined that FoxM1 did indeed play an important role.

60% PPx stimulated Foxml up-regulation within islets and β cell proliferation in Control mice. Proliferation was enhanced in both the splenic (regenerating) and
duodenal (expanding) lobes of the pancreas, indicating that β cells were responding to
general cues, such as growth factors, initiated by injury of only the splenic portion of the
pancreas. However, in FoxM1<sup>Δ</sup>panc mice β cell proliferation was only significantly
stimulated within the splenic/regenerating lobe, although to a lesser extent than in
Control mice. Furthermore, β cell proliferation in the splenic lobe was significantly
blunted by loss of FoxM1 specifically within definitive islets of 9 or more β cells, but not
within small clusters of 8 or fewer β cells. As small endocrine cell clusters likely formed
via neogenesis, while larger islets were likely pre-existing, these results once again
suggested that β cells have different requirements for FoxM1 at different developmental
stages (Figure 79).

Other studies from our laboratory indicated that Foxm1 transcripts were up-
regulated in islets during pregnancy and that FoxM1<sup>Δ</sup>panc female mice exhibited a failure
of β cell mass expansion and β cell hyperplasia during pregnancy that ultimately resulted
in gestational diabetes (Hongie Zhang and Jia Zhang et al., manuscript in preparation).
In contrast to the results observed following 60% PPx, no increase in β cell proliferation
was observed in FoxM1<sup>Δ</sup>panc female mice in response to pregnancy, further supporting the
conclusion that FoxM1 is absolutely required for proliferation of pre-existing β cells in
the adult.

Because of the interest in stimulating β cell proliferation as a therapeutic method
for diabetic patients, understanding the proliferative cues to which β cells respond and the
pathways activated by such cues could greatly improve this endeavor. Currently, the
growth factors HGF and IGF-1 and the pregnancy hormone PL are being investigated in
our laboratory to determine whether they act upstream of FoxM1. Additionally, it could
Figure 79. Working model of FoxM1’s role in β cell proliferation. β cells differentiate from Ngn3+ precursor cells in the ductal epithelium, both during development and during regeneration after 60% PPx. Initially, these newly-formed β cells can replicate in a FoxM1-independent manner. However, after a certain point, which has not yet been clearly determined, β cells become dependent on FoxM1 for continued proliferation.
prove useful to determine which growth factors are up-regulated and/or released in response to 60% PPx, as these are likely to act through FoxM1 to stimulate β cell proliferation.

These and other signaling pathways may act through FoxM1 by enhancing its transcription or its activity, both of which should be evaluated in future studies. As discussed in Chapter I, little is known regarding which factors and which regions of the Foxm1 promoter are responsible for controlling FoxM1 expression. Furthermore, based on the over-expression studies presented in Chapter III, in which Rosa26-FOXM1c Tg mice did not exhibit any effects of ubiquitous FoxM1 over-expression on β cells or glucose homeostasis after 60% PPx, it is possible that expression of FoxM1 does not always correlate with activity. Thus, there is also need for further study of FoxM1’s post-translational modifications and their influence on FoxM1 activity. It is known that FoxM1 is phosphorylated on multiple residues, some of which are necessary for FoxM1’s sub-cellular localization and/or transcriptional activity (Major et al., 2004; Ma et al., 2005), and it will be important to evaluate FoxM1 phosphorylation status as well as its expression in future studies. Additionally, with regard to manipulating β cell proliferation, it may be necessary to specifically activate FoxM1 or over-express a constitutively active form of FoxM1 in order to achieve the desired effect(s). This could be accomplished by activation of specific signaling pathways or kinases, or by phospho-mimetic mutation of specific FoxM1 amino acids.

Our laboratory is currently developing a monoclonal antibody for analysis of FoxM1 expression levels and sub-cellular localization (Chapter VI). However, phospho-specific antibodies may also be useful to better evaluate FoxM1 activity. Anti-FoxM1
antibodies could also be used in chromatin immunoprecipitation (ChIP) experiments to examine down-stream targets of FoxM1, both to verify putative targets in β cells, including those up-regulated after PPx along with FoxM1, and to identify new targets. Other laboratories have shown that FoxM1 directly activates transcription of genes, such as Lama4, ERA, and Jnk1, which have functions not exclusive to proliferation (Kim et al., 2005; Madureira et al., 2006; Wang et al., 2008a). Because we have identified a potential role for FoxM1 in β cell insulin secretory function, it is likely that other targets remain to be discovered in the β cell. ChIP on chip and ChIP-Seq techniques, in addition to microarray data comparing FoxM1Δpanc and Control islets, could be used to elucidate such targets.

Although insulin secretion may be impaired in FoxM1Δpanc mice, β cell differentiation does not seem to be impaired, as neither insulin expression per β cell nor β cell neogenesis, during either development or regeneration, are affected by loss of FoxM1. Thus, FoxM1 may regulate targets that are involved in the mechanics of insulin exocytosis, as observed in Foxa2floxflox;Pdx1-CreERT2 mice, which displayed insulin secretory defects associated with changes in expression of genes involved in insulin granule synthesis, vesicular trafficking, and exocytosis (Gao et al., 2007). Because impaired insulin secretion was only observed in FoxM1Δpanc mice fed a high-fat diet, FoxM1 may regulate genes that are involved in β cell compensation. It is known that enhanced insulin secretory function and β cell hypertrophy occur in response to diet-induced obesity and insulin resistance (Lingohr et al., 2002; Kahn et al., 2006), and it is hypothesized that these two responses are related. It is clear from the studies presented in Chapters III and IV that FoxM1Δpanc mice exhibit β cell hypertrophy under normal
conditions, and this basal state may impede adaptation to cellular stressors. Thus, further investigation of FoxM1’s role in β cell function may lend some insight into how β cells compensate for increased insulin demand.

Because Type II diabetes results from a relative insufficiency of β cell mass and function, it is possible that altered FoxM1 expression or activity may be related to susceptibility to this disease. Thus far, no direct link between diabetes and FoxM1 has been described in human studies. However, genome-wide association studies are in their infancy, and the fact that polymorphisms in only a handful of genes have thus far been linked to Type II diabetes, which is an admittedly complex and multigenic disease, suggests that more susceptibility loci remain to be identified. Additionally, FoxM1 may be indirectly implicated by its association with pathways that regulate its expression and/or activity. Again, further characterization of FoxM1’s transcriptional regulation and post-translational modification may lend insight into potential defects associated with diabetes.

This dissertation described the effects of loss of FoxM1 on β cell mass regeneration and expansion, which are summarized in Figure 78A,B. These experiments demonstrated that FoxM1 played an important role in proliferation of pre-existing β cells but not newly-differentiated β cells, and that β cell hypertrophy occurred in the absence of FoxM1. However, neither β cell neogenesis nor apoptosis were affected by loss of FoxM1. Therefore, FoxM1 does play a role in β cell mass regeneration following 60% PPx, but its role in β cell mass expansion in response to diet-induced obesity or other stimuli of β cell proliferation has yet to be determined.
REFERENCES


241


